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Of recent advances in the treatment of breast cancer and acute leukaemias, peripheral
blood progenitor cell (PBPC) transplantation is a very prominent milestone, and the
reverse is also true, that these diagnoses are among the commonest indications for
such procedures. Inevitably, there is concern that malignant cells may contaminate
progenitor cell harvests and be re-infused during transplantation and cause disease
relapse. Various methods are available for the detection of such minimal residual
disease (MRD), and the key aim of this project was to evaluate the feasibility of using
a tumour-specific marker, namely mutations within the p53 gene, for this purpose.
This provided a useful model to assess the feasibility of using subtle genetic changes
in the detection ofMRD within PBPC harvests from patients with malignant diseases.
The first step involved the use of denaturing gradient gel electrophoresis (DGGE) to
screen original tumour tissues for mutations in 5 individually PCR-amplified DNA
fragments (A to E) covering exons 5 to 8 of p53, to be used as disease markers. The
technique was first optimised using cell lines known to contain p53 mutations in each
fragment. Optimisation was performed with respect to electrophoresis temperature,
time, voltage and polyacrylamide cross-linker. The sensitivity ofDGGE in detecting a
mutation in a mixed cell population was determined by diluting tumour cells in wild
type (WT) cells. Although the presence of a mutation could be demonstrated when
tumour cells occured as 5% of total, a representation of at least 40% was required for
the mutant homoduplex to be isolated for sequencing. Clinical samples studied were
from 51 breast cancer patients, 38 ofwhom had metastatic disease or at high risk of
metastasis, and 13 had high risk stage II/III disease randomised in a clinical study
investigating PBPC transplantation as adjuvant therapy, and from 29 patients with
acute leukaemias. A positive result was obtained in 14 of 51 primary breast cancer
patients (1 was positive in 2 different fragments) and 3 of 29 patients with acute
leukaemias. The second step was to isolate the mutant species from DGGE gels and
to obtain the exact sequence. In the breast cancer series, sequencing failed in 2 of the
positive samples, a further 2 had an identical mutation, and 2 others were silent
polymorphisms. A total of 10 different somatic missense mutations were identified. In
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the leukaemia samples, 2 were silent polymorphisms and only 1 somatic mutation was
found, a novel 8 bp insertion sequence in codon 281 representing the more aggressive
of 2 leukaemic clones in this patient.
The third step used the amplification refractory mutation system (ARMS) technique
to screen PBPC harvests for MRD in patients whose original tumours contained p53
mutations. This involved allele-specific PCR in which the specific sequence of the
ARMS primer and the unique reaction conditions allowed the mutant but not the WT
DNA to be amplified. First, parameters important for the optimisation of an ARMS
system were determined using the T47D cell line. Conditions studied included PCR
annealing temperature, concentrations of magnesium, dNTP's and primers, the
presence of glycerol and formamide, cycle number and the use of additional deliberate
mismatches. Only 5 of 10 systems with missense mutations could be optimised. WT
and mutant DNA could not be distinguished in a further 3, and in the remaining 2 the
PCR products from the mutant DNA were too weak to be of value in MRD detection.
MRD detection sensitivities for the 5 optimised systems were only from 1 in 102 to
10\ ARMS primer design and optimisation were easier for the 8 bp insertion with
sensitivity of 1 in 104. The use of nested PCR and radiolabeled ARMS to improve
sensitivity were largely unsuccessful. A restriction site-generating (RG-) PCR
approach was attempted as an alternative. All identified missense mutations either
already resulted in abolition of a restriction enzyme recognition site, or a mutagenic
primer could be designed to enable restriction ofWT but not the mutant sequence.
Although PCR itselfwas efficient, when products were treated with restriction
enzymes after PCR, the detection senstivity of the mutant DNA was extremely low, at
approximately 1 in 10. This approach as used in this project was therefore, not useful
in MRD detection. Using ARMS, 3/5 breast cancer patients and 8/12 of their PBPC
harvests demonstrated MRD. With such small numbers, little can be said of the
correlation between MRD in PBPC harvests and outcome, but disease-free survival
appeared to depend more on the clinical stage of disease. By studying sequential
marrow and PBPC harvest samples, clonal evolution was shown in the leukaemia
patient with the 8 bp insertion. He was re-infused with leukaemia-contaminated
xv i
PBPC's but the disease was aggressive and failure of disease eradication was also
likely to be the cause of his relapse.
In conclusion, the use of single base changes of p53 in MRD detection is, therefore,
laborious and insensitive and only applicable to a small number of patients and to
certain mutations. They appear to be of little value in general use, although with very




Over the last 2 to 3 decades, the use of cytotoxic chemotherapy, in combination with
advances in supportive care, has revolutionised the treatment and prognosis of
patients with many type ofmalignancies. In the modern treatment ofmany of these
diseases, despite the addition of other therapeutic approaches such as cytokines,
monoclonal antibodies, immuno- or gene therapy, the ability to deliver a high dose of
chemotherapy over a short period of time remains for many the key to prolonged
survival. Inevitably, the higher the dose of chemotherapy given, the more likely for
toxic events to occur. These may indeed be dose-limiting. Whatever the underlying
disease, the bone marrow (BM) is a site very vulnerable to cytotoxic drugs, and
toxicity to which often determines the maximum dose possible. Very high doses of
chemotherapy have been made possible by the use ofpreviously harvested autologous
or allogeneic BM (and latterly peripheral blood progenitor cell) support. In the
autologous setting, however, concerns have also grown for the re-infusion of
malignant cells which have contaminated these haemopoietic grafts, as gene-marking
studies have demonstrated that re-infused tumour cells can contribute to disease
relapse (Rill et al, 1994), and occult tumour cells can be mobilised along with
peripheral blood progenitor cells (PBPC) (Brugger et al, 1994). The presence of
morphologically undetectable occult tumour cells is termed minimal residual disease
(MRD) and depending on the disease in question, various techniques are available to
identify them. The advent of the exquisitely sensitive polymerase chain reaction (PCR)
technology (Saiki et al, 1988) opened up a whole new arena in the field ofMRD
detection, and in this project, it is my aim to assess the usefulness of a PCR-based
molecular technique which employs mutations within the p53 tumour suppressor gene
as markers ofMRD. p53 is the single most commonly altered gene in human cancers
and should serve as a patient- and tumour-specific marker of disease. In Edinburgh,
as in many units nationwide and worldwide, PBPC have largely superseded BM as the
preferred source ofhaemopoietic progenitor cells, and here acute leukaemias and
breast cancer are amongst the diseases for which PBPC transplantation is most often
1
performed. For these reasons, these should provide a satisfactory platform on which
to assess such a technique.
In this introduction, I shall first describe the current state of opinion on PBPC
transplantation, focusing on the 2 diseases studied in this project. Then mention will
be made of the issue ofMRD and its clinical relevance, followed by a description of
the p53 gene and the possible methods for mutation detection, which forms a key part
of this project. Finally the aims of the project will be listed.
1.1 HAEMOPOIETIC PROGENITOR CELL TRANSPLANTATION (HPCT)
Breast cancer and the acute leukaemias are the diseases for which assessment of the
techniques ofMRD detection in this project are based, and the main 'tissue' in which
MRD is sought, is PBPC harvests. As a background to the study ofMRD for these
diseases, I shall first review some of the clinical aspects ofHPCT as applied to these
diseases, and outline the findings of a number of controlled trials which reflect the
current understanding of the usefulness of high dose therapy and transplantation in
this context. In current literature, transplantation may be performed using BM or
PBPC, and to encompass both, I have used the term HPC in the wider context, but
specified the source of the graft where appropriate.
1.1,1 HPCT IN BREAST CANCER
Breast cancer is the most common non-cutaneous malignancy affecting women. In the
UK, 1 in 12 women will be diagnosed with breast cancer during their lifetime, and
25,000 new cases and 16,000 deaths from the disease occur annually (ACCOG
Clinical Trial Protocol, 1994). There is wide heterogeneity in the natural history of the
disease, and although in many patients the disease can be aggressive, in others it has a
very protracted course over many years. One important stratification of prognosis is
according to clinical stage, and the tumour-node-metastasis (TNM) and International
Union Against Cancer (UICC) classifications are most commonly used. As the stages
of disease will be frequently referred to in this thesis, I shall first define the stages
2
according to these 2 systems (Table 1.1; Sainsbury et al, 1994). Stage IV or
metastatic breast cancer is not curable by conventional dose chemotherapy; with
chemotherapy, the overall response rates are 40 - 60% with a median time to relapse
of 6 - 10 months (Leonard et al, 1994). Stage II and III disease if associated with
many positive axillary lymph nodes, also have very poor outlook. In this latter group,
40 - 50% of patients with 4-9 positive nodes and 70 - 80% with 10 or more nodes
will ultimately relapse (Cagnoni et al, 1996). This is the reason why alternative
therapies, particularly high dose chemotherapy, are being intensively assessed.
1.1,1.1 THEORETICAL CONSIDERATIONS
The rationale of using high dose chemotherapy is based on experimental tumour
models, and reviewed in recent commentaries by Peters and Dansey (1997) and
Bezwoda (1997). The main consideration here is the phenomenon of (Skipper and
Schabel) dose-response relationships. When tumours are treated with cytotoxic drugs,
for a given dose, a constant proportion of cells are killed, and there is a logarithmic or
exponential relationship between drug dose and cell kill. For some cytotoxic drugs,
especially the alkylating agents, the curve is steep. For each drug in a combination
regimen, exponential cell-kill exists, hence the effects are additive, and with a lack of
cross-resistance provide the rationale of using combination high dose therapies.
Another reason for using high dose therapy (HDT) is based on the Gompertzian
model which states that tumour-doubling time increases with increasing tumour size,
predicting more rapid proliferation in the early stage of disease and slowing ofgrowth
when the tumour reaches a clinically detectable size. This justifies the use of courses
of cytoreductive induction chemotherapy, followed by a single course of ablative
HDT, and this may be particularly relevant for adjuvant therapy as any putative
micrometastasis is presumed to be rapidly proliferating. In the dose range of
conventional chemotherapy, the benefit of dose intensification has been demonstrated
for both metastatic breast cancer (Tannock et al, 1988) and as adjuvant therapy for
stage II disease (Wood et al, 1994).
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Table 1.1. TNM and UICC Staging Systems for Breast Cancer
TNM Classification
T: Tumour size
Tis Cancer in situ
T1 <2 cm
T2 > 2 cm - 5 cm
T3 > 5 cm
T4a Involvement of chest wall
T4b Involvement of skin
N: Axillary lymph node status
NO No regional node metastasis
N1 Palpable ipsilateral axillary nodes
N2 Fixed ipsilateral nodes






I Tl, NO, MO
II Tl, Nl, MO; T2, NO-1, MO
III any T, N2-3, MO; T3, any N MOIV any T. any N. Ml
1.1.1.2 CLINICAL EXPERIENCE
Early attempts at using HDT were performed in the 1980's where patients mostly had
poor prognosis because of relapsed or refractory disease (Ayash, 1994). These
authors found a response of 50%, and 25% achieving temporary complete remission
(CR). Results improved with time, and CR rates of 50%, 25% being durable beyond 5
years, were reported (Eddy et al, 1992). Procedure-related mortality also fell from
around 25% in early studies to under 5% currently (Leonard, 1998) with improved
supportive care. Most studies have been non-randomised and used HDT as
consolidation in chemosensitive disease. In this context, a 20 - 40% conversion rate
from partial remission (PR) to CR, and 18 - 25% of patients disease-free at 2 years is
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observed (reviewed by Bezwoda, 1997). Peters et al (1995b) described a survey of
the experience ofAmerican bone marrow transplant centres. For metastatic disease, in
1106 patients from 37 centres, overall survival (OS) at 3 years ofpatients given HDT
+ PBPCT as first-line therapy after induction is 37% and compares favourably to 5 -
20% in historical controls, although disease-free survival (DFS) data were not
available. Data on 662 patients with high risk primary disease (median of 13 positive
lymph nodes) from 33 centres showed 3-year OS of 79% and event-free survival of
69%. Unfortunately, no comparison with controls was made. Our unit in Edinburgh
has used high dose cyclophosphamide (4 gm/m2) with G-CSF to mobilise progenitor
cells from patients with stage IV breast cancer after a 12-week induction course of
chemotherapy, and found 88% success in mobilisation, and rapid post-transplant
haematopoietic recovery (Cameron et al, 1996). No procedure-related mortality was
observed.
Despite the huge numbers of breast cancer patients treated with PBPCT worldwide,
only 2 randomised studies have been published, both in the context of stage IV
disease. Bezwoda et al (1995) compared the use of high dose cyclophosphamide,
mitoxantrone and etoposide (HD-CNVp) with conventional dose cyclophosphamide,
mitoxantrone and vincristine (CNV) as first-line therapy in stage IV patients. With the
relatively small number studied (45 in each arm), a CR rate of 51% in the high dose
group compares with 4% in the conventional group, and the median durations of
response are 80 weeks and 34 weeks, respectively. A major criticism of this study is
the particularly low survival of the conventional group patients, although the disease
in many of these patients is particularly aggressive, so that these response rates are
consistent with published figures and are believable (Kennedy, 1995). A further
criticism is that follow-on tamoxifen given to only the responders may have accounted
for the better survival by amplifying the benefit of a higher response rate in the UDT
group. Peters et al (1996) randomised chemosensitive patients in CR to receive either
immediate HDT or observation, the latter group offered HDT upon relapse. The HDT
group had a significantly longer DFS, but paradoxically shorter OS than the
observation group. This paradox may be explained in terms of the biology of a
resistent clone ofmalignant cells whose proliferation in the 'observation' patients was
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delayed by the observation period (Bezwoda, 1997). Both available randomised
studies, therefore, demonstrated that high dose therapy is beneficial, although in very
different contexts both in terms of patient selection and timing. Results of other on¬
going randomised trials are awaited.
Enthusiasm in the use ofHDT in the adjuvant setting has been fuelled by non-
randomised trials suggesting benefit. An influential study by Peters et al (1993)
reported 85 women with 10 or more positive axillary nodes treated with 4 courses of
induction chemotherapy then HDT and BM support. Event-free survival of 72% was
noted at 2.5 years, and compares with 38 - 52% in historical controls. Bearman et al
(1997) studied the safety and feasibility ofHDT / PBPCT in patients with 4-9
positive nodes, and reported 15/54 (29%) pulmonary toxicity (1 fatality) and
otherwise acceptable safety. Their 4-year DFS of 71% is within the historical range
for standard dose therapy. A number of randomised studies assessing the efficacy of
HDT and HPCT as adjuvant therapy in high risk stage II or III breast cancer are in
progress worldwide, not least the Anglo-Celtic Cooperative Oncology Group study in
the UK, comparing high dose cyclophosphamide and thiotepa + PBPCT, versus
conventional dose cyclophosphamide, methotrexate and 5-fluouracil, after a common
induction regimen, in patients with 4 or more positive axillary nodes. Accrural for this
study (target of 300) is ahead of schedule at present.
1.1.2 HPCT IN ACUTE LEUKAEMIAS
Unlike breast cancer, HPC transplantation for acute leukaemias may involve cells
derived from the patient him- or herself (autologous), or from a histocompatible
donor (allogeneic) who may be a sibling or an unrelated person. The screening of the
HPC graft for MRD is obviously only relevant in autologous transplants, and as a
result, in the context of this project, this review will largely focus on the clinical
aspects of autologous transplantation for acute leukaemias. In clinical trials that assess
the benefit of transplantation as compared with conventional chemotherapy, data on
patients who have undergone allogeneic transplantation are often included, and will
therefore be mentioned here. In ALL, no data are available for the role of autologous
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transplants, and for completeness, a description of the current status of allogeneic
transplantation will be given
11.2.1 HPCTIN AML
Despite advances in cytotoxic chemotherapy and supportive measures with the use of
powerful antibiotics, the mortality from AML remains high. In the region of 65 - 80%
of adults with AML will achieve first remission (Cassileth et al, 1998; Burnett et al,
1998), but most will relapse if no further post-remission treatment is given. As a
result, a number of groups have undertaken to study the benefit, or otherwise, of high
dose chemotherapy with either autologous or allogeneic BM support. As only one
patient in 3 or 4 is likely to have an HLA-compatible sibling, autologous
transplantation is more often performed for this indication. Several published studies
are available to date, and all have used harvested BM rather than PBPC as
haemopoietic support. All but one compared the merits ofBMT with an alternative
'intensive' but not myeloablative course of therapy. There is a degree of heterogeneity
in the design and treatment schedules of these studies, and some studies used marrow
purged with 4-hydroperoxycyclophosphamide whilst others did not. Although
randomisation to receive BMT or not took place for patients who did not have an
HLA-compatible sibling marrow donor, those who had a suitable donor were usually
offered allogeneic transplantation and included in statistical analyses.
Harousseau et al (1994) studied 470 adults with de novo AML. Patients who
achieved CR were given either 2 further consolidative courses (course 1: high dose
cytarabine and idarubicin or rubidazone; course 2: amsacrine and etoposide) or one
consolidative course then autologous BMT with BuCy conditioning and
unmanipulated BM. There was no significant difference in the relapse rate (30 - 44%),
event-free (48 - 56%) and OS (56 - 59%) whether they received chemotherapy,
ABMT or allogeneic BMT. Another large study (Zittoun et al, 1995, for the EORTC
/ GIMEMA groups) used a post-remission consolidative course of amsacrine and
intermediate-dose cytarabine, then randomised patients without a suitable marrow
donor to receive a second course of intensive chemotherapy with high-dose cytarabine
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and daunorubicin, or unpurged BMT conditioned with cyclophosphamide and TBI or
the BuCy regimen. A clear disease-free survival (DFS) advantage was demonstrated
for the BMT groups over the chemotherapy group: 55%, 48% and 30%, repectively
for allogeneic BMT, ABMT and chemotherapy. Although relapse rates were also
highest in the chemotherapy group, no OS difference was shown in the 3 groups.
Whilst the above studies were European initiatives, the American experience was
published recently (Cassileth et al, 1998). A total of 740 adolescent and adult AML
patients were given induction chemotherapy, 70% ofwhom achieved CR. A
consolidative course of idarubicin and cytarabine was given, following which those
with a compatible marrow donor were offered an allogeneic transplant, whilst the rest
were randomised to receive high dose cytarabine or an autologous transplant
conditioned with BuCy. With a median follow-up of 4 years, there was no difference
in the DFS in all 3 groups, and in fact, there was a marginal OS advantage in the
chemotherapy-only group.
Similar studies have also been performed in children. Ravindranath et al (1996)
compared continuing intensive therapy with 6 courses and 5 drugs in varying
combinations, with purged ABMT using BuCy conditioning. The main difference in
the design of this study is, apart from age, high dose cytarabine was used pre-
randomisation, and the numerous courses of'alternative' therapy. DFS at 3 years was
similar (36% and 38%), as was OS (44% and 40%) which balanced a lower relapse
rate in the ABMT group by a higher procedure-related mortality.
In contrast to the above, patients in the MRC AML 10 study (Burnett et al, 1998),
after 3 courses of intensive chemotherapy, and in complete remission, were
randomised to receive, after a forth course of treatment, unpurged ABMT or no
further therapy if a suitable marrow donor was not available. Superior DFS was
demonstrated at 7 years for the ABMT group (53% versus 40%), with fewer relapses
(37% versus 58%). The trend for OS for the ABMT group was better, although not
statistically significant (57% versus 45%, p=0.2).
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It seems that additional ABMT carries a survival advantage over 4 courses of
standard chemotherapy, but it is still not clear ifABMT is definitely superior to an
alternative intensive course such as with high dose cytarabine. The apparent
discrepancy between better disease-free but not OS in the ABMT group has often
been explained by the fact that patients randomised to receive the alternative regimen
were more likely to be salvaged with ABMT when relapsed, in which situation a
significant proportion still had sensitive disease and survived longer. Nevertheless,
high dose chemotherapy and autologous transplantation, especially with PBPC, is
very much in routine practice in most units for patients with AML. No conclusion can
be drawn from the above studies regarding the role ofMRD in the haemopoietic
grafts, but those which demonstrate lower relapse rates in the ABMT group may
suggest that residual disease in the patient, rather than the graft, is most important.
1.1.2,2 HPCT IN ALL
There is a relative paucity of randomised studies of high dose chemotherapy and HPC
transplantation in ALL, by comparison with AML as outlined above. The majority of
cases ofALL are in children. In childhood acute leukaemia, ALL makes up
approximately 80% of cases, and the reverse (20%) is true for adults. Childhood ALL
in general has a good prognosis. Results from the MRC UKALL X study (Chessells et
al, 1995) demonstrated that a 5-year DFS of 71% was achieved if 2 blocks of
intensification therapy were given, and even the arm with the worse outcome (no
intensification) achieved a figure of 57%. As a result of this, there is a general
reluctance to transplant children in first CR. On the other hand, children who relapse
are deemed to have such poor prognosis that should a HLA compatible sibling donor
be available, transplantation is usually carried out. For these reasons, to date, no
prospective randomised study comparing conventional chemotherapy with autologous
transplantation in first or second CR has been published and the role of autografting in
childhood ALL is completely unknown. Attention has been focused on the role of
allogeneic BMT in both first and second CR. Only 1 prospective study (also within
the MRC UKALL X framework) has been published that investigated the role of
allogeneic BMT in poor-risk childhood ALL, defined by a high leucocyte count at
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presentation of> 100 x 109 /1 (Chessells et al, 1992). Of 111 patients who were
HLA-typed, 41 had a compatible sibling donor, ofwhom 34 received an allograft.
Comparison of this group with 144 similar children treated with conventional
chemotherapy showed no significant difference in event-free survival at 5 years,
although no OS data were given. Treatment-related mortality was higher in the
transplant group and relapse rate was higher in the chemotherapy group, however.
With BMT in second or subsequent CR, again only 1 prospective study has been
published (Johnson et al, 1981). Patient numbers in this early study were small, 24 in
the transplant group and 21 in the conventional chemotherapy group. Crude survival
data suggest a clear advantage for allogeneic transplantion. These 2 prospective
studies aside, there have been a number of cohort studies looking at the role of
allografting in second CR, and the study by Barrett et al (1994) is the largest, drawing
cases from the International Bone Marrow Transplant Registry. The DFS at 5 years
for the BMT group was 40%, versus 17% for the chemotherapy group, and the
probabilties of relapse at 5 years were 45% and 80%, respectively. This has provided
fuel for advocates ofBMT, which currently seems to be common practice in this
context.
Prospective studies in adult ALL are likely to be even more difficult to conduct,
owing to the smaller number of cases, and like childhood ALL, firm conclusions in
favour of either transplantation or conventional treatment cannot be drawn. For
example, Sebban et al (1994) studied adult ALL patients in first CR, and in those with
no compatible sibling donor, found no difference between autografting and
conventional chemotherapy. Those with a sibling donor and therefore allografted also
did not appear to enjoy any survival advantage over the autograft and chemotherapy
group as a whole. In general clinical practice, because of the adverse prognosis
associated with adult ALL, patients young enough and with a compatible sibling
donor usually receive an allograft, whilst those without such a donor may receive an
allograft from a matched but unrelated donor identified through national or
international registries.
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1.2 MINIMAL RESIDUAL DISEASE DETECTION IN BREAST CANCER
The issue ofmicrometastasis is not a new one and circulating malignant cells were
recognised in the peripheral blood in cancer patients in the 1950's. There has been a
surge of interest in the detection ofMRD since the 1980's, both in the context of
haematological malignancies and in solid tumours, especially breast cancer and
neuroblastoma. In the management of breast cancer, 2 aspects ofMRD research have
emerged over the last decade. Before high dose therapy and PBPC transplant became
popular for this disease studies were performed on the detection ofmicrometastases
in BM and attempts were made to correlate these to clinical prognosis (Mansi et al,
1989; Cote et al, 1991). More recently, with the common use ofBM / PBPC
transplantation, many groups have focused their efforts on correlating transplant
outcome to the presence ofMRD in haemopoietic grafts (Sharp et al, 1992 and
1995a; Fields et al, 1996; Vredenburgh et al, 1997). Inevitably, in line with clinical
interest is a large body of literature on ultra-sensitive techniques in detecting MRD.
1 2,1 SIGNIFICANCE OF MRD IN BONE MARROW
It has been known for some time that a proportion of patients with apparently early
stage breast cancer can harbour micrometastatic disease in their BM. But the mere
presence of these cells may not indicate that they are truly 'metastatic', and may not
actually be viable or clonogenic. By immunocytochemistry, Mansi et al (1989) found
that, in patients with primary breast cancer after surgery but prior to overt relapse, 2 -
3% had evidence ofMRD in the marrow. This compares with 26% before surgery
(albeit from a different study by the same authors), and 27% ofBM positive patients if
the tumour was left in situ. When patients relapsed, their likelihood of having BM
micrometastasis progressively increased with the extent of relapse. They concluded
that 'shedding' of non-viable cells could account for many observed cases of
micrometastases. The presence ofBM micrometastases before surgery, however, does
seem to correlate with various poor prognostic factors such as vascular invasion,
positive axillary lymph nodes, and primary tumour size, and predicts early relapse
(Mansi et al, 1987 and 1991) and poor OS. Risk of relapse is also dependent on the
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number of cancer cells in the marrow. Patients with higher micrometastatic tumour
burden have a much higher (5.2x) risk of relapse than those with a low burden (Cotes
et al, 1991).
1.2.2 SIGNIFICANCE OF MRP IN HAEMATOPOIETIC GRAFTS
The use of high dose therapy and haematopoietic cell transplantation is now
commonplace in metastatic, and often high risk stage II and III breast cancer, and as a
result much effort has focused on the detection ofMRD in these grafts. There is
concern that patients may suffer disease relapse as a result of re-infusion ofmalignant
cells when their disease is otherwise eradicated. This phenomenon has been
demonstrated in acute leukaemia, neuroblastoma and chronic myeloid leukaemia
(CML) by using gene marking studies. For example, Rill et al (1994) retrovirally
transfected the neomycin-resistant gene into target cells in PBPC harvests from
children with neuroblastoma. Both the PBPCs and the contaminating neuroblastoma
cells (if any) were labelled. The authors estimated that 1% of clonogenic neuroblasts
would be labelled with the marker gene. When the labelled PBPCs, with the
unlabelled aliquots, were returned to 8 patients, subsequent follow-up showed that, of
3 patients who relapsed, the marker gene was detectable in the recurrent tumours in
all cases, thus offering direct evidence that re-infused tumour cells could lead to
disease relapse. Tumour cells may be mobilised into the peripheral blood (PB) at the
same time as PBPC after chemotherapy and G-CSF, and the kinetics of this process
was reported for the first time by Brugger et al (1994). Peripheral blood samples from
46 patients, ofwhom 9 had stage IV or high risk stage II / III breast cancer, were
studied with immunocytochemistry (ICC). 29% of stage IV breast cancer and 20% of
small cell lung cancer (SCLC) patients had circulating tumour cells before PBPC
mobilisation. 21% of patients without steady state circulating tumour cells, and all
stage IV breast cancer patients and 50% of SCLC patients mobilised tumour cells at
the same time as PBPC, at a concentration of 4 - 5,600 tumour cells / 1,6xl06
mononuclear cells (MNC). Tumour cell mobilisation occurred early (days 1 - 7) in
patients without marrow metastasis, but between 9 and 16 days in those with marrow
disease, within the optimal period for PBPC harvesting. All 7 stage IV breast cancer
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patients, but neither of the 2 with stage II / III disease, mobilised tumour cells.
Although there is little doubt that cancer cells do mobilise along with PBPC, it is
difficult to be certain of the patterns of mobilisation on the basis of this study owing
to the small number ofpatients involved.
Using ultra-sensitive detection technologies, various authors have correlated clinical
outcome with the presence ofgraft contamination. Using culture assays Sharp et al
(1992) demonstrated 6/32 (18.7%) breast and solid tumour patients had
contaminated PBPC, and 4 of these patients had very short survival times, while
culture negative patients had a more favourable prognosis. The exquisitely sensitive
(1:107 MNC) cytokeratin 19 RT-PCR of Fields et al (1996) showed an increasing
likelihood ofmarrow MRD with advancing stage following initial chemotherapy: 52%
for high risk stage II, 57% for stage III and 82% for stage IV. BM was used as
haematopoietic support and survival benefit was demonstrated for stage IV patients in
whom those positive for marrow MRD had a probability of relapse at 3 years of 94%
versus 14% for those who were MRD negative. Although the corresponding figures
of 32% and 10% did not reach statistical significance for stage II / III disease,
Vredenburgh et al (1997) found, using ICC with 4 monoclonal antibodies (Moab),
that in this group (> 10 axillary nodes) disease-free and OS are also compromised in
those with marrow MRD, and the larger the number of contaminating cells, the worse
the prognosis.
1.2,3 METHODOLOGIES OF MRD DETECTION
Table 1.2 is a compilation of several studies using various methods to detect MRD in
breast cancer, also illustrating the reported sensitivities for each technique and some
data on detection rate and the quantity ofmalignant cells detected. There are 3 broad
groups of techniques used (Pantel et al, 1994a; Ross, 1998):
(1) Moab-based methods. ICC, which has been the gold standard ofMRD detection,
employs one or a cocktail ofMoabs to stain cells cytospun onto a glass slide, and the
signal amplified and visualised by an APAAP or immunoperoxidase technique. These
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Moabs are directed against surface membrane antigens, typically the cytokeratin
family of proteins found on epithelial cells. Immunofluorescence is based on the same
principle except the Moabs used are conjugated to a fluorochrome which can be
directly visualised with a fluorescent microscope without further staining / counter-
staining. Moab labelled cells may also be visualised by flow cytometry (FACS
scanning), with the main advantage of being much less labour-intensive and a large
number of cells may be analysed rapidly. Specificity ofMoab's may vary (Thor et al,
1988), and cocktails ofMoab's are often used (Ross et al, 1993 and 1995).
(2) Clonogenic / culture methods. These are the only assays that directly demonstrate
the clonogenic potential of contaminating cancer cells, but are time-consuming.
Culture may be performed in a liquid medium (Sharp et al, 1992 and 1995b) or a soft-
agar based medium containing recombinant growth factors and serum (Ross et al,
1993). After cell culture, tumour cells are visualised by ICC. Some authors have
reported extraordinary sensitivities with culture techniques, e.g., 1:103 before culture
and 1:107 after culture (Joshi et al, 1990), and the presence ofMRD correlated with
poorer clinical outcome (Sharp et al, 1992).
(3) PCR-based methods. The majority of these methods are based on amplifying the
epithelial cell-specific cytokeratin 19 (CK19) mRNA message by RT-PCR. The
primers used vary between studies, but most include a nested system plus Southern
hybridisation using an internal probe to maximise sensitivity, often in the region of
1:106 - 107 (Fields et al, 1996; Traystman et al, 1997). Gerhard et al (1994) used
carcinoembryonic antigen (CEA) as a marker, and reported a sensitivity of 1:2-5xl07
which is the highest yet reported, although the authors did caution the possibility of
over-estimation.
14







































































































22.9/105 0.8/10s 1-62/ltf 6/2.x106 1-97/l(f
ICC-immunocytochemistry;M ab-monoclonala tib dies;MNC-( mal)m nonuclearc ls;T A-umourclonogcnicas ay;BM-b nemarrow;PBPC-peripheralbloodprog nitorc lls;FACS-flu r scentactivatedllsorting;K-cytokcratin;EMA-epithelialmembr nean gen.



















































CEA-carcinoembryonicantigen:RT-PCR-reversetranscriptasepolym raseh ine ction:IME-immunomagneticenrichment.
1.3 MINIMAL RESIDUAL DISEASE DETECTION IN ACUTE
LEUKAEMIAS
The techniques involved in detecting MRD in acute leukaemias are totally different
from those for breast or epithelial cancers, owing to their different surface markers
and molecular genetic characteristics. Whilst epithelial characteristics such as
cytokeratin 19 are not expressed in haematopoietic tissues and can be used as markers
for breast cancer, leukaemias are of haematopoietic origin and share certain
characteristics with normal haematopoietic progenitors, and it is essential that
techniques for their detection employ features that are not shared and are able to
differentiate between these populations. MRD in leukaemias have also been more
extensively reviewed than for breast cancer (Campana and Pui, 1995; Lin and Cross,
1995). Most of the literature focuses on acute lymphoblastic leukaemia (ALL) in
children, simply because various distinct molecular markers are available in this
disease, enabling approximately 90% of cases to be studied (Campana and Pui, 1995;
Steward et al, 1995), and ALL occurs predominantly in childhood. The same
approaches cannot be used for AML, because as a whole, they lack consistent
molecular and surface markers that can be use to distinguish disease from normal
tissues. As a result MRD in AML is still not satisfactorily or as extensively studied.
The body of literature on aspects ofMRD in acute leukaemias is much more extensive
than that for breast cancer, and a detailed review is beyond the scope of this
Introduction. Here, some of the techniques available will be outlined.
1.3.1 MRD DETECTION IN ALL
Detection ofMRD in ALL is generally focused on using molecular markers which
reflect the lineage origin of the leukaemic progenitor cells. T-cell receptor (TCR) gene
rearrangements and immunoglobulin heavy chain (IgH) gene rearrangements are most
often used (Deane and Norton, 1990). The rationale in using these markers lies in the
fact that rearranged genes for a particular clone of cells is unique to that clone,
ensuring specificity, and also the incidence of detecting a rearrangement is high,
making it possible for a molecular marker to be found in the great majority of cases.
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In normal lymphoid maturation, these genes comprise 3 discontinuous germline
segments, named variable, diversity and joining segments (V, D, J segments). IgH
genes also contain a CH segment which specify the particular class of immunoglobulin
(ie. IgA, D, E, G or M). Different TCR (a, P, y, 6) and IgH loci have different
numbers ofV, D and J segments. For example, the IgH locus on chromosome 14q
contains 86 V, 30 D and 9 J gene segments (Strachan and Read, 1997). On the other
hand, TCR y and 5 loci contain 0 and 3 D segments, respectively. Each lymphoid cell
is committed to produce only one type of IgH or TCR, and during maturation, these
segments are juxtaposed by splicing of the intervening sequences at the DNA level,
and at the same time, non-template derived nucleotides (known as N regions) are
inserted between V and D, and between D and J segments. Because the large numbers
ofgene segments for the V, D and J regions, the possible combinations of these
segments as a result ofDNA splicing is huge. In a normal lymphoid population,
different gene rearrangements within individual cells mean that, as a whole, the
molecular repertoire is a mosaic. In a leukaemic population, however, the clonal
nature of the cells means that all the leukaemic blasts will have the same
rearrangement. This characteristic may be detected by PCR using primers that span
the rearranged junctions, and produce a single product seen as a single band on
polyacrylamide gel electrophoresis. This contrasts with a normal lymphoid population,
in which PCR will result in a polyclonal smear plus one or two faint bands
representing unrearranged germline configurations in immunologically naive cells.
IgH, TCR5, TCRy and TCRP genes may be found to be rearranged, respectively, in
95%, 54%, 55% and 33% ofB-lineage ALL, and 14%, 68%, 91% and 89% of T-
lineage ALL (Campana and Pui, 1995). Hence it is possible to study the majority of
cases ofALL with these markers. In general, for B-lineage ALL, IgH gene markers
are most often used, and for T-lineage ALL, TCR y and 5 genes, which cover
approximately 90% of cases (Cave et al, 1994).
In the IgH gene, Vh segments may be further grouped into 3 conserved framework
(FR) regions, and 3 hypervariable 'complementarity-determining regions' (CDR).
Clonal IgH rearrangement may be detected using PCR primers corresponding to
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different Vh segments, in conjunction with a consensus Jh segment primer. Owen et al
(1995) used a combination of a consensus FR3 as well as 6 CDR1 primers, visualised
using a fluorescence based system, and reported a sensitivity of one ALL cell in 103 -
104 normal cells with FR3 PCR and a higher sensitivity by up to 1 log with CDR1
PCR. In general, the combination ofPCR analysis of gene rearrangements with
Southern blotting using clonospecific probes provide the highest sensitivity, possibly
capable of detecting one leukaemic cell in up to 106 normal cells, but probably more
reliably 104 or 103 cells (Bartram, 1993; Ouspenskaia et al, 1995).
Clonal evolution during the course of disease may be a potential problem, leading to
false negative MRD detection. However, the incidence of this is relatively low and
false negative results may be minimised by using a combination ofmarkers. Steward
et al (1994) found only 3 patients out of 52 studied had complete change in pattern of
amplification between presentation and first relapse, despite the fact that some change
was observed in 31% of cases with an IgH marker and 25% with a TCR5 marker at
presentation.
The clinical relevance ofMRD detection in childhood ALL is now in little doubt, and
several recent publications highlight the prognostic implications. Cave et al (1998)
used ICR y and 5, and IgH rearrangements plus clonospecific probes with a detection
sensitivity of 1 cell in 2xl04 normal cells, to study 178 patients within 6 months of
complete remission and were able to assign patients to risk groups with respect to
MRD. At the end of induction chemotherapy, those whose marrow contained > 1
residual blast in 100 had a relative risk of relapse 16 times higher than those with < 1
blast in 1000. When assessed at 3 later time points, 'standard risk' patients had a
significantly shorter time to relapse if they contained detectable MRD, and particularly
ifmore than 1 blast in 1000 (>15 times higher risk). In reverse, Goulden et al (1998)
reported that in standard risk patients who ultimately relapsed, a much higher
incidence ofMRD was detected at 1, 3, and 5 months into therapy, compared with
those remaining in CR in whom all had cleared MRD from the marrow by 5 months.
In the context of allogeneic BMT for ALL, Knechtli et al (1998) studied 71 children
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using IgH and TCR rearrangements plus clonospecific probes, with a sensitivity of at
least 1 in 104 cells. A significantly higher incidence ofMRD (88%) was detected in a
group of 32 patients who subsequently relapsed, when compared with 36 patients
who remained in continuing CR in whom only 22% had MRD at any time after BMT.
In the former group, more than half had detectable MRD at all times, and the
remainder were initially negative but became positive at a median of 3 months. The
authors concluded that any evidence at all ofMRD after allogeneic BMT is a poor
prognostic sign. This finding is supported by others who used immunological
techniques for MRD detection with comparable sensitivity (Coustan-Smith et al,
1998).
Other molecular approaches are available, although, as indicated in the review by
Campana and Pui (1995), candidate markers are very rare amongst ALL cases, except
perhaps for deletion of the TALI gene from chromosome 1 in T-lineage ALL (up to
30%). As in AML, flow cytometry has also been studied, but the general applicability
in a cross-section of cases is low, except in T-ALL in which the (extra-thymic) co-
expression of terminal deoxynucleotide transferase (TdT) and T cell markers such as
CD3 and CD5 on blasts in the majority of cases may serve as a marker. The generally
accepted level of detection using flow cytometry is in the order of 1 cell in 104 (Lin
and Cross, 1995; Coustan-Smith et al, 1998).
Yet another approach may be to use a combination of flow cytometry, cell sorting and
colony-forming assay. Uckun et al (1993) studied the pre-transplant leukaemia burden
in 83 patients with ALL with this technique, which has a detection sensitivity in the
region of 5 in 105 cells. Not only does this technique provide functional information
on the clonogenic ability of any leukaemic cell detected, the authors also
demonstrated prognostic relevance in that patients with greater than 51 leukaemic
cells per 106 MNCs in the BM just prior to transplantation were 3.5 times more likely
to relapse than patients with lower burdens. The obvious disadvantage of this
technique is the multi-step nature and the need for cell culture.
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1 3 2 MRP DETECTION IN AML
MRD studies in AML is much less clearly defined than for ALL, largely because of
the lack of consistent molecular markers in the majority of cases. Nevertheless, a
range of techniques are available (Sievers and Loken, 1995). The most commonly
used markers are certain unique chromosomal translocations resulting in juxtaposition
of known genes, but unlike receptor and IgH markers for ALL, only a minority of
cases ofAML have such available markers. All these markers, when present, can be
detected using RT-PCR. In acute promyelocytoic leukaemia (FAB M3),
t( 15; 17)(q22;q 11-22) results in the PML-RARa fusion transcript which can be
detected using RT-PCR (Miller et al, 1993). Again, favourable clinical outcome is
reported to be associated with molecular negativity after treatment. Eleven of 13
patients with BM RT-PCR positivity 4 months after clinical remission relapsed 1 to 4
months later, whilst all 22 patients who were negative at 4 months remained in CR 3
months to 5 years later (Lo Coco et al, 1992). This molecular marker has also been
used to demonstrate the possibility that MRD in BM may be too low to be detected
even with RT-PCR, but may reach detection level after enrichment by PBPC
apheresis, as found in a patient who had been marrow RT-PCR negative for 20
months (Karlic et al, 1995). The t(8;21)(q22;q22) translocation is characteristic of
AML FAB M2, and results in the AML1-ETO fusion gene. The clinical significance
of detecting this transcript in patients in remission is less clear, and patients in
continuing remission may often be found to contain the transcript, and it has been
hypothesised that t(8;21) is an early step in leukaemogenesis, but insufficient in
leading to frank leukaemia which may require other genetic changes (Sievers and
Loken, 1995). AML FAB M4-Eo, associated with an eosinophilic predominance is
associated cytogenetically with inv(16)(pl3q22) which results in the CBF(3-MYH11
transcript. Again, patients in continuing remission have been found to be positive for
the transcript, throwing into doubt the clinical usefulness of this assay (Poirel et al,
1995).
Flow cytometric techniques have been used in determining MRD in AML. Many
AML blast cells aberrantly express antigens such as terminal deoxynucleotide
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transferase (TdT) or CD7, antigens associated with early lymphoid, especially T cell,
differentiation. One early study reported 19.1% and 9.8% expression, respectively, of
these antigens co-expressed with myeloid markers in AML (Campana et al, 1990), but
this technique obviously lacks universal application. A more detailed study of the
patterns of aberrant antigen expressioin in AML by Terstappen et al (1991)
demonstrated 4 different categories, covering the majority of cells, thus potentially
allowing most patients to be studied. Features identified here include expression of
non-myeloid antigens, asynchronous expression of myeloid antigens (representing
different stages of maturation), and over- or non-expression ofmyeloid antigens.
Subsequently, another study reported the identification of aberrant phenotypes in 85%
of AML blasts, using a panel of 22 Moab's and multi-parameter flow cytometry
(Reading et al, 1993). Significant correlation between cytogenetic abnormalities and
coexpression of surface antigens was also noted. When 16 AML patients in remission
were studied, aberrant expression of antigens reflecting residual leukaemia was found
to the proporton of 0.03 - 1.4% of nucleated BM cells. Quantification of the residual
blasts enabled the authors to attach some prognostic value to their MRD analysis, as
all of 6 patients with more than 0.2% of cells with aberrant expression relapsed within
1-7 months, in contrast to 9 of 10 patients with less than this number remaining in
remission. The follow-up was short, however. Although seeding experiments were not
reported by these authors to determine the sensitivity of detection, this is illustrated by
the detection down to 0.03%, equivalent to 3 AML cells in 104 normal cells, a level
comparable to other technologies. The need for so many Moab's to achieve the 85%
applicability obviously limits the general usefulness of this approach.
Other techniques have been studied in AML, including fluorescent in-situ
hybridisation (FISH) which is increasingly used in routine diagnostic service.
However, the sensitivity of this is only in the region of 1%, making it unsuitable of
ultra-sensitive detection ofMRD. The sensitivity of FISH is mainly hampered by the
presence of background non-leukaemic aneuploid cells, the potential total number of
cells that can be studied, and technical artefacts (Gray et al, 1990). The additional step
of short-term culture is another requirement.
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1.4 THE p53 TUMOUR SUPPRESSOR GENE
1.4 1 p53 BIOLOGY
1411 INTRODUCTION
p53 is a 53 kDa nuclear phosphoprotein which, since its original description in the
1970's, has emerged as having a vital role in the regulation of the cell cycle,
implicated in DNA repair, cell differentiation, genome plasticity and apoptosis
(programmed cell death). Over the years it has been extensively studied, and the gene
controlling it is now known to be a major tumour suppressor gene, and is the single
most frequently mutated gene in human cancers. The p53 protein was first described
in 1979 by groups using 2 different experimental approaches: virological (Lane et al,
1979) and serogical (DeLeo et al, 1979). The former approach, which is better
known, demonstrated that, in simian virus-40 (SV-40) transformed hamster or mouse
fibroblasts, the SV-40 large T antigen (AgT) co-precipitated immunologically (using
monoclonal antibody Pab419) with a 53 kDa cellular protein. As this protein was
demonstrated to accumulate in the nuclei of various virus transformed cell lines as
well as chemically-induced tumours (DeLeo et al, 1979) but not in normal cells, it was
felt likely to be an oncoprotein and associated with malignant transformation. An
extensive body of literature followed over the ensuing years, first pointing to p53
being associated with cellular proliferation and tumour formation, and then others
demonstrated the opposite and hinted that p53 might actually have anti-tumour
effects.
14.12 p53 AND CELLULAR PROLIFERATION - AN ONCOGENE?
Various evidence suggested that p53 was required for progression of the cell cycle.
First, an increased p53 mRNA transcript and protein synthesis in induced murine
Swiss 3T3 cells, maximally at the late Gl/S phase junction prior to DNA replication,
was found, suggesting a role for p53 in the progression of cells from a growth-
arrested to an actively dividing state (Reich et al, 1984). Mercer et al (1984)
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performed microinjection ofMoab's against p53 (Pabl22 and 200-47) into the nuclei
of quiescent 3T3 cells and found that entry of the cells into S phase was inhibited if
given at the time of serum stimulation ofDNA synthesis, but no inhibition was
observed ifgiven at other times, and the progression through G1 was not inhibited.
The authors concluded that there appeared to be a role for p53 in the transition of
cells from a resting to a growing stage. The various pieces of evidence taken together
suggested that p53 was a positive cell cycle regulator. Other evidence to implicate
p53 as an oncogene includes the finding of a cooperation between p53 and an
activated H-ras oncogene in cellular transformation (Eliyahu et al, 1984). Later
studies, however, provided much evidence to suggest that wild-type p53 had, in fact,
anti-proliferative properties.
1.4.1.3 p53 AND CELL CYCLE NEGATIVE REGULATION - A TUMOUR
SUPPRESSOR GENE?
Mowat et al (1985) studied spleen cells obtained from mice in whom
erythroleukaemia was induced by the Friend erythroleukaemia virus, and found that
the provirus genome was integrated into the p53 gene, causing rearrangement of the
latter and expression of a truncated p53 protein or its total absence. Another example
is the finding of a mutated p53 gene leading to a 46 kDa truncated protein in a similar
erythroleukaemia cell line (Munroe et al, 1988). The authors reported that the
deletion, in exons 7 and 8, involved a highly conserved and therefore functionally
important region of the gene. When other groups demonstrated that, in such
situations, the second allele was usually deleted, it appeared that p53 loss conferred a
growth advantage to these malignant cells. Two further important pieces of evidence
came separately in 1989. Finlay et al (1989) reported that DNA clones ofwild type
p53, co-transfected either with a combination of activated oncogenes like ElA and
ras, or ofmutant p53 and ras, inhibited the ability of such oncogenes to transform rat
embryo fibroblasts. Most of the ones that did transform, even though they contained
p53 in their genome, failed to express the protein; and the cell lines that did express
p53 had the mutant conformation. Eliyahu et al (1989) confirmed these findings and
also found that plasmids carrying mutant p53 totally failed to inhibit oncogene-
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induced transformation and often even slightly stimulated it. These effects were more
marked in early-passage rather than established tumour cells, suggesting a role for
mutant p53 in tumourigenesis. p53 was therefore becoming established as a tumour
suppressor gene.
1.4.1.4 p53 PROTEIN STRUCTURE
Three separate structural regions of p53 are recognised: the amino and carboxy
terminals and the central region. The amino terminal contains acidic residues and is
proline-rich. It is the transcriptional transactivator domain, amino acids 20 - 42 being
functionally most important. It is the binding site ofmany viral and cellular proteins
including the EIB protein from adenovirus type 5 and the murine double minute 2
(MDM2) protein which is an up-stream regulator of p53. The carboxy terminal is
hydrophilic and contains the 3 nuclear localisation signals of the p53 protein (Soussi,
1995), mutations ofwhich may render p53 cytoplasmic. Some non-specific and
specific DNA-binding functions have also been assigned to this region. The carboxy
terminal also contains a region required for tetramer formation, and residue 315 which
is the phosphorylation site for cyclin-dependent kinases (cdk), and a role for the latter
in nuclear localisation has been suggested though not proven (Soussi, 1995). The
central region of p53 appears to be the most important functional domain of the
protein. Spanning amino acids 91 to 301, it contains the sequence-specific DNA-
binding domain of p53. By a process of immunoprecipitation and PCR amplification
ofDNA co-precipitated with wild type p53 (El-Deiry et al, 1993; Vogelstein and
Kinzler, 1992), a consensus DNA-binding motif consisting of 2 repeats of a 10 bp
sequence 5'-PuPuPuC(A/T)(T/A)GPyPyPy-3' separated by 0 - 13 bp. Through this
motif, p53 binds to DNA as a tetramer. The central region is also reported to contain
86% ofmutations affecting p53, as well as 4 of the 5 of highly conserved domains of
the protein (Keith and Russell, 1996). The SV-40 AgT also binds to this region.
1.4.1.5 p53 PROTEIN FUNCTION
p53 is a nuclear phosphoprotein which, in wild type conformation, has a very short
half-life of approximately 20 minutes and is not usually detectable in normal cells.
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Mutant p53, however, has a much longer half-life of 24 hours or so, and may be
detected by immunocytochemistry. In normal cells, p53 occurs in the cytoplasm
during G1 phase of the cell cycle, and enters the nucleus during Gl/S transition, until
the end of the G2/M phase. Described as a 'guardian of the genome' (Lane, 1992),
p53 is now known to have a major role in protecting the integrity ofDNA from
damage by arresting the cell cycle in G1 hence enabling DNA repair, or else mediate
apoptosis to prevent continued growth of an abnormal cell. In response to DNA
damage, for example by UV light, radiomimetic drugs (Maltzman et al, 1984), y-
radiation or cytotoxic drugs (Fritsche et al, 1993), G1 arrest is induced by an
elevation of the level of p53 protein, which is in turn mediated by a post-translational
stabilisation mechanism. Several down-stream effectors are recognised to mediate this
process. p53 acts as a transcription factor for these genes. WAF1 is expressed in the
nuclear p21 protein, an inhibitor of cyclin-dependent kinases (cdk) whose normal
association with G1 cyclins allows progression of the cell cycle. Up-regulation of p21
by increased p53 therefore, leads to cycle arrest. GADD45 (growth arrest and DNA
damage-inducible) is also transcriptionally activated by p53 and may be involved in
DNA repair. The murine double minute 2 (MDM2) gene is a cellular proto-oncogene
which is transcriptionally activated by p53, but rather than being a down-stream
effector, is a negative regulator of p53 function, acting in a feed-back loop. It is
proposed that, ifDNA damage is repairable, MDM2 continues to suppress the up-
regulated p53; but if damage is too severe, p53 is so much up-regulated as not be
suppressible by MDM2, and an irreversible apoptotic response ensues (Haines, 1997).
One mechanism by which over-expressed MDM2 is associated with human
malignancies is via its suppressive effect on p53.
As mentioned, p53 may mediate apoptosis in cells whose DNA is too severely
damaged to be repaired. Bax is an apoptosis gene which is up-regulated by p53, in
response to, for example, ionising radiation (Miyashita et al, 1994), and is likely to be
a down-stream effector of apoptosis for p53. On the other hand, the product of the
bcl-2 gene, which has anti-apoptotic effect, may form heterodimers with bax, and the
ratio of the two determines cell survival or death (Oltvai et al, 1993). High levels of
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bcl-2 may inhibit p53-mediated apoptosis (Wang et al, 1993), and in human
malignancies, an inter-relationship between the 3 genes may exist, with p53 loss,
reduced expression of bax and increased expression of bcl-2 (Miyashita et al, 1994).
1 4 2 p53 AND CANCER - GENERAL ASPECTS
The p53 gene is situated within approximately 20 kb ofDNA on the short arm of
chromosome 17, mapped to 17pl3.1. The entire gene contains 11 exons, the first of
which is non-coding and is 8 - 10 kb upstream of exon 2. The remaining exons are
spliced together during transcription to produce an mRNA of 393 codons. Much
effort has been spent in understanding the relationship between biology and function
of p53, and its DNA structure. Of the entire p53 cDNA sequence, 5 regions
(domains) are described to be highly conserved, by comparing sequences across
different species as diverse as humans, mouse and X. Laevis. These 5 domains contain
more than 90% identity between species. 4 of them correspond to the central, DNA
binding region of the p53 protein as described above, while domain I is in the amino
terminal. These are (Soussi et al, 1990; Hollstein et al, 1991):
Domains Codons Exons
I 13 - 19 exon 2
II 117 - 142 exons 4 and 5
III 171 - 181 exon 5
IV 234-258 exon 7
V 270 - 286 exon 8
Fig. 1.1 illustrates the lay-out of the p53 gene, showing the number of bases
associated with each exon and intron. The lower panel maps the conserved domains
to the corresponding exons. Because of the reported high level of conservation, these
domains are likely to be functionally important to the p53 protein, and have been at
the heart of studies of p53 mutations in human cancers. p53 is the most frequently
mutated gene in human cancers. The great majority of p53 mutations associated with
malignancies are somatic mutations, but in certain families with strong histories of
cancers, p53 mutations may occur in the germline, giving rise to the Li-Fraumeni
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Fig 1.1 Layout of p53 gene. E denotes exon and Int denotes intron. The numbers denote the number of bases. The lower
figure represents the conserved domains.
cancer, childhood sarcomas, brain tumours, osteosarcoma, leukaemia and
adrenocortical carcinoma (Harris and Hollstein, 1993; Malkin et al, 1990). They have
a 50% chance of having cancer by the age of 30, and 90% chance by the age of 65,
and this high-lights the crucial role of p53 in keeping check on the cell cycle to
prevent the development of cellular immortality. Mutations of p53 have been found in
most types ofmalignancies, and taken together, the frequency is 45 - 50% of cases
(reviewed in Soussi, 1995), the highest frequency being found in squamous carcinoma
of the oral mucosa (81%), SCLC (70%) and anaplastic thyroid cancer (68%). In
general, mutation of one allele is associated with loss of the second. This implies that
it is the loss of a functional gene product that leads to tumour formation. 95% of
mutations in p53 are found in the hydrophobic central region, and 68% in domains II,
III, IV and V, between codons 117 and 286 (Levine et al, 1991). These mutations are
not randomly distributed and, in particular, 6 hot-spots have been identified in codons
175, 245, 248, 249, 273 and 282, accounting for 30% of all p53 mutations found in
malignancies. Also, 44 codons are relative hot-spots, being arbitrarily defined as
having > 12 reports in the database. Overall about 80% of p53 in human cancers are
missense mutations (Harris and Hollstein, 1993; Greenblatt et al, 1994). These are
results from an extensive study by Greenblatt et al (1994), who compiled a list of
2567 mutations from > 300 papers. From these, of 560 mutations reported in 50
studies in which the entire coding region ofp53 were sequenced, 87% ofmutations
are in exons 5-8, 8% in exon 4 and 4% in exon 10. Because of the concentration of
mutations to these domains of p53, many (ifnot most) mutational studies focus on
exons 5 to 8 of the gene.
As mentioned, loss of heterozygosity (LOH) in which loss of the normal allele is seen
with a mutated one, is often the case in most tumours studied, and is a hallmark of
tumour suppressor genes. LOH at 17p, however, may be found without a p53
mutation, for example in cases ofbreast cancer, and explanations, apart from the fact
that a mutation may exist outside the region of the gene studied, may include the
possibility of another tumour suppressor locus in 17p (Coles et al, 1990). These
authors reported a 58% incidence of allelic loss mapped to 17pl3.3 which is
29
approximately 20 Mb telomeric to p53. From the opposite perspective, Nigro et al
(1989) examined 19 tumours of various histological types with 17p allelic loss, and
only 3 did not have a mutated gene on the other allele.
1.4,3 PROFILES OF p53 MUTATIONS IN HUMAN CANCERS
Mutational spectrum analysis is the study of the numbers, types and locations ofDNA
alterations, and since there can be a great diversity of a combination of these
parameters, spectra may be very different from one type of tumour to the next. These
spectra may describe footprints of specific DNA alterations by endogenous or
exogenous mutagenic processes, and form the basis of the important area of
molecular epidemiology in cancer research (Jones et al, 1991). Hollstein et al (1997)
compiled the most recently updated mutation pattern in the 5 commonest cancers in
the world, based on the European Bioinformatics Institute database, shown in Table
1.3. Of the 6 hot-spot codons, 5 contain CpG dinucleotides (codons 175, 245, 248,
273 and 282). These are endogenous mutagenic sites where the cytosine residue is
methylated and may undergo spontaneous deamination to thymine, resulting in a G:C
> A:T transition. Certain malignancies not known to be related to exogenous
carcinogens, such as colonic cancer, have a particularly high incidence ofmutation at
CpG dinucleotides indicating that these mutations arise from endogenous processes
(Caron deFromentel and Soussi, 1992).
Table 1.3. p53 point mutation pattern in the 5 commonest cancers
Rank Site Total Base Substitutions Substitutions
mutations insertions/ at G:C at A:T (to
deletions to A:T to T:A to C:G T:A,G:Cor
at CnG non-CnG C:G1
1 Lung 437 11% 10% 16% 39% 10% 16%
2 Stomach 146 13% 26% 24% 6% 4% 26%
3 Breast 388 14% 21% 19% 13% 9% 24%
4 Colon/ 369 7% 47% 14% 9% 6% 12%
rectum




Mutational analyses have also revealed associations between various external
carcinogens and particular p53 mutations. The association between hepatocellular
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carcinoma and aflatoxin B1 was realised when a predominance of G:C > T:A
transversions in the third base of codon 249 (Arg to Ser), mainly in countries, such as
Mozambique and Qidong province of China, where the diet involves foods
contaminated by aflatoxin Bl, produced by Aspergillus flavis. The incidence ofG:C >
T:A in HCC in this part ofChina is an overwhelming 95% compared with 26% in
Taiwan and Japan (Greenblatt et al, 1994). This contrast is again high-lighted in
Mozambique with a 50% incidence of this transition in HCC, compared with 10% in
neighbouring countries without aflatoxin B1 but a similar hepatitis B carrier rate,
another risk factor for HCC.
Other examples of exogenous mutagen footprints include the association between
squamous cell skin cancer and UV radiation, in which the hallmark is mutations in
pyrimidine dimers, particularly tandem mutations ofCC > TT (Dumaz et al, 1994),
and G:C > T:A transversions (mainly on non-transcribed strand) in tobacco-related
lung cancers in which bezo(a)pyrene has been implicated.
1.4,4 p53 DATABASES
A number of databases of reports of p53 mutations are available to the scientific
community, the most extensive ofwhich is probably the one deposited in the
European Molecular Biology Laboratory (EMBL) in Heidelberg (Hollstein et al,
1994), which is being intermittently updated. As of April 1997, there were reports of
5867 p53 mutants, and these are openly available on the internet. Also widely
available on the internet is a large database compiled at the Curie Institute, Paris, by
T. Soussi, who regularly updates mutational spectrum analyses on a variety of
malignancies (http://perso.curie.fr/thierry.soussi/p53_database.html). Another
database is that described by De Vries et al (1996) also available through the internet
via EMBL, and contains mutations reported to the English world literature. The
printed publication by these authors contains an abbreviated summary of p53
mutations reported to September 1993, from which I estimated the coverage of
possible p53 mutations by primers used in this project (Section 5.1.4).
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14 5 p53 AND SPORADIC BREAST CANCER
Much work can be found in the literature regarding p53 in sporadic breast cancer,
particularly with respect to the following: incidence of p53 mutations or increased
expression, prognostic value of p53 alterations, and molecular epidemiology. The
incidence of p53 gene mutations in breast cancer is 15 - 40%, and more closely in the
20 - 25% range in most studies. Most studies have used SSCP or DGGE to screen
individual exons, mainly exons 5-8, but some have sequenced the entire coding
region (Bergh et al, 1995). In an up-to-date analysis (Novermber, 1997) by Soussi on
the Curie Institute database (internet, see above) of 869 breast tumours and cell lines,
the key hot-spot codons for mutations are 273, 248, 175 and 245, which together
account for 20.8% of all p53 mutations in breast cancer. Most tumours that contain
mutations have also lost the remaining allele by restriction fragment length
polymorphism (RFLP) analysis (loss of heterozygosity, LOH). Immunocytochemical
(ICC) studies tend to reveal a rather higher incidence of p53 protein accumulation,
but the range is also wide, eg, 22% (Davidoff et al, 1991), 33% (Thorlacius et al,
1995) and 52% in the largest series to date (Allred et al, 1993). ICC and mutation
analysis do not always correlate and reasons may include mutations occurring outwith
the regions screened, or the presence of contaminating normal tissue making mutation
detection difficult. Alternatively, p53 protein accumulation may be due to factors
other than mutations.
p53 alterations (genetic or ICC) have relevance both in tumour biology and in clinical
prognosis. Cattoretti et al (1988) studied 200 primary breast tumours with p53
Moab's Pab421 and Pabl801 and found a significantly higher proliferative index, as
measured by the expression of Ki-67 antigen, in tumours that stained positive. This is
supported by data from Allred et al (1993 ) who measured proliferation in terms of the
percentage of cells in S phase of the cell cycle. p53 alterations are also correlated with
negative oestrogen receptor (ER) and progestogen receptor (PgR) status, suggesting
more advanced disease (Mazars et al, 1992; Andersen et al, 1993; Thorlacius et al,
1995). Various authors have studied the correlation between p53 status and clinical or
pathological parameters. It is apparent that breast tumours containing p53 mutations
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carry adverse prognostic implications and associated with shorter DFS and an
increased risk of relapse (Elledge et al, 1993). Andersen et al (1993), who found 21%
and 22% of 163 tumours positive for mutation (in exon 5 through 8) or ICC,
respectively, performed multivariate analyses, and reported a positive correlation
between p53 mutations and/or positive ICC with positive axillary lymph node status, a
tumour size (T) score of > 1 and invasive ductal histology, all with known adverse
prognostic implications. These authors also performed univariate survival analyses
and found strong negative correlation between p53 alterations and both overall and
DFS. Bergh et al (1995) studied the prognostic implications of p53 mutations
anywhere in the coding sequence. Direct sequencing of tumours from 298
informative patients detected a 21.8% incidence of mutations. Axillary node positive
patients whose tumours had a p53 mutation had significantly shorter survival than if
the tumours were p53 negative. Statistical significance was not achieved in node-
negative patients. p53 alteration as measured by ICC, however, correlated with
survival in node-negative patients in the study of Allred (1993). Another prognostic
variable that emerged from Bergh's study is that tumours whose p53 mutations
occurred in the conserved regions II and V are associated with significantly poorer
OS than those with mutations in other regions. Because of the small numbers these
data must be interpreted with caution, particularly when set again the finding of
Borresen et al (1995) who reported poor prognosis associated with mutations in
sequences more closely related to regions III and IV, the zinc-binding domains L2
(codons 163 - 195) and L3 (codons 236 - 251). To extend their observation on the
clinical relevance of these mutations, the latter authors (Aas et al, 1996) demonstrated
that breast cancer patients harbouring a p53 mutation are much more likely to show
primary resistance to doxorubicin chemotherapy by having progressive disease during
treatment -4/18 patients (22.2%), versus 2/45 (4.4%) patients without mutations.
Also the mutations of 3 of these 4 patients occurred in the L3 domain.
Close scrutiny of the nature of p53 mutations in breast cancer may shed light on its
epidemiology. Although no carcinogen has been conclusively implicated, some
features of the mutation spectrum may suggest involvement of exogenous factors:
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nearly half of mutations are either G:C > T:A transversions, G:C > A:T transitions at
non CpG sites, or A:T > G:C transitions, all with heavy non-transcribed strand bias
(Greenblatt et al, 1994). DNA repair on the non-transcribed strand tends to be slower
than the transcribed strand, and such strand bias tends to indicate DNA damage by
exogenous physical factors. To support this is the observation that breast cancer
incidence increases in Oriental immigrants to America (Ziegler et al, 1993), even
within one generation. When the nature of mutations between different racial and
geographical groups are compared, differences emerge that would suggest the
possibility of different aetiologies in these groups. For example, a high frequency of
G:C > T:A transversions (88%) is observed in a Scottish population (Coles et al,
1992), A:T > G:C transitions (31.2%) in black Americans (Blaszyk et al, 1994), A:T
> T.A tranversions in Austrians, and microdeletions in white Americans (Sommer et
al, 1992a). An exceptionally high incidence (55.5%) of p53 mutations has been
observed in a certain Japanese population (which has a low incidence of breast
cancer), suggesting p53 alterations may be aetiologically important in this group
(Hartmann et al, 1996).
For this project, I have chosen p53 as a marker for MRD studies largely because of
(1) the relatively high incidence ofmutations compared to other candidate genes, (2)
the choice of patients who have come to have PBPC harvesting and transplantation,
or with metastastic disease means that they are already in an adverse prognostic group
and p53 mutations may therefore be more prevalent, and (3) the heterogeneity of
mutations should provide a good system to test the feasibility of using diverse single
base changes as disease markers.
14 6 P53 AND ACUTE LEUKAEMIAS AND MYELODYSPLASIA (MPS)
Much work has also been done to elucidate the relationship between p53 and the
haematological malignancies, in which mutations of this gene are relatively infrequent
except for certain subgroups of disorders. Those in which p53 mutations are relatively
more prevalent are: blast crisis of chronic myeloid leukaemia (CML), Burkitt's
lymphoma or its leukaemic equivalent (L3 sub-type of acute lymphoblastic leukaemia,
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ALL) and Richter's immunoblastic transformation of chronic lymphocytic leukaemia
(CLL). Ofmost haematological malignancies studied, several general conclusions may
be drawn regarding p53 Mutations of p53 are associated with: (1) more advanced-
stage or terminal disease, (2) adverse clinical outcome, and (3) resistance to cytotoxic
chemotherapy. Here, I shall describe what is known in the acute leukaemias and
MDS, as relevant to the cohort of patients that I am studying in this project. Table
1.4 illustrates results from some of the studies on these disorders. In AML, the
incidence of p53 mutations is usually less than 10%, but evidence suggests that these
are much more frequent in relapsed disease than at presentation. Zhu et al (1996)
found 10 mutations of 31 samples (32.3%) at relapse, whilst when diagnostic samples
from 8 of these patients were evaluated, only 3 were positive. The use ofmore
sensitive allele-specific PCR methods demonstrated that a minority clone was present
at diagnosis in some of these patients, indicating that the p53 mutation containing
cells had undergone clonal evolution to become the majority clone, allowing them to
be demonstrated by single strand conformation polymorphism (SSCP) (with
sensitivity of 5 - 10%). The same observation was made by Hsiao et al (1994) in T
cell ALL. None of 15 samples at diagnosis had a p53 mutation, but mutations were
demonstrable in 10 of 38 samples (28%) at relapse. In this series, 6 patients from
whom relapse samples were available also had diagnostic samples, and in 3 of these, a
missense mutation was present only in the relapse sample, indicating that relapse had
arisen with the presence of a p53 mutation. The fact that CML blast crisis and
Richter's syndrome have higher frequencies of p53 mutations emphasises the fact that
such genetic changes are hallmarks of aggressive disease. In a landmark paper, Wattel
et al (1994) set out clearly some of the prognostic and biological implication of
various haematological malignancies containing p53 mutations. In AML, 3/9 (33%)
of cases with mutations achieved complete remission (CR) when treated by intensive
anthracycline-cytosine arabinoside base regimens, compared to 66 / 81 (81%) of the
non-mutated cases. Likewise, for patients treated by low dose cytosine arabinoside,
CR rate was also lower for the mutated patients - 0 / 5 - compared to non-mutated
ones -3/6 (50%), although just failing to achieve significance (p=0.06).





































































































































































the mutated group (2.5 months) was highly significant. Similar trends were observed
in MDS patients. When all chemotherapy and remission status (CR and partial
remission (PR)) were taken together, response rate was 1/13 (8%) for the mutated
group versus 23 /38 (60%) of the non-mutated group. One argument against these
observations is that the p53 mutated patients were significantly more likely to have
complex cytogenetic abnormalities, which could have been the cause of the adverse
prognosis. The authors argued, however, that the role ofDNA repair ofwild type p53
would be lost with mutations, which in turn, could have contributed to the other
genetic and cytogenetic abnormalities rather than being the results of them. Activation
of the multidrug resistance (mdrl) gene promotor by mutant p53 has been reported,
although, at least in MDS, has not been proven to be of relevance in the adverse
clinical outcome of these patients (Preudhomme et al, 1993).
p53 may seem an unlikely candidate gene as a marker for MRD detection in acute
leukaemias, given the low incidence, but reports of the more frequent occurance in
relapsed disease (to a level comparable to breast cancer) makes it worth studying, and
may also shed light on the prevalence of the phenomenon of clonal evolution of one
leukaemic clone over another.
1.5 MUTATION DETECTION
The abililty to detect genetic mutations is important in many areas of medicine and
biology. This is only likely to become increasingly important as the rate of
identification and characterisation of genes that cause inherited diseases in man gains
momentum, and more and more mutations are identified in particular genes. More
importantly this trend will be fuelled further by the Human Genome Project. Cancer
genetics and the molecular biology of cancer is another area where there is a huge
amount of interest, and with the increasingly central role molecular biology is playing
in the diagnosis, detection of residual disease, and sometime treatment of these
diseases, to be able to detect both unknown and previously described mutations has
now become essential rather than being a luxury for the research laboratory. For these
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reasons, a number of techniques have emerged over the last decade or so, that enable
mutations to be detected or screened more readily. Prior to this era, it was only
possible to screen for gross genetic lesions such as deletions, insertions and
rearrangements by Southern blotting or RFLP's. RFLP's, although a powerful
technique, however, are often limited by the fact that many mutations known to cause
human diseases do not lead to alterations in restriction enzyme cleavage sites (for
example (3-thalassaemias) or that long stretches of the genome may be devoid of
polymorphisms, making it unsuitable for the study of these. The real 'dawn' of the
mutation detection era when small alterations, for example single base changes, came
in 1985 when two independent methods were described for the detection of
previously unknown mutations: denaturing gradient gel electrophoresis (DGGE) and
RNase cleavage ofmismatched heteroduplexes. Since this time, a host of other
technique have been described by workers in the West and in Japan. Examples are
chemical cleavage of mismatch (CCM), single-strand conformation polymorphism
(SSCP), heteroduplex analysis (HA), carbodiimide chemical modification of mismatch
(CDI), and variations of some of the above, such as dideoxy finger printing (ddF) and
constant denaturant gel electrophoresis (CDGE). To enable more efficient detection
ofmutations by these techniques, specially designed apparatuses, improved
polyacrylamide gels (e.g. the Hydrolink MDE), and computer software to help
determine DNA fragment melting characteristics and design primers for the
polymerase chain reaction (PCR) have become available over the last few years. Apart
from unknown mutations, methods are available also to screen for previously
described mutations. All these out-lined methods have been revolutionised by the
advent of the PCR.
This review will concentrate on the 2 main techniques in this project, namely DGGE
and the amplification refractory mutation system (ARMS), and other available
technologies will be touched on. It will be divided broadly into methods used for
screening unknown mutations in a DNA fragment, and those which screen and detect
previously described mutations.
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15.1 DENATURING GRADIENT GEL ELECTROPHOESIS (DGGE)
DGGE was one of the first techniques to be introduced to allow the detection of
single base changes within DNA fragments, described by Fischer and Lerman in
1983, who with Fischer published their studies on the theoretical basis ofDGGE two
years previously.
1.5.1.1 PRINCIPLE
DGGE distinguishes DNA fragments of identical size and differ only in changes as
small as a single base substitution by virtue of the fact that they often have different
melting temperatures (Tm), and migrate differently through a standard polyacrylamide
gel containing a linear increasing gradient of denaturants such as urea and formamide.
Much work was done in the 1970's on the area ofDNA melting, and Fischer and
Lerman (1983) first described their study of using denaturing gradient polyacrylamide
gels to separate DNA fragments differing by single base pair substitutions, and
demonstrated a correlation with predictions made with melting theories. While the
original Fixman melting map only takes into account 2 stability values, one for G.C
and one for A.T base pairs, Lerman and Fischer found the best correlation with the
actual behaviour of X strain DNA fragments in a denaturing gradient gel is by devising
maps using a set of 10 temperature values for a set of 10 nearest-neighbour doublets.
Within a double-stranded DNA fragment in solution, base sequences melt not
individually but in blocks known as domains, which are characteristically between 25
and several hundred base pairs in length. Adjacent domains may have very different
Tm's and have sharply defined borders. DNA fragments from 100 to 1,000 base pairs
usually have between 2 and 5 domains, with Tm of approximately 65 - 80°C. Within
the DNA double helix, stacking interactions between bases contribute greatly to its
thermodynamic stability, help maintain the fragment in a helical form, and contribute
more energy to stabilisation than hydrogen bonds that link complementary bases in
opposing strands. The degree of stacking, and hence the Tm of a fragment, is
determined by the order in which the bases are arranged in a strand. Small changes,
even single base substitutions, can alter stacking interactions sufficiently to change the
Tm by 1°C. These differences in Tm may be translated into different migration
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patterns between wild type and single-base mutated DNA fragments on a
polyacrylamide gel with a linear gradient of denaturants. The electrophoretic
apparatus is set at a high temperature but below the Tm of the domain to be studied.
The polyacrylamide gel is standard, and contains a cross-linker, polymerisation
initiated by the addition of 10% ammonium persulphate and N,N,N,N'-
tetramethylethylenediamine (TEMED), but contains a linear gradient of urea and
formamide from top to bottom of the gel. As a DNA fragment, e.g. in the form of a
PCR product, is electrophoresed, at some point down the gel it encounters a
concentration of denaturant which, in addition to the high temperature, causes the
double-stranded domain with the lowest Tm within that fragment to melt and the 2
strands to separate. Owing to the fact that the adjacent domain still remains double-
stranded, the molecule assumes a Y-shape as the first domain 'forks'. Mobility of this
entire fragment through acrylamide is then dramatically slowed down. Indeed, further
migration is often neglible and the band tends to be sharply focused as a result of this
mobility arrest. Mutant DNA fragments melt at a slightly different denaturant
concentration to wild type, and produce bands on the gel at different levels, enabling
them to be identified. Fig. 1.2 illustrates the principle ofDGGE.
1.5.12 USE OF GC-CLAMPS
DGGE is therefore able to examine DNA fragments with a minimum of 2 domains.
When the domain with the highest Tm within that fragment melts, single strands will
result which are able to migrate through the gel with ease and mutant and wild type
sequences can no longer be seperated. For a standard PCR product, therefore,
mutations within the highest melting domain cannot be screened. In general,
approximately 50% of single-base changes in DNA fragments ranging from 50 to
1000 bp can be detected (Sheffield et. al., 1989). Myers et al (1985a) attached a 300
bp GC-rich (80% GC) DNA fragment to the sequence studied, and found that nearly
all single-base substitutions can be detected (Myers et al, 1985b). With the advent of
PCR, this technique was made much easier (Sheffield et al, 1989). During PCR this
region is also amplified, and the resulting PCR product contains a double-stranded










shaded area represents 40bp GC-clamp
open circle represents WT base
closed circle represents point mutation
Fig. 1.2 Schematic diagram of the principle of DGGE.
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GC-rich region (GC-clamp) predictably has a much higher Tm than the rest of the
product, such that it remains double-stranded throughout DGGE and enables the
whole of the original fragment to be studied. The application of GC clamps enables
the sensistivity of detection to increase from 40% to approximately 95% (Myers et al,
1985b). Further refinement suggested that a clamp as short as 30 bp would suffice
(Myers et al, 1989), but most authors would now probably use a 40 bp clamp.
1513 PCR PRIMER DESIGN
Although DGGE is able to study DNA fragments up to approximately 1 kb in length,
100-500 bp fragments are optimal (Myers et al, 1988). The main reasons are that the
longer the fragment, the lower the resolution between mutant and wild type, and the
electrophoretic times involved are too long to be practical. Longer fragments should
be screened in separate sections, each with a GC-clamp added during PCR. Although
the Tm of the GC-clamp is likely to be higher than the rest of the fragment, primers
should not be selected at random, and there are means to predict the melting
behaviour ofDNA fragments based on nucleotide sequences such that the best
sequence to be studied and hence the best primers to produce it can be determined.
Primers should be 20 - 25 bp, with at least 50% GC and not contain indirectly
repeated sequences (Myers et al, 1989). Computer programmes that help determine
melting behaviours ofDNA fragments are available (e,g, MacMelt, Melt87, SQHTX)
and plot the Tm at each base pair position against the bp number from the end of the
fragment. Some can translate this Tm data into differences in migration on a gel.
Ideally the Tm of the domains studied should be as far below that of the GC-clamp as
possible. The optimal length of the GC-clamp is 40 bp. Although shorter clamps may
work with certain DNA fragments, this does not apply to others. The sequence may
be any random GC combinations, and should be 100% GC in content to maximise the
Tm.
1.514 GRADIENT CONCENTRATIONS
It is important to have information on the melting profile of a DNA fragment in order
to design the optimal concentrations of denaturants to use in the gel, in order to
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maximise the separation between mutant and wild type bands. Computer algorithms
such as the programmes mentioned above can be used to determine the Tm's, and the
gradient concentrations calculated as follows. Take a DNA fragment that melts as one
domain, with the GC-clamp as the second domain. The concentration of the
denaturants in the gel should represent approximately 10°C around the Tm of the first
domain. The conversion factor for Tm and percent denaturant is roughly 1°C for each
3% denaturant. Therefore, for this fragment with a Tm of 75°C (GC-clamp Tm
95°C), the percent denaturant should represent 70 - 80°C, and with the gel heated to
60°C, percent denaturants required is therefore (70-60)x3 = 30% at the top, and (80-
60)x3 = 60% at the bottom of the gel. Although satisfying these theoretical
parameters is likely to produce the best results, this need not always be the case. In
this project, I found that for simplicity, a common gradient of 30 - 80% denaturants
worked well for all the fragments screened.
1.5.15 CONSTANT DENATURANT GEL ELECTROPHORESIS ICDGE)
This variation on DGGE utilises the same principle, except that denaturing conditions
are optimised such that only the concentration of denaturant most likely to cause the
widest seperation between wild type and mutant (Borresen et.al., 1991). This
simplifies the procedure as gradients are not required, and because wild type and
mutant DNA migrate differently from the beginning of electrophoresis, seperation is
likely to be wider.
1.516 TEMPERATURE GRADIENT GEL ELECTROPHORESIS (TGGE)
Again the same principle is applied, except that the gradient is a steadily increasing
temperature rather than a chemical one (Rosenbaum and Reissner, 1987). This has
been applied in the study of mutations of the p53 gene (Ke et.al., 1993), and the
androgen receptor gene (Tincello, 1995).
1.5.2 SINGLE STRAND CONFORMATION POLYMORPHISM (SSCP)
SSCP is currently among the most commonly used screening methods for the
detection of unknown mutations (Orita et al, 1989a and b). It is one of the few
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techniques where single rather than double stranded DNA is examined. The sequence
of interest is amplified by flanking primers in the presence of a 32P labelled
deoxynucleotide triphosphate (dNTP), usually a-32P-dATP or -dCTP, which renders
the PCR product radiolabeled. Samples are then denatured by heating and
immediately electrophoresed in a polyacrylamide gel under non-denaturing conditions.
Migration of single stranded DNA product is highly dependent on their tertiary
structure, and SSCP is said to be able to detect subtle changes caused by as small a
change as a missense mutation. Unlike DGGE which has a sound theoretical basis and
where the melting behaviour ofDNA fragments may be predicted with computer
programmes, no such model is available to predict the three-dimensional structure of
single-stranded DNA. As intra-molecular interactions are important in determining
DNA folding, mobility in the gel is often different even between complementary
strands. Different physical conditions within the polyacrylamide gel, such as
temperature and ionic strength, may affect the precise tertiary structure of single-
stranded DNA, and so the conditions at which electrophoresis is run may need to be
adjusted for each fragment ofDNA studied, and rigidly controlled for reproducibility.
Usually electrophoresis at room temperature with 5-10% glycerol or at 4°C without
glycerol is employed as a starting point. A low level of polyacrylamide cross-linking
(e.g. < 2%) is desirable, and the shorter the fragment ofDNA to be studied the more
sensitive the technique. From analysis of a number of studies using SSCP, mutations
in fragments of less than 200 bp have an over 90% likelihood of being found, and the
figure for fragments of 300 - 350 bp is over 80% (Hayashi and Yandell, 1993). Larger
PCR products may also be studied with SSCP after restriction enzyme digestion and
each product screened separately. Characteristically, DNA containing wild type alleles
gives 2 bands on the gel corresponding to the 2 complementary strands, and mutant
alleles produce bands with different mobility. The total number ofbands in a lane is
not predictable, however, as some fragments may have more than one stable
conformation. Modifications of the original description of SSCP include the use of
non-radiotopic labels and silver-staining which may simplify the technique although
the ultimate sensitivity may be compromised. Sarkar et.al. (1992) described using
DNA-derived RNA for SSCP with the rationale that RNA can assume a larger
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number of conformations than DNA. By comparing the detection rates ofDNA and
RNA-SSCP on a number ofmutated samples, they demonstrated a clear advantage of
the latter (80% vs 59%), although the detection rate of 59% with DNA-SSCP is low.
SSCP remains one of the most commonly used technique in mutation screening
because of its simplicity and the fact that no specialist equipment is required.
1,5,3 CHEMICAL CLEAVAGE OF MISMATCH fCCMl / HYDROXYLAMINE-
OSMIUM TETROXIDE (HOTl TECHNIQUE
This method is based on the observation (Cotton et.al., 1988) that, in double-stranded
DNA, mismatched thymine and cytosine (hence presence ofheteroduplexes) are
particularly sensitive to chemical modification by osmium tetroxide and
hydroxylamine, respectively, and after subsequent cleavage of these fragments by
piperidine, the resulting fragments may be analysed on denaturing polyacrylamide gels
alongside an end-labelled molecular weight marker, so that not only the presence but
also the location of the mutation may be determined. This procedure involves first
preparing a radio-labelled 'probe' which is the 32P end-labelled PCR product of
normal (control) DNA. Mutant DNA is separately amplified by PCR. Heteroduplexes
between mutant and wild type PCR products are produced by boiling them together,
precipitated, the radioactivity determined with a (3-counter and then resuspended in
water to 1,000 cpm/ul. Aliquots are treated separately with hydroxylamine and
osmium tetroxide at 37°C, and cleaved by 1M piperidine at 90°C prior to
electrophoresis in an 8% denaturing polyacrylamide gel. An aberrant band produced
by the cleaved, mismatched fragment is visible. The sensitivity ofCCM is high as all T
and C mismatches are detected. However, because certain GT mismatches are
unreactive to osmium tetroxide, labelling mutant DNA as the probe for hybidisation
with wild type ensures that the mutation is detected by the reciprocal AC mismatch
with hydroxlamine. Apart from the theoretical 100% detection sensitivity, another
advantage ofCCM/HOT is able to screen large DNA fragments, up to 2kb. The major
disadvantages are the need for multiple steps, and the use of toxic chemicals in the
fumehood. Modifications such is non-isotopic labelling may increase its application,
but no other (safer) candidate chemical has thus far been identified to substitute HOT.
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15 4 RNASE A CLEAVAGE OF HETERODUPLEXES
Radio-labelled wild type RNA is heteroduplexed with potentially mutant RNA or
DNA, and cleaved by RNase A. Fragments are separated on a denaturing gel by size
to help locate the site of the mutation. Although a single step is required, preparing an
RNA probe is time-consuming. Detection efficiency is also low as RNase A cleaves
well only at pyrimidines. Using a probe for the complementary strand circumvents this
but creates extra work. Overall sensitivity is about 70% only, accounting for the lack
of appeal.
1.5.5 CARBODIIMIDE (CDI) MODIFICATION
The bulky reagent CDI reacts more rapidly with the imino sites ofmismatched
thymine and guanine bases than with fully matched ones, and such treated
heteroduplexes are refractory to primer extension, and can therefore be detected by
the presence of a smaller than full size product on electrophoresis (Ganguly and
Prockop, 1990). Although only one relatively non-toxic chemical is used, two sets of
incubation conditions are required for complete detection. Apart from the original
laboratory, wide-spread use of this method has not been found. One remarkable
feature, though, is that the largest heteroduplex successfully screened, albeit with the
aid of anti-CDI antibodies and immuno-electron microscopy, is 7.2 kb.
1.5.6 HETERODUPLEX ANALYSIS (HA)
Fleteroduplexes are created during the latter cycles ofPCR when the template
consists of both mutant and wild type species ofDNA. Alternatively, they may be
produced by boiling a mixture ofmutant and wild type PCR products, followed by
slow cooling. They consist of a mutant strand ofDNA annealed onto a wild type
strand, and may be differentiated on a denaturing polyacrylamide gel from
homoduplexes by having different mobilities. The concept ofHA is similar to SSCP
except that double-strands are involved (White et al, 1992; Soto and Sukumar, 1992;
Glavac and Dean, 1995; Prosser, 1993; Cotton, 1993). There is no theoretical basis to
predict the influence of environmental factors such as buffer ionic concentrations and
temperature of electrophoresis, and like SSCP, these also have to be optimised.
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Electrophoretic retardation of heteroduplexes is dependent on the nature of the
mismatch: large insertions or deletions give stable heteroduplexes leading to greater
retardation. Base substitutions, however, create 'bubble'- type heteroduplexes with
looser structures and are less easily discernable. The sensitivity ofmutation detection
by HA is around 80% (Cotton, 1993) and the optimal length of fragment screened is
200-300 bp. HA and SSCP may be used in combination, thus increasing the
sensitivities of the techniques. As heteroduplexes formed between wild type DNA and
single-base-mismatched mutant may be practically undetectable, mixing suspected
mutants with another deletion-mutant before HA renders these samples positive (van
den Akker, et. al., 1992). Thus HA is easy to perform, and although not 100%
sensitive, is a popular technique for mutation detection.
1.5.7 COMPARISON OF TECHNIQUES
Surprisingly few pieces of published work have systematically compared the detection
sensitivity between various techniques. Condie et.al. (1993) compared the efficacy of
SSCP, CDGE and the HOT technique in detecting point mutations of the p53 tumour
suppressor gene. Three laboratories specialised in each of these techniques,
participated, and each sent DNA (9 or 10 mutant, 2-5 normal controls) to the other
two for analysis by their own techniques. SSCP detected 90% ofmutations, CDGE
detected 88% although further optimisation of conditions after the presence of
mutations was known picked up 100%, and HOT detected 100%. This study has been
criticised for its fundamental design flaw ofusing three separate laboratories to test
three different techniques, and using each of the techniques as the basis for labelling a
sample 'positive' to be screened by the other two.
Theophilus et.al. (1989) compared RNase cleavage, CCM and DGGE in screening
mutations in the human acid B-glucosidase gene, responsible for Gaucher's disease.
GC-clamped DGGE emerged as the best of the three, being the only method
successfully detecting the five mutations used. CCM was effective in detecting C
mismatches but high background with osmium tetroxide prevented T mismatches to
be identified. RNase cleavage only picked up 3/5 mutations. One further study
(Moyret et.al., 1994) directly compared SSCP and DGGE in detecting 52 different
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mutation of exons 5-8 of the p53 gene. 100% detection was achieved by DGGE,
compared to 90% by SSCP.
1.5.8 AMPLIFICATION REFRACTORY MUTATION SYSTEM (ARMS)
The detection of known or characterised mutations generally is more straigtforward
that screening unknown ones, and a totally different set of techniques is applied.
These techniques are also more likely to be used for medical diagnostic purposes,
which makes it even more important for them to be highly sensitive as well as specific,
and be simple enough to perform for everyday diagnostic use. Most of these are PCR-
based. ARMS was first described in 1989 (Newton et.al., 1989a) when it was used in
the differentiation of disease carrier status in patients with a1-antitrypsin (AAT)
deficiency with respect to the S and Z loci, each ofwhich differs from normal by a
single base substitution. In general, ARMS employs 2 PCR reactions with one
common primer between them, and the other primer of each pair is specific for each
of the 2 alleles in question. In this way, one can differentiate these genotypes by
observing which reaction with which specific primer produces amplification products.
It is expected that genomic DNA with the opposite allele would not amplify. This
specificity is dependent on the nucleotide at the 3' end of these primers being
complementary to one allele. Taq DNA polymerase is used in these reactions owing
to its lack of a 3' to 5' exonucleolytic proof-reading activity. Enzymes with this
activity are able to recognise mismatches between primer and template, and excise
such mismatches and insert the correct nucleotide, and hence not suitable for ARMS
application.
Primers with one single base mismatch will not necessary fail to amplify, and may
create problems with poor specificity. Newton et.al. (1989a) described the technique
of introducing further deliberate mismatchs near the 3' end of the ARMS primer, and
makes DNA with the opposite allele even more refractory to amplification. The closer
the second mismatch is to the 3' end, the more the annealing is destabilised, and the
less likely for a product to form. Pyrimidine/pyrimidine and purine/purine mismatches
have greater destabilising effect then pyrimidine/purine mismatches. The rank order of
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destabilisation is therefore: CC>CT>GG=AA=AC>GT. Frameshift mutations do not
require such a manoeuvre as any deletion or insertion already produces further
mismatching.
ARMS, also known as allele-specific PCR (ASPCR) and PCR with sequence-specific
primers (PCR-SSP), has found wide application and been used in the prenatal
diagnosis and carrier assignment of cystic fibrosis (Newton et.al., 1989b),
identification of specific strains of bacteria (Lampel et al, 1996; Cebula et al, 1995),
detection of 3 of the common genetic polymorphisms of the apolipoprotein E gene
(Wenham et.al., 1991a), diagnosis of familial defective apolipoprotein B-100
(Wenham et.al., 1991b), diagnosis of sickle cell anaemia (Wu et. al., 1989), HLA
typing of the DR locus (Patel et.al, 1993), and typing of the HPA-1 platelet antigens
(Metcalfe and Waters, 1993). Lo et.al. (1991) also described the 'double ARMS'
technique where 2 allele-specific primers (instead of one allele-specific and one
common) were used to study a highly polymorphic region of the human 5-globin
gene, and found it more sensitive and specific than single ARMS. This was applied in
the detection of chimaerism after allogeneic BMT (Lo et.al., 1993). In cancer
diagnostics, Takeda et.al. (1993) described the application ofARMS (or MASA,
mutant-allele specific amplification) in the detection of Kirsten-ras oncogene
mutations in sputum of lung cancer patients, and this technique was adopted in the
use ofK-ras and p53 gene mutations to detect the presence of sub-microscopic
deposits of colonic cancer in intra-abdominal lymph nodes (Hayashi et.al., 1995). The
authors of the latter study were able to demonstrate survival benefit in patients
without evidence ofMRD as detected by MASA. Althought these authors claimed
that MASA is capable of detecting one tumour cell amongst 'thousands' of normal
cells, they did not present evidence of the precise sensitivity and specificity of their
method.
Other modifications of ARMS have been described, including the introduction of a
new enzyme restriction site near the 3' end (ARMS with restriction enzyme cleavage
or restriction site-generating PCR, RG-PCR). This is achieved by the fact that a
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primer mismatch, not being at the 3' base and therefore allows amplification, may
create a recognition site in one but not the other allele.
In the current project, ARMS is one of the major techniques where tumour tissue
carrying a mutation may be recognised.
1.6 AIMS OF THE PROJECT
Primary aim:
To assess the feasibility of using subtle genetic alterations, e.g., single base changes,
associated with human cancers as markers for the detection of minimal residual
disease (MRD) in peripheral blood progenitor cell (PBPC) harvests. The models used
are the p53 tumour suppressor gene, and patients with breast cancer and acute
leukaemias who have undergone PBPC harvesting / transplantation.
Secondary aims:
(1) To assess the sensitivity and optimisation parameters for a denaturing gradient gel
electrophoresis (DGGE) technique employed for mutation detection, using cell lines
with known p53 mutations.
(2) To determine the incidence of mutations of the p53 gene in primary breast cancers
and acute leukaemias in a local cohort of patients, such that these may be
characterised by sequencing and be used as disease markers.
(3) To determine the optimisation parameters and sensitivity of the amplification
refractory mutation system (ARMS) technique employed in MRD detection, using cell
lines with known p53 mutations.
(4) To determine the incidence ofMRD in PBPC harvests of patients whose tumours
or leukaemic blast cells contain a p53 mutation.
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(5) To correlate, if possible, clinical outcome of patients whose PBPC harvests can be
assessed for MRD.
CHAPTER 2
MUTATION DETECTION AND ANALYSIS
2.1 MUTATION DETECTION - GENERAL METHODS
2 11 SELECTION OF CONTROL CELL LINES AND DNA
As 5 DNA fragments of the p53 gene (covering 4 exons) were screened, at least one
cell line was selected as a positive (mutant) control for each of the fragments.
Information was obtained from the extensive p53 database of the European Molecular
Biology Laboratory (EMBL) housed in Heidelberg, Germany (Hollstein et.al., 1994
and 1996). Negative (wild type) control DNA was extracted from a pool of human
tonsils taken from normal children undergoing tonsilectomy. One human breast cancer
cell line (MCF7) documented to contain wild type p53 sequence in the entire coding
region was also available. The characteristics of positive controls are listed in Table
2.1.
Table 2.1 Characteristics of cell lines known to contain p53 mutations used as positive
controls in this project.


















































As described below, 5637, T47D and Raji cell lines were grown in our laboratory.
DNA from H69, HT-29 and Ovcar-3 were kindly donated by Dr. Hamish Phillips,
Medical Research Council Human Genetics Unit, Edinburgh. DNA from BT-20 was
kindly donated by Dr. Sigrid Lystad, Norwegian Radium Hospital, Oslo, Norway.
Several of the cell lines have documented loss of heterozygosity (LOH) in the allele
concerned, and can be considerd as a pure source ofmutant DNA sequence, and
hence produce only the single mutant homoduplex band on DGGE.
2.1.2 TISSUE CULTURE TECHNIQUES
2.1.2.1 MATERIALS
Iscove's Modified Dulbeco's Medium (IMDM) (Sigma, Poole, UK)
Penicillin/Streptomycin solution (Sigma, Poole, UK)
Gentamicin solution (Sigma, Poole, UK)
Foetal calf serum (FCS) (Sigma, Poole, UK)
L-glutamine (Sigma, Poole, UK)
Hank's Balanced Salt Solution (HBSS) (Sigma, Poole, UK)
Trypsin-EDTA solution (0.25%)
Dimethylsulphoxide (DMSO) (Sigma, Poole, UK)
25cm2 Tissue culture flasks (Costar, High Wycombe, UK)
75cm2 Tissue culture flasks (Costar, High Wycombe, UK)
5637 bladder carcinoma cell line
T47D breast carcinoma cell line (ECACC, Porton Down, UK)
Raji non-Hodgkin lymphoma cell line
2.1.2.2 GENERAL CULTURE METHOD
Of the 7 positive control DNAs for the 4 exons of p53, 3 were obtained from cell lines
cultured during this project, whose p53 genes are documented to contain point
mutations in the relevant exons: exon 8 for 5637, exon 6 for T47D and Raji. 5637 and
Raji cell pellets were already available in our laboratory, stored in the vapour phase of
liquid nitrogen. One viable T47D cell pellet was obtained from the European
Collection ofCell Cultures (ECACC). All 3 cell lines were cultured and propagated,
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excess pellets again stored in liquid nitrogen for future use. During repeated cultures,
a number of flasks were taken out for DNA to be extracted from the cells. The initial
culture was performed in a 25 cm2 tissue culture flask. Optimal culture medium
(OCM) for all 3 cell lines consisted of IMDM with 10% FCS, 1%
penicillin/streptomycin, 0.1% gentamicin, and 1% L-glutamine. The presence of the
antibiotics, penicillin and streptomycin with half-life in culture of 2 to 3 days
prevented infection of the cell culture. Gentamicin, with a longer half-life of 5 days,
was synergistic and covered mycoplasma. A viable cell pellet was taken from liquid
nitrogen storage and thawed in a 37°C water bath. It was washed once with HBSS in
a 15 ml tube by centrifiigation at 1,000 g for 5 min. HBSS supernatant was removed,
the cell pellet resuspended in 1 ml of prepared OCM, and added to a further 9 ml of
OCM in a 25 cm2 culture flask. The lid was loosened 1/4 turn and place in a tissue
culture incubator at 37°C in air with 5% C02. Epithelial carcinoma cells adhered to
the bottom of the flask, spreading along the surface in a single-cell layer. Raji
lymphoma cells grow in suspension. The flasks were checked daily by observing with
a light microscope, and the cells re-plated when either the cells fully covered the flask
surface, or when the medium had acquired an orange colour indicating exhaustion of
essential components. Raji, being non-epithelial and non-adherent, was re-plated
empirically when numbers increased or when the medium changed colour.
2.1.2 3 RE-PLATING OF CELLS
Cells were re-plated to a 75 cm2 flask. Culture medium was poured off, and 5 ml of
HBSS added and left for several minutes at room temperature. The HBSS was then
poured off and 0.5 ml of trypsin-EDTA solution added to strip the cells from the
plastic. After 1 min excess was removed to leave a wet cellular film. The flask was
incubated at 37°C for a few minutes to loosen the cells from the plasticware. With
gentle tapping of the flask, a film of cells could be seen to run down the culture
surface. Two ml ofOCM was then added to resuspend and transferred to a 75 cm2
flask where a further 23 ml ofOCM was introduced. The flask was incubated with the
lid loosened 1/4 turn. Further re-plating was performed in 75 cm2 flasks, by splitting
54
the cells from a fully confluent culture into two. Trypsin-EDTA was not required for
Raji, which was centrifuged and resuspended in OCM.
212 4 CRYOPRESERVATION OF CELLS
From a fully confluent culture in a 75 cm2 flask, cells were stripped from the
plasticware with trypsin-EDTA, washed once in HBSS, resuspended in 1 ml FCS and
split into 2 equal (0.5 ml) portions. 0.5 ml of 10% DMSO was added to each aliquot,
so that the final concentration ofDMSO was 5%. The pellets were frozen in the
vapour phase of liquid nitrogen (-170°C) until required.
2.1 3 DNA EXTRACTION
2.1.3.1 MATERIALS
QIAamp Tissue Kit (Qiagen GmbH, Crawley, UK), each designed for 50 extractions
of up to 25 mg of tissue each, includes the following:
QIAamp spin columns Wash buffer AW
2 ml collection tubes Elution buffer AE
Lysis buffer ATL Proteinase K
Buffer AL
Proteinase K was supplied in lyophilised form, and was reconstituted by added 1.4 ml
of sterile distilled water. This was divided into aliquots and stored frozen at -20°C
until use.
Buffer AL was reconstituted by mixing the 2 components, buffer AL1 and buffer
AL2, and was stable for 1 year stored at room temperature.
40 ml of 100% ethanol was added to the concentrate ofwash buffer AW, which
washed off impurities after DNA binding to the spin column.
100% ethanol (BDH, UK)
Xylene (BDH, Poole, UK)
1.5 ml Eppendorf tubes (Costar, High Wycombe, UK)
50 ml Falcon centrifuge tubes (Costar, High Wycombe, UK)
Red Cell Lysis Solution (RCLS) containing the following:
Ammonium chloride (150 mM)
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Potassium carbonate (6 mM)
Disodium EDTA (10 pM)
2.1 3 2 DNA EXTRACTION FROM PARAFFIN BLOCKS
The Qiagen Tissue Kit was chosen for its simplicity and speed. It used the adsorption
/ elution priniciple where genomic DNA, extracted from cells lysed with proteinase K,
was bound to a silica membrane mounted on a spin column, washed of impurities, and
eluted with a buffer of pH > 9.
Two 15 pm sections of breast tumours cut with a clean microtome blade were placed
in a 1.5 ml Eppendorf tube. Paraffin was first removed by extraction with 1.2 ml of
xylene, and vortexed vigorously to mix. The tube was centrifuged at 16,000 g for 5
min, and the supernatant removed. Care was taken not to remove any of the tissue
pellet as it often remained suspended rather than spun to the bottom of the tube.
Residual xylene was removed by 2 washes with 1.2 ml of ethanol (5 min at 16,000 g).
The opened tube was warmed to 37°C for 15 min to evaporate residual ethanol, and
the tissue pellet resuspended in 180 pi of buffer ATL. 20 pi of proteinase K was
added, mixed thoroughly and incubated at 55°C, with regularly vortexing 2-3 times
per hour, until the tissue was completely lysed. Lysis was often continued over-night
in a water-bath at 37°C. Buffer AL was then added, vortexed and incubated at 70°C
for 10 min. Ethanol (210 pi) was added and vortexed thoroughly. The resulting
extraction mixture (610 pi + tissue) was placed in a QIAamp spin column within a 2
ml collection tube, and centrifuged at 6,000 g for 1 min. Care was taken not to
moisten the rim of the column and to ensure adequate sealing to prevent aerosol
formation. Extracted DNA was now bound to the membrane, and the column was
placed in a clean 2 ml collection tube. Washing was achieved by adding 500 pi of
buffer AW, centrifuging at 6,000 g for 1 min, and repeating this step, with a longer 2
min spin at 16,000 g at the end. Bound DNA, now free of impurities, was eluted twice
with the same 200 pi ofbuffer AE warmed to 70°C, incubated in the spin column for
2 min and centrifuged for 1 min at 16,000 g. The eluate collected in the final
Eppendorf tube contained the purified genomic DNA.
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2.13 3 DNA EXTRACTION FROM HAEMOPOIETIC TISSUES
The procedure for DNA extraction from peripheral blood and PBPC harvests was
similar to the procedure for paraffin sections, and could be performed with the
QIAamp Tissue Kit and proteinase K supplied. The starting material was a washed
cell pellet containing up to 107 cells. A peripheral blood sample of 10 ml, for example,
was transferred to a 50 ml Falcon tube and 40 ml of RCLS added. Red cell lysis was
achieved by gently rotating the tube until a clear red solution was obtained.
Centrifugation was performed at l,000rpm for 5 min, after which the supernatant was
removed. Residual red cells above the cell pellet were lysed by repeating this step
once. The cell pellet was washed with PBS once, resuspended in an empirical small
volume ofPBS, divided into aliquots, placed in 1.5 ml Eppendorf tubes, centrifuged
at 16,000 g in a microfuge for 3 min, and the supernatant removed. The resulting cell
pellet was stored at -80°C until required for DNA extraction. The Qiagen Blood and
Body Fluid Protocol was used. Twenty five microlitres of proteinase K and 200 pi of
buffer were added to the cell pellet and mixed immediately by vortexing for 15
seconds followed by incubation at 70°C for 10 min followed. Ethanol (210 pi) was
then added and vortexed. The sample (435 pi + pellet volume) was transferred to a
QIAamp spin column, and binding, washing and elution steps were as for solid tissues
above. DNA was eluted in 200 pi of buffer AE.
2,1.3.4 MEASUREMENT OF DNA CONCENTRATION
The concentration of extracted DNA was measured with a spectrophotometer with in¬
built ultraviolet lamp (Unicam Helios). Each sample to be measured was diluted 100
fold in distilled water to a total volume of 1 ml. The optical densities (OD) at
wavelength of 260 nm and 280 nm were measured, calibrated against a blank of
distilled water. OD260 is a factor of the amount ofDNA, and OD280 is a factor of
the amount of protein present. The ratio of the 2 values (OD260/OD280) should
ideally be between 1.8 and 2.0. Too high a ratio would suggest the presence of excess
RNA, whilst too low a ratio would suggest excess protein contamination. The DNA
concentration ([DNA]) was calculated as follows:
[DNA] ng/pl = OD260 x 50 x dilution factor (i.e. 100)
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2.1.3.5 DNA STORAGE
Samples whose [DNA] were greater than 100 ng/pil were diluted with sterile distilled
water to this concentration, divided into aliquots, and stored frozen at -20°C until
required. Longer term storage of samples was at -70°C.
2 14 POLYACRYLAMIDE AND AGAROSE GEL ELECTROPHORESIS
2.14,1 MATERIALS
POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
Hoefer SE 600 Electrophoresis Unit, with internal heating unit connected to a water
bath via rubber tubings
Power Pack, max capacity 500 V or 200 mA (Biorad, Hemel Hempstead, UK)
16x18 cm glass plates
1.5 mm spacers
15-well combs
40% Acrylamide solution with 19:1 acrylamide to N,N'-methylene-bisacylamide
(Scotlab, Paisley, UK)
Ammonium persulphate (APS) powder (BDH, Poole, UK)
N,N,N',N'-tetramethylethylenediamine (TEMED) (Sigma, Poole, UK)
20X Tris-Acetate-EDTA (TAE) buffer (per litre containing: Tris base 98.8 gm, glacial
acetic acid 22.84 ml, 0.5 M disodium EDTA (pH 8) 80 ml)
Ethidium bromide (10 mg/ml) (Sigma)
Ultra-violet (UV) light box
AGAROSE GEL ELECTROPHORESIS
Biorad 10x15 cm gel size horizontal electrophoresis tank
Nusieve 3:1 agarose powder (Sigma, Poole, UK)
30-well comb
Power pack




In this project, PAGE was mainly used to confirm the presence or absence ofPCR
products after ARMS reactions (Chapter 3), but was also sometimes used to confirm
or purify PCR products from secondarily amplified mutant homoduplex bands cut
from denaturing gradient gels (Section 2.6). It is described here for completeness. For
sizes ofPCR products relevant to this project, a 6% polyacrylamide gel allowed good
resolution and was routinely used. With the restriction-site-generating PCR (RG-
PCR) approach described in Chapter 4, some of the products were smaller, and gels
ofhigher concentrations were used. Gels were 1.5 mm thick. After diluting 40%
acrylamide solution to 6% and 20X TAE to IX TAE with distilled water, 10% APS
(w/v) solution (70 pi per 10 ml) and TEMED (10 pi per 10 ml) were added to initiate
polymerisation. Gels were left to polymerise for 30 min before use. Three litres of
TAE buffer was used in the lower tank, and 500 ml in the upper tank. The large
volume in the lower tank ensured full immersion of the gels with even temperature
preventing lane distortion at the ends of the gels. After loading of samples,
electrophoresis was carried out at a constant current of 45 mA per gel for 1 hr 15
min. Staining with ethidium bromide (0.1 mg/1) for 20 min was followed by de-
staining in distilled water for 20 min, and gels were viewed under UV light.
AGAROSE GEL ELECTROPHORESIS
Electrophoresis using agarose was performed to confirm PCRs had been successful
prior to analysis of these products by DGGE. High-resolution Nusieve 3:1 agarose
was uniformly dissolved in IX TAE buffer by heating in a microwave oven and
poured onto the platform of a standard Biorad horizontal electrophoresis tank to
approximately 5 mm thick and allowed to set for 30 min with a 30-well comb in situ.
The gel was immersed in IX TAE buffer and, after loading of samples,
electrophoresed at a constant voltage of 100 V for 45 min. Staining and de-staining
with ethidium bromide was carried out for 10 min each, and viewed under UV light.
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2 15 THE POLYMERASE CHAIN REACTION (PCR)
21,51 MATERIALS
Hybaid Omnigene Thermocycler (Hybaid, Life Sciences, Basingstoke, UK)
Deoxynucleotide triphosphates (dNTPs) : 1 OOmM solution of each of dATP, dCTP,
dGTP and dTTP (Promega, Southampton, UK)
Taq DNA Polymerase (5 units / ul) in storage buffer consisting of 50% glycerol,
50mM Tris-HCl (pH 8.0), lOOmM NaCl, O.lmM EDTA, ImM DTT and 1% Triton
X-100 (Promega, Southampton, UK)
10X Reaction buffer: 500mM KC1, lOOmM Tris-HCl (ph 9.0), 1% Triton X-100
(Promega, Southampton, UK)
MgCl2 25mM (Promega, Southampton, UK)
Oligonucleotide primers (Oswel, Southampton, UK). See Table 2.3
Sterile distilled water
Sterile light mineral oil (Sigma, Poole, UK)
Glycerol (Molecular biology grade) (BDH, Poole, UK)
Eppendorf tubes (Costar, High Wycombe, UK)
PCR 0.5ml reaction tubes (Costar, High Wycombe, UK)
21.5.2 PREPARATION OF REAGENTS
The 4 dNTPs were mixed together, in equal volumes, to a concentration of 25 mM.
The mixture was further diluted 1:12.5 to a working concentration of 2 mM.
Oligonulceotide primers were diluted to a working concentration of 2.5 pMol/pl (i.e.
2.5 pM). During hot-start of PCR, Taq DNA polymerase was diluted 1:10 to lU/pl,
to a volume appropriate for the number of reaction tubes.
215 3 p53 EXONS AMPLIFICATION
Five fragments of p53 (fragments A-E), covering 4 hot-spot regions (HSR) in exons 5
to 8, where mutations are most commonly found, were amplified separately with 5
sets of primers (Borresen A-L et.al., 1991). Fragment E was introduced to cover exon
6 which was omitted from Boressen's description. The relationship of each designated
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fragment to the exons and codons is outlined in Table 2.2. The properties of all
primers used in exon amplifications are outlined in Table 2.3.
Table 2.2 Relationship between the designated DNA fragments A - E in this project
and codons and exons of p53.
Fragment Codons Exons
A 124 - 148 5
B m00iinin 5
E 187 - 222 6
C 237 - 253 7
D 264 301 8
Every PCR reaction mixture contained the following: 10X buffer, deoxynucleotide
triphophates (dNTPs), magnesium chloride, a pair of oligonucleotide primers, Taq
DNA polymerase, sterile distilled water, and a DNA template (usually high molecular
weight genomic DNA) or water for 'blank' control reactions. For each set of
reactions in which the same fragment was being amplified, the quantity of each
reagent in each tube was determined, and each volume was multiplied by the number
of tubes plus one (to allow for wastage) to give the volumes required in a 'master
mix'.
e.g. For 9 amplifications of fragment E, a master mix for 10 was made up:
Each tube (ul) Master mix (pi x 101
1OX Buffer 5 50
dNTPs (2mM) 5 50
MgCl2 (25mM) 4 (2 mM) 40
E-GC primer (2.5pM) 5 (12.5 pmol) 50
E-Bio primer (2.5pM) 5 (12.5 pmol) 50
Taq polymerase (0.5U/pl) 2 (1U)
DNA template (lOOng/pl) 3 (300 ng)
Sterile water 21 210
Total volume 50 450
45 pi ofmaster mix was aliquoted to each of 9 reaction tubes, DNA template was
added to each separately, and layered with 45ul of sterile light mineral oil. For hot-
start, reaction mixtures were heated to 94°C and held at this temperature for 7 min
during which all DNA double strands were fully dissociated. Two pi (1 unit) of Taq
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polymerase was then added to each tube and cycling continued. Standard cycling
conditions for exon amplification are based on the 3 step PCR, consisting of a
denaturing step, an annealing step, and an extension step. Based on published data
(Borresen et al, 1991) fragments C-E shared the same cycling conditions, whilst
fragment B required longer denaturing and annealing steps, and fragment A, after
some optimisation, required a higher annealing temperature to produce a clear, clean
product. Table 2.4 outlines cycling conditions for the 5 fragments.
A total of 35 cycles were run. PCR products were kept at 4°C until electrophoresed
to confirm presence of amplification products, or otherwise. Prior to DGGE, 4%
agarose gel electrophoresis was carried out on a 5 pi aliquot of each reaction product
to confirm successful amplification.
Table 2.4 PCR cycling conditions for p53 fragments as defined and used in this
project. For all PCR's, hot-start was performed with the denaturation step of the first
cycle held for 7 min, and the extension step of the final cycle held for 10 min.
Fragment A Fragment B Fragments €,DtE
Denaturing
temperature (°C) 94 94 94
Denaturing
duration (sec) 75 75 45
Annealing
temperature (°C) 59 55 55
Annealing
duration (sec) 75 75 45
Extension
temperature (°C) 72 72 72
Extension
duration (sec) 75 75 45
[Mg] mM 2 1 2
2,1,6 DENATURING GRADIENT GEL ELECTROPHORESIS (DGGE)
21 6.1 MATERIALS
Hoefer SE 600 Electrophoresis Unit, with internal heating unit connected to a water
bath via rubber tubings
Water bath delivering water at 60°C
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Power pack with max capacity 500 V or 200 mA (Gibco, Paisley, UK)
Electrophoresis apparatus (as described in Section 2.4.1) consisting glass plates,
spacers, combs
Gravitational gradient gel former (Biorad, UK)
Magnetic stirring system (Stuart Scientific)
40% acylamide solution (BDH, Poole, UK)
N,N'-diallyltartardiamide (DATD) (BDH, Poole, UK)
Urea (BDH, Poole, UK)
Formamide solution (BDH, Poole, UK)
Ammonium persulphate powder (BDH, Poole, UK)
N,N,N',N'-tetramethylethylenediamine (TEMED) (Sigma, Poole, UK)
AG501-X8 resin (Biorad, Hemel Hempstead, UK)
20x'DGGE Running Buffer': 800 mM Tris base, 400 mM sodium acetate, 20 mM
EDTA, pH 7.4
80% denaturant stock solution for 12.5% polyacrylamide gel
0% denaturant stock solution for 12.5% polyacrylamide gel
(100% denaturants correspond to 7M urea and 40% formamide; denaturant stock
solutions contain acrylamide 12.5%, 0.93 gm DATD / 100 ml and IX 'Running
Buffer')
6X gel loading buffer (bromophenoblue, xylene cyanol, ficoll, BDH, Poole, UK)
2.1.6 2 PARALLEL DGGE
Virtually all the DGGE performed during this project were of the parallel variety, i.e.,
the denaturant gradient was in the same direction as the electric current, in order to
screen primary tumour tissues for the presence of p53 mutations. Perpendicular
DGGEs, the principle ofwhich is outlined in Chapter 1, helped to visually
demonstrate the presence of a denaturant gradient, will be described below. During
this project, a universal gradient of 30 - 80% denaturants was used for all 5 DNA
fragments screened. The optimal denaturant concentrations for each of these
fragments was demonstrated to fall within this range (Borresen et.al., 1991; Busby-
Earle, 1992). Glass plates, cleaned with 100% ethanol on the inner aspects in contact
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with the gel, were set up and clamped as per usual procedure. Acrylamide gel was
poured from a Biorad gradient gel former at a height slightly above the vertical glass
plates via a thin rubber tubing, the distal end ofwhich was inserted between the
plates, half-way from each end. The gel former consisted of 2 interconnected
chambers which could be isolated from each other, and the first chamber contained
the outlet which is controlled by a 3-way tap. The gel former was rested on a
magnetic rotator, with a stirrer within the first chamber to enable even mixing of the
denaturant solutions. 80% denaturant solution was placed in the first chamber, and
0% denaturant solution in the second, and 10% ammonium persulphate (50 pi / 10
ml) and TEMED (15 pi /10 ml) are added to each chamber to initiate polymerisation.
When the 3-way tap was opened and the 2 chambers connected, 80% denaturant
solution flowed out first, and was the denaturant concentration at the bottom of the
gel. As the gel was cast, with mixing from the non-denaturing solution, concentration
of the denaturant in the first chamber fell. The amount of denaturant solution added
to each chamber was determined graphically (Fig. 2.1). A line was drawn through the
coordinates [0 ml, 80%] and [33.6 ml, 30%], 33.6 ml being the volume of the gel cast
(14 x 16 x 0.15 cm). The X-axis was intercepted at 54 ml giving the total volume of
denaturant solutions used, hence 27 ml of 80% and of 0% denaturant solutions were
added to each of the 2 chambers. The gradient gel should not be cast in less than 5
min (when the gradient may disperse) or longer than 10 min (when acrylamide may set
within the apparatus). By trial and error, the optimum was approximately 8 min. A 2
cm gap was left at the top of the gel. Immediately after the gel was cast, a thin film of
water-saturated butan-l-ol was gently applied onto the surface of the gel to prevent
oxygen interfering with the polymerisation process. The gel was allowed to set for at
least 20 min. The butan-l-ol was then removed and the 2 cm gap washed with
distilled water before a 7% acrylamide stacking gel was poured, when a 15-well comb
was inserted, clearing the interface by 1 - 2 mm. This prevented contact between PCR
products in the wells and denaturants in the main gel body before electric current was
applied. The lower concentration of acrylamide in the stacking gel prevented the set
gel swelling into the wells thus reducing volume. When the stacking gel was set, the
wells were washed with IX running buffer. If the gradient gel was not used
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Denaturant(%) 80 70 60 50 40 30 20 10
01023345546 Totalvolumefacrylamid(ml)
Fig.2.1Determinationofvolumeacry amidrequiredtcasgr dientl.Volu felis14x16x0.15c=33 ml.Gradientrequiredis30-80%Alinextrapolat dfro8 %nthY- x sth oughc rdi ate33m/ , givingtotalvolumereq iredb54ml,i ,27lf0%and80den turantsol tions.\1volumefgel
immediately, the sandwich was wrapped in cling film and stored at 4°C for not more
than 48 hr.
To perform DGGE, the Hoefer SE600 vertical tank was set up with the heating
element (inter-connected glass tubes) in the centre connnected to a water bath heated
to 62.5°C. The tank sat on a magnetic stirring base, and the stirrer within the tank
ensured the entire volume of buffer was heated to a uniform temperature of 60°C. The
extra 2.5°C allowed for heat loss. Four litres of IX running buffer was placed in the
tank, in which the denaturing gradient gel set-up was immersed. The large volume of
buffer ensured that the gels were electrophoresed at a uniform 60°C. Six hundred
milliltres of 1X running buffer was placed in the top chamber, and the gels were
electrophoresed at a constant voltage of 185 V which produced a current of 80 - 90
mA across each gel of dimensions described above. Fig. 2.2 is a schematic
representation of the apparatus.
Forty microlitres ofPCR product was mixed with 8 jlxI of 6X loading buffer and
loaded onto each lane. Running time was approximately 6 hr when the xylene cyanol
band (dark blue colour) reached the bottom of the gel.
2.1.6.3 PERPENDICULAR DGGE
Perpendicular DGGE was not a regular technique in this project, but was performed
to confirm that a linear gradient was satisfactorily achieved by gel casting with the
gravitational caster, and to show that denaturation occured within a relatively narrow
range of denaturant concentration. The 30 - 80% gradient was poured as described
above, but 3 spacers were required, arranged in a U-shape. Petroleum jelly, bull-dog
clips and electrical tape were use to ensure a tight seal between spacers. The gel was
poured in the usual manner through the fourth side of the plates, leaving a gap
equivalent to the width of a spacer. After polymerisation, the 2 vertical spacers were
removed, the plates turned 90°, and a new spacer inserted into the gap through which
the gel was poured. The result was an apparatus with 2 vertical spacers and a gradient
gel with a gradient running left to right rather than top to bottom. There was also a 1
- 2 cm space at the top of the gel into which the PCR product to be studied was
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placed. Electrophoresis time required was determined empirically and was shorter
than for parallel DGGE, approximately 3 .5 hr. PCR product travelling through the
30% denaturant end of the gel did not denature and migrated furthest, whilst that at
the 80% end denatured as soon as electrophoresis started and hardly migrated.
Somewhere in between was a denaturant concentration at which denaturation first
took place and represented an abrupt slowing down of migration. The overall result
was a sigmoid curve (See Section 2.2.7).
2.2 OPTIMISATION OF DGGE
2.2.1 SUITABILITY OF TONSIL DNA AS A WT CONTROL
A large stock of human tonsil DNA was previously prepared in 1989 in our
department from a pool of tonsils obtained from children undergoing elective
tonsillectomy at the Royal Hospital for Sick Children, Edinburgh (J.Craig, personal
communication). DNA was extracted using standard proteinase K / phenol /
chloroform methods, and was kept at -70°C over the years. It was decided to use this
supply ofDNA simply because of its ready availability. DNA concentration was
measured by recording the optical densities (260 and 280 nM) ofDNA diluted 1:100
in water. Tonsil DNA was diluted to a working concentration of 100 ng/gl and
aliquoted. OD260/OD280 ratios were confirmed to be within the optimal range of 1.7
- 2.0. It was important to determine if tonsil DNA contained any mutations of p53 in
the fragments to be studied. For this purpose, tonsil DNA, DNA from a breast cancer
cell line, MCF7, known to contain wild type sequence in the entire coding sequence of
p53, and a positive mutant control, were amplified with primers of each of the five
p53 fragments studied. PCR products were electrophoresed in DGGE (Fig. 2.3), and
the results clearly showed tonsil DNA co-migrated with MCF7 DNA in each
fragment, and all 5 positive controls migrate differently. This confirmed the legitimacy
of tonsil DNA as a wild type control, and that, with a universal gradient of 30 - 80%
denaturants, mutations in all 5 fragments ofDNA were identified.
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DNA WT t M
LANES 1 2 3
LANES 1 2 3 4 5 6 7 8 9 10 11 12
DNA WT t M WT t M WT t M WT t M
Fragment BB B CCCDD DE EE
Fig. 2.3 Suitability of tonsil DNA (t) as WT control (Section 2.2.1). For
each of the five DNA fragments (A-E), PCR products were studied with
DGGE for a) MCF7, a breast cancer cell line known to contain WT
sequence, b) tonsil, and c) a positive control cell line known to contain a
mutation. For all 5 fragments, PCR product of tonsil DNA co-migrated
with MCF7 DNA, indicating that it containedWT sequence. Both migrated





2.2 2 SENSITIVITY OF DGGE IN DETECTING MUTATIONS
The primary starting point ofmutation screening for a particular patient was, for
breast cancer patients, either a frozen section or archival paraffin-embedded section of
primary tumour, and for acute leukaemia patients, an aliquot of diagnostic bone
marrow aspirate. It is conceivable that such biological samples 'never' entirely
consisted of cells of the malignant clone, and invariably normal stromal tissues were
interspersed amongst the malignant cells, to varying proportions. In order to account
for sample variability, it was important to determine the approximate sensitivity of
DGGE, which might have a bearing on the choice ofmaterial to be screened. A model
was based on cells of a bladder carcinoma cell line, 5637, known to contain a point
mutation within fragment D (exon 8) of p53. 5637 cells were spiked in normal blood
donor buffy coat white cells in serial dilutions in the following proportions: 80%,
40%, 20%, 10% and 5%. DNA was extracted from a 107 cell pellet of each of these
dilutions, subjected to fragment D PCR as previously described, and electrophoresed
by DGGE. Fig. 2.4 illustrates the pattern of such PCR products on DGGE. Mutant
homoduplex of 5637 migrated marginally faster (or denatures later) than WT
homoduplex, and as the proportion of tumour cells decreased, a transition was seen,
whereby the mutant homoduplex band was no longer visible in proportions of 40% or
less. It was, however, still possible to see that a mutation was present on the basis of
the presence of heteroduplexes, down to a malignant cell fraction of 5%. Therefore,
tumour tissue with as high a proportion ofmalignant cells as possible should be used
as a clear and distinct mutant homoduplex band was required for sequencing.
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LANES 1 2 3 4 5 6 7
M DNA(%) 100 80 40 20 10 5 0
WTDNA(%) 0 20 60 80 90 95 100
Fig. 2.4 Sensitivity of DGGE in mutation detection (section 2.2.2). 5637
cells were spiked in buffy coat cells in various dilutions expressed as a
percentage and extracted DNA studied with DGGE. The slightly faster
mutant homoduplex band is no longer clearly visible (and be physically
isolated) when the proportion of tumour cells is 40% or less, although
heteroduplex bands indicate the presence of a mutation down to at least 5%.
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2.2.3 EFFECT OF ELECTROPHORESIS TIME ON DGGE
Duration of electrophoresis was a factor of the power delivered through , or the
voltage across, the polyacrylamide gel. A 'travel schedule' DGGE had to be
performed for each fragment studied to determine the duration of electrophoresis. In
this set up, paired wild type and mutant PCR products were loaded onto the gradient
gel sequentially, and electrophoresed for varying lengths of time. Fig. 2.5(a) shows
such a gel. Fragment B PCR products were used in this model. Paired mutant (H69
colonic carcinoma, left lane of each pair) and WT (tonsil) fragment B PCR products
were electrophoresed at a constant 200V, 60°C, at hourly increments from 2 to 6 hr.
After 3 hr of electrophoresis, migration of the mutant PCR product was noticably
retarded compared to that ofWT. Further eletrophoresis up to 6 hr contributed little
in the resolution ofmutant DNA from wild type. Comparing the distance travelled
from 2 to 3 hr, and subsequent time intervals, it was clear that the migration ofboth
DNA species was markedly retarded owing to denaturation of the double strands.
Empirically, to ensure that any difference between mutant and wild type bands were
maximised, all subsequent DGGE's were performed at 200 - 220V for 5 to 6 hr,
when the xylene cyanol component of the loading buffer reached the bottom of the
gel. This was found to be a reliable indicator for the duration of electrophoresis.
2.2.4 EFFECT OF POLYACRYLAMIDE CROSS-LINKER ON DGGE
In any PAGE, bisacrylamide is most commonly used as a cross-linker to achieve
polymerisation between acrylamide molecules. However, in the method described by
Borressen, et.al. (1991), N,N'-diallyltartardiamide (DATD) was routinely used. After
initial failure in mutation screening using acrylamide/bisacrylamide, It was decided to
assess the difference between using bisacrylamide and DATD in DGGE under defined
conditions. Figs. 2.5(a) and 2.6 illustrate the result. Both of these denaturing gradient
gels were performed in the 'travel schedule' manner, with paired mutant and WT PCR
products of fragment B loaded at hourly intervals, and electrophoresed for 2, 3, 4, 5
and 6 hr, respectively, as described in Section 2.2.3 above. Fig. 2.6 shows a gel with
bisacylamide as cross-linker, and Fig. 2.5(a) has DATD. Apart from this, the 2 gels
were identical, with 12.5% acrylamide, and a 30 - 80% denaturant gradient from top
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LANES 12 34 56789 10
DNA H69 WT H69 WT H69 WT H69 WT H69 WT
TIME (hr) 66 55 443322
LANES 1 23456789 10
DNA H69 WT H69 WT H69 WT H69 WT H69 WT
TIME (hr) 6655443322
Fig. 2.5 a & b Effect of running temperature on DGGE, with DATD
as cross linker (section 2.5.5). (a) Travel schedule DGGE of H69 cell
line and WT DNA fragment B PCR products, electrophoresed at 60°C.
DGGE was at a constant voltage of 200V. (b) is identical except the
gel was electrophoresed at 55°C. At lower running temperature,
differential mobility retardation is noted after 5 hours of
electrophoresis, while much earlier retardation at 3 hours is observed
when electrophoresed at 60°C.
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LANES 12 3456789 10
DNA H69 WT H69 WT H69 WT H69 WT H69 WT
TIME (hr) 66 5544332 2
Fig. 2.6 Effect of crosslinker on DGGE (section 2.2.4). Travel
schedule DGGE of H69 cell line and WT DNA fragment B PCR
products with bisacrylamide as cross linker. DGGE was at 60°C at
constant voltage of 200V. This is contrasted with Fig 2.5a which is
identical except with DATD as cross linker. This experiment showed no
mobility loss during electrophoresis when bisacrylamide was used, but
differential retardation of mobility between WT and mutant PCR
products was apparent after 3 hours of electrophoresis when DATD was
used.
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to bottom. Both gels were electrophoresed simultaneously in the same tank at 60°C.
The DNA bands in the gel with bisacrylamide showed no sign of retardation with
increasing electrophoresis time, and no difference was apparent between mutant and
wild type DNA. The gel with DATD, in contrast, showed that migration of both
mutant and wild type DNA were markedly retarded after approximately 3 hr of
electrophoresis, when the difference in migration (and hence denaturation properties)
between them became apparent. Experiments with the other p53 fragments,
comparing bisacrylamide and DATD yielded the same results. In the p53 system,
therefore, bisacrylamide, at least at a acrylamide/bisacrylamide ratio of 37.5:1, was
unsuitable as a cross-linker for DGGE, whilst DATD was able to confirm the
mutations in all 5 positive controls.
2.2.5 EFFECT OF RUNNING TEMPERATURE ON DGGE
'Travel schedule' DGGEs were performed as described, using buffer temperatures of
55°C and 60°C, in order to assess the running temperature at which denaturation of
DNA was most reliably achieved when all other variable factors were kept constant.
As an increase of 1°C in the running temperature is equivalent to an increase of 3% in
denaturant concentration, it was hypothesized that raising the running temperature of
the buffer, e.g., from 55°C to 60°C should reduce the distance a GC-clamped DNA
fragment had to travel before denaturation took place, and hence reduce the time of
electrophoresis required. Fig. 2.5(a) shows a travel schedule gel run at a buffer
temperature of 60°C, and indicates that DNA denaturation began after approximately
3 hr. Fig. 2.5(b), the same reactions run at 55°C, indicates that DNA continued to
migrate down the gel for much longer and did not begin to denature until 4 to 5 hr
after electrophoresis began. They also ran further into the gel before denaturation
took place, indicating that a higher denaturant concentration was required to
compensate for the lowered temperature. The quality of the separation and sharpness
of the bands did not appear to be impaired at a higher temperature, and, therefore,
60°C became the standard buffer running temperature for this project.
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2.2.6 EFFECT OF ELECTROPHORESIS VOLTAGE ON DGGE
During this project, a range of electrophoresis voltages was tested to study the effect
on the appearance of the bands. Some have reported the superiority of using a lower
voltage and longer electrophoresis time (B.Cohen, personal communication), and to
enable electrophoresis to be performed within the scope of a working day. A narrow
range of voltages, from a constant 160V to 220V, which created a current varying
between approximately 70mA and 100mA across each 1.5 mm thick, 14x16 cm
polyacrylamide gel was tested. A higher voltage had no undesirable effect on the
appearances of the bands, but very conveniently shortened electrophoresis time from
7 hr to 5 hr, by the criteria indicated in Section 2.2.3 above. Care was taken not to
create too high a current across the gel, and a maximum current of 100 mA was not
exceeded.
2.2.7 USE OF PERPENDICULAR DGGE TO ASSESS EFFECTIVENESS OF
DENATURANT GRADIENT
As described by Busby-Earle et al (1992) a universal denaturant gradient of 30 - 80%
was adequate in screening the 5 p53 fragments described, and this was the experience
in this project. However, to maximise the sensitivity ofDGGE, the profile of the
melting domain in question should be determined, such that the denaturant range
should represent a temperature gradient of 5°C on either side of the optimal
temperature, as described in Section 1.5.1. This may be achieved by one of 2
methods. Computer programmes (e.g. Lerman and Silverstein, 1987; Melt87;
SQHTX) are now available to help design PCR primers to produce double-stranded
products suitable for DGGE, and determine the optimal denaturant range. They may
also predict, as a function of electrophoresis time, the expected difference in gradient
level (separation) between a WT homoduplex DNA molecule, and a related
heteroduplex created with a mutant species differing by a single-base mismatch at
each selected position along the sequence. An alternative is to determine the
denaturant range experimentally, by performing a perpendicular DGGE, in which the
direction of the denaturant gradient is at right angles to the direction of current. The
set up of this apparatus is described in Section 2.1.6.3. Because of reproducible
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success with the parallel DGGE system with the universal gradient to detect
mutations in all 5 p53 fragments, it was not necessary to perform perpendicular
DGGE for each fragment to determine the effective range. Nevertheless, it was
important, and interesting, to confirm that the technique of linear gradient gel casting
did produce a linear denaturing gradient. Fig. 2.7 shows the resultant appearance of
such a gel on which 600 pi each of fragment B PCR products, using H69 colonic
cancer positive control and WT tonsil DNA as templates, amplified separately, were
electrophoresed. Electrophoresis time was 3.5 hr, at a constant 200V. The denaturant
gradient, from left to right, was 30-80%. Samples were loaded across the top of the
gel. At the low denaturant concentration end of the gel, no denaturation ofPCR
products occurred and products travelled to the bottom. At the high concentration
end, PCR products were denatured immediately upon entering the gel and stayed near
the top. Between these 2 extremes, there occured a denaturant concentration at which
the double-stranded, GC-clamped products denatured suddenly, resulting in a sigmoid
courve. Here, assuming a linear gradient, this occured at approximately 64.4%.
2,2.8 QUALITY OF THE DENATURANT SOLUTIONS AND AGE OF THE
GELS
Although not formally assessed over the course of the project, the quality of duplex
bands on DGGE was significantly influenced by the age of the 80% denaturant
solution used in the gels. It is conceivable that, with high concentrations of
denaturants like urea and formamide in solution, the quality of the cross-linking of
acylamide molecules would be influenced. The interactions between these chemicals
may be more pronounced with time, affecting the quality of electrophoresis. Quality
of DGGE was especially poor if the 80% denaturant was over 4 weeks old, and
routinely, it was ensured that the solution was used within 2 weeks of preparation, or
otherwise discarded. As the 0% denaturant stock solution contained only acrylamide,




Denaturant 30% 55% 64.4% 70.6% 80%
Concentration
Fig. 2.7 Perpendicular DGGE with fragment B PCR products from
WT and H69 cell line DNA which contains a point mutation (Section
2.2.7). Current is from top to bottom and 30% - 80% denaturant
gradient from left to right of the gel. Mixture of WT and mutant PCR
product was loaded in a well spaning the whole width of the gel and
the sigmoid curve confirmed the presence of a gradient from left to
right. The 2 split bands in the steep slope represent mutant DNA on
the left and WT DNA on the right. Assuming a linear gradient, by
measuring the distances from each end, the denaturant concentration
range in which sharp mobility retardation occurs during electrophoresis
is 50 - 70.6%, with the centre of the slope, 64.4%.
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Denaturing gradient gels were routinely poured the day before use, wrapped in cling¬
film and kept at 4°C overnight, and it was ensured that the polymerised gel was used
within 24 hr of preparation because of the potential risk of diffusion of the
denaturants from the higher to the lower concentrations.
2.3 MUTATION DETECTION IN BREAST CANCER PATIENTS
2.3.1 PATIENT SELECTION
All patients studied were or are being treated at the Department of Medical Oncology,
Western General Hospital, Edinburgh, and were referred either locally or from other
hospitals in Lothian or Fife. A total of 51 patients were studied and were divided into
two broad groups: (1) Group 1: 38 patients, the great majority with metastatic breast
cancer who had undergone PBPC harvesting at the Scottish National Blood
Transfusion Service Cell Separator Unit, Royal Infirmary of Edinburgh. Most of these
patients were also treated with high dose chemotherapy and the progenitor cell
harvests returned. Whilst it is noted that in the early to mid 1990's the policy was to
offer PBPCT to eligible patients with metastatic disease, occasional patients with
relapsed disease were also treated this way. In this project, to distinguish patients in
this group from Group 2 described below, they are designated the 'metastatic' group.
(2) Group 2: 13 patients with high risk stage II or III breast cancer (4 or more
positive axillary lymph nodes but not known to have distant metastases) who took
part in the Anglo-Celtic Cooperative Oncology Group (ACCOG) study comparing
adjuvant conventional chemotherapy with adjuvant high dose therapy and PBPC
support (see Section 1.1). Having earlier stage albeit high risk disease, these patients
should provide a contrast to those in Group 1 above, and as halfwere randomised to
HDT and had PBPCH cryopreserved, it would be of interest to study these aliquots
for MRD in those in whom a disease marker is available. Patient characteristics are
summarised in Table 2.5.
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2.3.2 NATURE AND SOURCE OF MATERIALS
A total of 51 primary breast tumours were studied and came from one of 3 different
sources: (1) 22 frozen sections taken at the time ofprimary surgery, courtesy ofProf.
W.R. Miller, Imperial Cancer Research Fund (ICRF); 17 patients had metastatic
disease and 5 in the ACCOG study; (2) 7 paraffin-embedded sections, courtesy ofDr.
K. McLaren, Department ofPathology, University ofEdinburgh. All patients had
metastatic disease; and (3) 22 paraffin-embedded sections, courtesy ofDr. T.
Anderson, Department of Pathology, Western General Hospital, Edinburgh; 14
patients had metastatic disease and 8 in the ACCOG study. All frozen were kept in the
vapour phase of liquid nitrogen since the initial surgery, and aliquot sections
(approximately 25 gm) were cut for DNA extraction. Any remaining tissue was re-
frozen in the liquid nitrogen tank. Paraffin-embedded sections were retrieved from the
archive, and two to three 15 pm sections cut from each block with a clean microtome
blade and placed in an Eppendorf tube until DNA extraction. Procedures are described
in Section 2.1.
2.3.3 RESULTS
Of the entire group of 51 patients, an abnormal banding pattern was detected in 14
individual patients (27.5%), one ofwhom had an abnormal pattern in 2 different p53
fragments. Of these 15 positive lanes on DGGE, 13 had the clear-cut 4-band pattern,
representing mutant and WT homoduplexes and 2 mutant-WT heteroduplexes. The
remaining 2 cases showed a clear band which co-migrated with WT on DGGE, and 2
extra bands with markedly different mobility (earlier retardation) suggesting that they
were likely to be heteroduplexes. Section 2.5.4 describes the use ofTaqI restriction
endonuclease to resolve these samples.
The distribution ofmutations among the 5 fragments are: 5 in fragment B (exon 5), 2
in fragment C (exon 7), 2 in fragment D (exon 8) and 6 in fragment E (exon 6). 12 of
these were found in the metastatic group, and 3 in the ACCOG group. As described in
Section 2.6, sequence information suggests that 2 of the fragment E positive results
were constitutional silent polymorphisms in codon 213, including patient B15 who had
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Table 2.5 Characteristics of breast cancer patients studied.
Metastatic Disease Patients
Patient IE Patient Initials Sample II) Source Age date surg Type surg TN1V1 at diaf
B1 LB1 LB1 1 ICRF 27 Dec-91 ans/wle T2
B2 EMcC EMcC ICRF 33 Dec-92 met T3
i
B3 BD BD ICRF 34 Jun-88 mx/anc T2
B4 JPh JPh ICRF 45 Aug-92 wle/ans T2N0M0
B7 MW MW ICRF 37 Oct-83 mx/anc T2
B8 PY PY ICRF 35 Dec-87 ans/wle/mx T1N0M0
B9 JD JD ICRF 42 Nov-89 mx'anc T2N0M0
BIO LMcL LMcL ICRF 31 Mar-92 nil T4
Bll HB HB ICR1: 41 Nov-92 mx/anc T2N2M1
B12 JR JR ICRF 29 Jul-91 mx/anc T2N0M0
BI3 JS JS ICRF 34 Jun-91 wle/ans T2N0M0
B15 VK VK ICRF 39 Jul-90 wle/anc T2NOM0
B16 LB LB ICRF 31 Dec-92 wle/ans T2N0M0
B17 BB BB ICRF 54 90 mx T2N1M1
B20 JF JF ICRF 51 Jul-91 mx/anc T1NOM0
B21 F.r> ED ICRF 27 Mar-91 wle/rt T2N1
B22 JL JL ICRF 55 Mav-92 wle/ans T2N1M0
B23 AD 23046/90 RIE 34 Jul-89 mx T2
B24 LA 15380/90 RIE 38 Jul-90 ans/wle/mx T1
B25 MJ 30155/89 RIE 34 Oct-89 mx/anc T2
B26 JF 25590/90 RIE 37 Nov-90 mx/ans T2
B27 KE 7071/90 RIE 43 Apr-91 wle/rt/mx T2N0M0
B28 EM 8375/91 RIE 39 Apr-91 wle/ans T1
B29 MM 5346/89 RIE 43 Mar-89 mx/anc T2N1M0
B31 CM 6623/93 WGH 43 n/a n/a T2/met
B32 EL 11925/95 WGH 32 n/a n/a T4N1M0
B33 SF 3757/94 WGH 28 Apr-94 mx/anc T1N0M0
B34 BS 4048/94 WGH 51 Apr-94 wle/anc T2N1M0
B35 PC 2694/95 WGH 35 n/a nil/met T4N2M1
B36 ER 4552/97 WGH 39 Sep-92 wle/anc T3N1M0
B39 GM 9267/93 WGH 31 Sep-93 wbx T4N1M0
B42 ID 331/94 WGH 50 Feb-94 wle/ans T2N1M0
B43 NT 6556/92 WGH 28 Mav-92 wle/ans T2N0M0
B44 MMcH 6137/94 WGH 42 Jul-94 wle-mx/anc T1N0M0
B45 MPr 1232/94 WGH 40 n/a n/a T2M1
B46 DJG 6342/93 WGH 43 Apr-91 mx/anc T2N1M0
B47 IOC 2515/96 WGH 51 Mar-96 wle/anc T1N0M0
B49 EA 3576/96 WGH 53 Apr-96 wbx T4N2M0
Anglo-Celtic Cooperative Oncology Group Patients
Patient II) Pt Initials Sample ID Source Age date surg Type surg TNM at diag Pos nodes (total) Therapy
B5 JP JP ICRF 52 Feb-96 mx/anc T1N0M0 9(14) HDT
B6 SP SP ICRF 43 Dec-95 wlc T1N0M0 17(20) CON
B14 MP MP ICRF 51 Aug-95 wle/anc T2N1M0 15(18) HDT
B18 LT LT ICRF 35 Jui-95 wlc/ans/mx n/a 5(20) HDT
B19 JC JC ICRF 46 Jul-95 mx/anc T1N1M0 4(9) HDT
B30 CL 2668/96 WGH 35 Mar-96 wle/anc/'mx T2N0M0 8(28) HDT
B37 SM 2477/96 WGH 34 Feb-96 wle/anc/mx T2N0M0 6(11) HDT
B38 JA 1442/97 WGH 32 Feb-97 wle/anc T1N0M0 13(25) HDT
B40 CMcD 1441/97 WGH 41 Feb-97 mx/anc T3N1M0 7(21) HDT
B41 MP 11277/96 WGH 52 Nov-96 mx/anc T2N0M0 9(22) HDT
B48 VF 4785/97 WGH 54 May-97 mx/anc T2N0M0 12(16) HDT
B50 JW 6098/97 WGH 51 Jun-97 mx/anc n/a 12 (27) CON
B51 MC 3701/96 WGH 51 Apr-96 mx/anc n/a 14(16) CON
wle - wide local excision, ans - axillary node sampling, anc - axillary node clearance, mx - mastectomy,
wbx - wedge biopsy, rt - radiotherapy. HDT - high dose therapy, CON - conventional therapy.
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this polymorphism and a fragment B mutation. Therefore, 10 of 38 patients (26.3%) in
the metastatic group and 3 of 13 patients (23%) in the ACCOG group had a somatic
mutation in exons 5 to 8 of p53. Fig. 2.8 illustrates DGGE demonstrating tumour
DNA with a positive pattern.
2.4 MUTATION DETECTION IN ACUTE LEUKAEMIA PATIENTS
2.4.1 PATIENT SELECTION AND NATURE AND SOURCE OF MATERIALS
All patients with acute leukaemia studied were referred to and treated at the
Department ofHaematology, Royal Infirmary ofEdinburgh. A total of 29 consecutive
patients were studied. Studied patients were unselected with regard the nature of their
disease or treatment, but were chosen on the basis of having available archival
extracted DNA from routine bone marrow or peripheral blood samples taken during
the course of their treatment, as has been the policy of our department for several
years. DNA from aliquots of these cellular samples was extracted by standard
proteinase K / phenol / chloroform methods, and stored at -70°C. A total of 34
representative bone marrow samples, or peripheral blood samples in which leukaemic
blast cells form a significant proportion of the white blood cell population, were
studied. This information was obtained by studying all bone marrow aspirate reports
or the case notes of the patients concerned, to ensure that the majority of the cells
were leukaemic blasts. Of these, 16 were taken at disease relapse, and 18 at diagnosis.
In 5 patients both diagnostic and relapse samples were screened. Fourteen patients
had de novo AML, 10 had de novo ALL, 1 biphenotypic leukaemia, 1 chronic myeloid
leukaemia (CML) transformed to AML, 1 CML transformed to ALL, 1 secondary
AML from Hodgkin's disease, and 1 secondary AML transformed from MDS. Table
2.6 illustrates the characteristics of these patients.
2.4.2 RESULTS
It is noted that in patients with acute leukaemia, fragment A was not studied by
DGGE. The reason for this is that during this project, leukaemia samples were first
studied, and fragment A PCR using published primer sequences (Borresen et al, 1991)
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LANES 1 2 3 4 5
DNA BR BR BR Ovcar3 WT
Fig. 2.8 An example of fragment C DGGE (Section 2.3.3).
The breast tumour in lane 1 is positive while those in lanes
2 and 3 are negative. Ovcar3 is a positive cell line. In lane
1, the 4 bands from bottom to top are respectively, WT
homoduplex, mutant homoduplex and 2 WT/mutant
heteroduplexes.
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did not result in consistent amplification of this part of exon 5. Screening for fragment
A was abandoned at this point, while subsequently, new primer sequences for this
fragment were obtained from this author's group in Oslo (S. Lystad, personal
communication). These were successfully applied to study breast tumours, but owing
to time constraints, I was unable to repeat fragment A DGGE for the leukaemia
samples. When all the relapse samples were screened by DGGE for fragments B to E,
3 samples demonstrated abnormal banding suggesting the presense of a mutation.
Two of these were in fragment E (patients L8 and LI 3) and one in fragment D
(patient LI 1). When all the diagnostic samples were screened, patient LI 1 was
negative for a fragment D mutation, while the other two patients remained positive in
fragment E. Again, in Section 2.6, patients L8 and L13 were found also to have a
silent constitutional mutation (CGA > CGG) in codon 213. Therefore, only 1 of 16
relapse samples from 16 individuals (6.25%) was positive for a somatic p53 mutation,
and none of 18 diagnostic samples was found to have a mutation. This incidence is
disappointingly low and I was unable to confirm the much higher incidence reported
by some authors (Zhu et al, 1996).
2.5 MUTATION ANALYSIS - GENERAL METHODS
2.5.1 MATERIALS
1.5 ml Eppendorf tubes (Costar, High Wycombe, UK)
0.5 ml PCR reaction tubes (Costar, High Wycome, UK)
Spin-X columns (Costar, High Wycome, UK)
23 gauge sterile hypodermic needles
Clean razor blades
QiaQuick PCR Purification Kit (Qiagen, Crawley, UK)
TaqI restriction endonuclease and buffer (Promega, Southampton, UK)
2.5.2 EXTRACTION OF MUTANT HOMODUPLEX BAND FROM DGGE
As described in the principles ofDGGE in Chapter 1, DGGE usually separates 4
different species ofDNA from a PCR product according to their melting properties,
namely, mutant and WT homoduplexes, and 2 heteroduplexes formed by hybridisation
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ofWT and mutant strands. Heterduplexes are usually characterised by their high
degree of instability, tend to melt first in a denaturing gradient gel, and appear highest
in the lane. The WT homoduplex can be recognised when a wild type control is run
alongside in the same gel. The mutant homoduplex may run faster or slower than the
wild type, and is usually recognised by exclusion. To obtain sequence information of
the mutant (Langlands et. al., 1995), this homoduplex band was cut out with a clean
blade, cropping tightly, and placed in a 0.5 ml PCR tube where 3 evenly spaced
perforations had been created close to the tip by puncturing with a 23 gauge sterile
hypodermic needle. This tube was, in turn, place inside a 1.5 ml Eppendorf tube
where 50 pi of sterile distilled water had been placed. The tubes were centrifuged at
14,000 rpm for 5 min during which the polyacrylamide gel was forced through the
perforations into the distilled water. The surface area of contact between gel and
water was therefore maximised, and the tube floated in a water bath at 37°C overnight
when DNA was eluted out from the gel into the water. The Eppendorf tube was
centrifuged and the contents place in the column of a Spin-X column, centrifuged at
14,000 rpm for 5 min. The spin column contained the remains of the polyacrylamide
gel and was discarded. The collection tube contained a solution of the mutant
homoduplex PCR product which was used as template for a second round PCR
amplification prior to sequencing.
2.5,3 PREPARATION OF SAMPLE FOR SEQUENCING
The extract of the mutant homoduplex band, hopefully free of wild type sequence,
was secondarily amplified by PCR using essentially the same primers which produced
the product for DGGE, except an alternative primer equivalent to the GC-clamped
primer but without GC-rich region was used. After confirming successful secondary
amplification with 4% agarose gel electrophoresis the product was purified with the
QiaQuick PCR Purification Kit which consisted of spin columns, 2 ml collection
tubes, Buffer PB and Buffer PE. Five volumes ofBuffer PB is added to 1 volume of
PCR product and mixed well. This was transferred to a spin column where DNA
binding to the membrane was allowed to occur. After centrifugation in an Eppendorf
micro-centrigfuge for 1 min at 10,000 g, bound DNA was washed with 0.75 ml of
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Buffer PE by centrifugation, first for 1 min at 10,000g, then at maximum speed
(14,000 g) for a further minute. The spin column with the DNA still in situ was placed
in a 1.5 ml Eppendorf tube, and the DNA eluted with 50 pi of distilled water by
centrifugaton after standing for 1 min.
The purified product was sent for sequencing commercially (Oswel, Southampton,
UK). Sequencing was performed by the Sanger dideoxy technique on an automated
ABI Prism sequencer, and the result expressed in a 4-colour chromatogram. I
originally attempted to perform manual sequencing myself, using the Sequenase
Version 2 Kit (Amersham, UK), but soon realised that the labour-intensiveness, the
time involved in sequencing all positive samples and the lack of reproducibility made
this unfeasible.
2.5.4 USE OF TaqI RESTRICTION ENDONUCLEASE IN DIFFICULT
SAMPLES
Not all samples positive for a mutation on DGGE show a distinct 4-band pattern, and
the mutant homoduplex may not appear sufficiently separated from the WT
homoduplex to enable a pure mutant species to be obtained for sequencing. This was
the case in 2 of the positive samples (patients B16 and B30), both with a mutation in
fragment E (exon 6). I reasoned that a GC-clamped DNA fragment slightly shorter
than the original fragment used in DGGE might have a significantly different melting
profile, and the same mutation might produce quite different banding patterns on
DGGE. The hypothesis of different melting profiles could not be verified without the
appropriate Lerman-type computer programme, but for fragment E, a common
restriction endonuclease, TaqI (recognising 5'-TCGA-3'), cuts once at 51 bases from
the non-GC-clamped end of the fragment (192 bp). Hence the majority of the
fragment would still be amenable to study by DGGE. For these 2 patients, a GC-
clamped fragment E produced by PCR in the usual way was incubated with 10 U TaqI
at 65°C as per manufacturer's protocol for 3 hr, to complete digestion, and the
resulting product seperated in DGGE. Fig. 2.9 illustrates the result. Lanes 1 - 4
represent the same samples as lanes 5-8, respectively, the former after TaqI digestion
and the latter without such treatment. Lanes 1 and 5 are fragment E from patient B30,
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LANES 12 3 4 5 6 7 8
TaqI digest + + + + -- - -
DNA B30 B16 T47D WT B30 B16 T47D WT
Fig. 2.9 Use of TaqI enzyme digestion of GC-clamped PCR products prior to
DGGE enhances mutant homoduplex bands in some cases (Section 2.6.3).
For both patients (B30 and B16), the previously indistinct or invisible mutant
homoduplex band (second band from bottom) became visible (and could be
physically isolated) when the PCR products were treated with TaqI prior to
DGGE, thus altering the melting profile of the remainder fragment. T47D
positive control andWT negative control are included
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showing a much more distinct mutant homoduplex band (second from bottom) after
TaqI digestion. Lanes 2 and 6 are patient B16. The formerly invisible mutant
homoduplex could be seen after TaqI digestion, migrating slightly more slowly than
the WT but sufficient separation to excise it from the gel. Lanes 3 and 7 are T47D cell
line positive control, and lanes 4 and 8 are WT control. The mutant bands from
patients B16 and B30 were isolated as described, although, as the primary products
had been cut with TaqI, secondary PCR prior to sequencing was not possible.
Fortunately, with the amount of product from the primary reactions, a mutant
sequence was obtained for both samples, and later used successfully in the design of
ARMS primers.
2.6 SEQUENCE RESULTS FROM BREAST CANCER PATIENTS
As indicated in Section 2.3.3, 15 positive results were detected in 14 patients.
Attempts were made to sequence all these samples, but unfortunately, despite
repeated sequencing, 2 samples, from patients B1 and B15, both for fragment B, gave
inconclusive results, and analysis could not proceed. Of the remaining 13, sequencing
revealed that patients B12 and B15, both containing fragment E mutations in their
tumours, had an identical constitutional silent polymorphism in codon 213 (CGA >
CGG, arginine > arginine) which is a known polymorphism (Carbone et al, 1991) and
the only reported one in the 5 fragments of p53 studied in this project. This base
change results in the loss of a TaqI restriction enzyme recognition site, and when
fragment E PCR products from tumours of these patients and from their PBPCFFs
(taken to represent normal tissues) were incubated with TaqI, failure of digestion in
all these tissues confirmed the presence of this base change in the germline and not a
somatic event.
Therefore, there were 11 positive samples which could serve as markers for MRD,
and sequencing of each of these revealed the information indicated in Table 2.7. The
sequence chromatographs are illustrated in Fig. 2.10. Two patients had an identical
mutation in codon 248, hence 10 individual mutations were recognised. All 10


















































































































































CAT -> GAT, codon 193
3CATCTTATCCGAGTGTAAG GAAAT
Patient B30
GAA -> TAA, codon 198
Patient B11
CGC -> CAC codon 175
nil vvu mi m
Patient B27
CCG -> CTG on antisense strand,
corresponding to CGG -> CAG on
sense strand, codon 267
Patient B37
CAT -> CGT, codon 179
Fig. 2.10 a-f Sequence chromatographs showing single base mutations
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Patients B33 & B28
CCG -> CTG on antisense strand.
Corresponding to CGG -> CAG on
sense strand, codon 248
I
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Patient B46
GTG -> TTG, codon 216
Patient B45
ACG -> ACA on antisense strand.
Corresponding to CGT -> TGT on
sense strand, codon 273.
I
TCG AC* TA G T A TGG T G G TG<
* 130 u
Patient B50
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Patient L11
CCCCCCGG on antisense strand,
corresponding to CCGGGGGG on sense
strand, codon 281.
Fig. 2.10 g-k Sequence chromatographs showing single base
mutations in patients B33 & B28, B45, B46, B50 and 8bp insertion in patient
L11. Mutations and insertion are indicated with an arrow.
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Four mutations occurred in one of the 6 hot spot codons (Section 1.4.2) - codons
175, 248 and 273. Five mutations occurred at CpG dinucleotides (codons 175, 193,
248, 267, 273) and 4 of these resulted in a G:C > A:T substitution.
2.7 SEQUENCE RESULTS FROM LEUKAEMIA PATIENTS
In the cohort of 29 patients with acute leukaemia, 2 (patients L8 and L13) also had
the silent constitutional polymorphism (CGA > CGG) in codon 213. This was
demonstrated by screening normal and leukaemic samples with TaqI restriction
endonuclease as described in the previous section. Apart from these patients, only
patient LI 1 was positive on DGGE in fragment D (exon 8). Despite a clear and
distinct mutant homoduplex band on DGGE, obtaining a pure double-stranded mutant
product proved more difficult than expected. Secondary amplification of the
homoduplex extract (Section 2.5) repeatedly yielded a significant WT product
suggesting contamination with WT. Purity was much improved when extract of the
mutant homoduplex was first electrophoresed on a polyacrylamide gel and the
resulting band physically cut out again before secondary PCR. With this extra step, a
clear mutant double-stranded PCR product was obtained, as evidenced by a larger
product than WT. Sequencing indicated a novel 8 bp (5'-CCGGGGGG-3') insertion
between the second and third bases of codon 281 (Table 2.7). Chapter 3 describes the
use ofARMS in detecting MRD, and because of the specific nature of this insertion,
ARMS primer design was straightforward, and Sections 3.2, 3.7.3 and 3.9 are
descriptions of the design, clinical association and application of the system for this
patient.
2,8 SUMMARY
This chapter describes the first of the 2 main stages in this project, namely the
detection and sequence analysis of p53 mutations in the studied clinical samples, the
other stage being the use ofARMS in detecting MRD (Chapter 3). Having chosen the
DGGE technique for mutation screening of the clinical samples, the technique was set
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up by studying various parameters which might influence the working of such gels.
Using primer sequences determined by Borresen et al (1991), exons 5 to 9 of the p53
gene were individually amplified. Cell lines known to contain mutations in each of
these DNA fragments (designated A to E) were used to confirm that the technique
was able to yield a positive result for each of these. Previously extracted DNA from
normal human tonsils was used as WT control. The sensitivity of DGGE was
determined by dilutions of DNA from the bladder cancer cell line 5637 in WT DNA.
It was demonstrated that, although the presence of a mutation can be detected when
tumour cells were out-numbered by normal cells 19:1, the proportion of tumour cells
should be much higher than this (approximately 40% or more) if the sequence was to
be determined by excising the mutant homoduplex band from the gel. This helped
with the choice of leukaemia samples to be studied, and in many cases with that of
breast cancer sections. Various optimisation parameters were analysed, such that an
optimal running temperature, voltage, cross-linker, electrophoresis duration, etc.,
were used. Instead of'fine-tuning' the conditions for each DNA fragments with
regards the denaturant concentrations, a universal gradient of 30 - 80% was found to
be satisfactory.
Having established a satisfactory set of running conditions, DGGE was used to screen
malignant tissues from 51 breast cancer patients and 29 acute leukaemics. Amongst
the breast tumours, 15 showed an abnormal banding pattern on DGGE. Two of these
were previously recognised as a codon 213 silent polymorphism (CGA > CGG), and a
mutant sequence could not be obtained from a further 2. Of the remaining 11,2 had
an identical mutation (codon 248, CGG > CAG). As a result, 10 different point
mutations could potentially be used in ARMS for detection ofMRD. Amongst the
acute leukaemia samples, 3 showed abnormal banding on DGGE. Again, 2 were the
same codon 213 polymorphism described. Of the remainder, only 1 sample showed a
genuine somatic mutation, which on sequence analysis was a hitherto unreported 8 bp
insertion sequence (5'-CCGGGGGG-3') between the second and third bases of codon
281. Therefore, at the end of this stage of the project, a total of 11 mutations (10 of
which were single-base missense mutations) were found, which could be assessed for
their suitability as markers for MRD. This is described in Chapter 3.
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CHAPTER 3
AMPLIFICATION REFRACTORY MUTATION SYSTEM
(ARMS)
In order to use p53 mutations as markers for MRD detection, allele-specific primers
(ARMS primers) have to be designed, based on the exact nature of the mutation as
determined by sequence analysis. The main characteristic of such primers is that they
allow amplification with the mutant but not the WT allele, and it is crucial that they
are 100% specific, i.e., at a particular set of optimal conditions, no detectable product
be produced with the WT allele, where the detection system may be ethidium bromide
staining with UV light viewing, or PCR with radioactive 32-phosphorus (32P)-
labelled dCTP with autoradiography. It is important to understand that, unlike using
tissue-specific markers such as CK 19 for MRD detection, ARMS involves a
difference in the efficiencies of amplification using a mutant versus a WT template
(differing usually by a single base), under identical conditions. A product is still likely
to be produced with a WT template, albeit in much smaller quantities, and the
optimisation process is an attempt to maximise this difference between WT and
mutant for a particular detection system used.
In this chapter, a high specificity of an ARMS system refers to its ability to produce
no detectable product with a WT DNA template, while a high sensitivity refers to its
ability to produce a strong product with a mutant DNA template at low
concentration. I shall (1) first describe the principles behind the design ofARMS
primers to be used in PCR, then (2) methods of optimising the specificity of such
reactions by varying each of a number of reaction parameters, (3) attempts at
improving the sensitivity of such reactions to detect minimal disease, (4) the results of
efforts to optimise individual ARMS systems for the patients found to have markers in
Chapter 2, and (5) finally, the results of screening PBPCH's with optimised ARMS
systems. With all ARMS reactions that did not involve incorporation of 32P, 20 pi of
each 50 pi PCR product was mixed with 4 pi of 6X gel loading buffer, and
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electrophoresed in a 1.5 mm thick 6% polyacrylamide gel at a constant 45 mA current
for approximately 1 hr 15 min, stained with ethidium bromide (0.1 mg/1) for 20 min,
de-stained with distilled water for 20 min, viewed under UV light and photographed
with Polaroid '665' ISO 80 black and white film.
3.1 MATERIALS
Fresh T47D and 5637 cell lines in culture
Blood donors' bufiy coat white blood cells (SEBTS, Edinburgh)
Phosphate Buffered Saline (PBS)
'Red Cell Lysis Solution' (RCLS, see Section 2.1.3.1)
Coulter STKS Cell Counter (Coulter Ltd, UK)
Hybaid Omnigene Thermocycler (Hybaid, Life Sciences, Basingstoke, UK)
PCR primers described in Table 3.1, and PCR reagents described in Section 2.1.5.1.
Electrophoresis apparatus (Hoefer SE 600 tank) and accessories (as described in
Chapter 2)
For 32P-labelled PCR.
Mini electrophoresis tank and accessories (Biorad, UK)
Kodak X-omat X-ray film (Sigma, Poole, UK)
a-32P-dCTP (3000 Ci/mmol) (ICN, Basingstoke, UK)
Y-32P-ATP (3000 Ci/mmol) (ICN) - see Section 3.6.2.2
T4 polynucleotide kinase and 10X buffer (Promega, Southampton, UK) (see Section
3.6.2.2)
3.2 DESIGN OF ARMS PRIMERS
All ARMS primers were approximately 20 bp in length. All mutations found in the
breast cancer patients were missense mutations. The 3' base of an ARMS primer
incorporates the mutation itself. A deliberate mismatch was routinely introduced in
the neighbouring base in order to increase specificity of reactions, making WT DNA
even more refractory to amplification. Hence, a WT template was mismatched to the
primer in the last 2 bases at the 3' end, while a mutant template was mismatched to
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the primer only in the penultimate 3' base but fully matched in the 3'-most base.
Refractoriness was maximised by choosing the second mismatch such that a purine-
purine or a pyrimidine-pyrimidine mismatch resulted, and using guidelines described
by Newton and Graham (1994) (see Section 1.5.8). The cell line T47D was studied
most extensively, and a second ARMS primer for its mutation, involving only the
single 3' mismatch to WT but fully complementary to the mutant, was also studied.
The 8 bp insertion associated with the patient with ALL (patient LI 1, Section 2.8)
was more straightforward with regards ARMS primer design. The anti-sense strand
sequence was used for ARMS primer design, as this primer sequence involves only 2
matched bases with a WT template (4 and 6 bases from the 3' end) which was
unlikely to allow strand extension, whilst an ARMS primer placed on the sense strand
would have 5 matched bases to the WT template and much more likely to allow
strand extension, as indicated here.
ARMS primer on anti-sense strand:
WT template: 5'-TCTGTGCGCCGGT C T C TCCCAGGACAGG-3'
ARMS primer: 5'-TCTGTGCGCCGGC C C C CGG-3'
ARMS primer on sense strand:
WT template: 5'-CCTGGGAGAGA CCGG C G CACAGAG-3'
ARMS primer 5'-CCTGGGAGAGA CCGG GGG-3'
Bases underlined are the insertion sequence and bold type indicates bases matched to
a WT template. It was noted that an error in primer design was made in that only 7
bases (instead of 8) were inserted, with the last 5' C missing. However, in practice
this did not appear to affect efficiency or specificity ofPCR, and so it was decided to
continue with this primer sequence (2007-ARMS1).
A list of all the ARMS primers used in this project appears in Table 3.1. Included are
GC content and Tm of each ARMS primer and the opposite primer in PCR for
comparison.
In this project, I have elected to use one of the exon primers with each ARMS primer
in PCR, rather than designing another new primer. The reason for this is in order to
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Table3.1ListofARMSprimersus d.




















































































































































































































5-GGGCCTAT CAAC TAAG GGTG-3'
limit the number of steps involved in this ARMS system for MRD detection, which is
already a multi-step process. Table 3 .1 compares the GC content and Tm
characteristics of these primers.
3.3 OPTIMISATION OF ARMS REACTIONS - CELL LINE MODEL
Three cell lines, T47D (breast carcinoma), 5637 (bladder carcinoma) and Raji (non-
Hodgkin's lymphoma), were used as models in the work-up to indicate the various
factors that can be altered to make ARMS more sensitive and specific. 100%
specificity is defined as the absence of a detectable PCR product when WT DNA is
used as template for amplification. Whilst all 3 cell lines were used to study the effect
of Ta on the specificity of ARMS PCRs, T47D was the most extensively studied, with
respect to all of the following conditions:
(1) Annealing temperature of the ARMS PCR.
(2) Magnesium concentration.
(3) Presence ofglycerol.
(4) Presence of formamide.
(5) Total number ofPCR cycles.
(6) Primer concentration.
(7) dNTP concentration.
(8) One or 2-base mismatch with WT sequence at the 3' end ofARMS primer.
PCR's were performed as described, using WT or mutant DNA as template.
Reactions were performed in duplicates, always including one tube in which water
substituted DNA as a blank. 200 - 500 ng ofgenomic DNA was used per 50 pi
reaction mixture. Molecular weight markers were <j>X174 DNA digested by Haelll
(Promega, Southampton, UK).
3.3,1 ANNEALING TEMPERATURE (Ta)
The Ta of the ARMS PCR appeared to be the single most important factor in
achieving specificity of the system. Using each of the 3 systems with cell lines T47D,
5637 and Raji, Tas were increased from 55°C in 3 - 4°C steps. Fig. 3.1 shows the
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LANES 1 2 3 4 5 6 7 8 9 10 11 12
DNA WT M WT M WT M WT M WT M WT M
Ta(°C) 55 55 58 58 61 61 64 64 67 67 69 69
Fig. 3.1a Effect of annealing temperature (Ta) on T47D ARMS (Section 3.3.1). At this [Mg]
64°C is closest to being optimal, and further optimisation is required by lowering [Mg].
< 127bp ARMS product
Lane in far left is (j)X174/HaeIII molecular weight marker
«
<
LANES 1 2 3 4 5 6 7 8
DNA M WT M WT M WT M WT
Temp (°C) 61 61 64 64 67 67 70 70
Fig. 3.1b 5637 cell line annealing temperature titration (Section 3.3.1).
ARMS is specific across the annealing temperature range.
< 104bp ARMS product
« 360bp AAT control product
Lane in far left is <J)X 174/HaeIII molecular weight marker
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effect this had on T47D and 5637 systems. Denaturing and extension temperatures
were 94°C for 45 seconds and 72°C for 1 min, respectively. The magnesium
concentration ([Mg]) was fixed at 2.0 mM and the total number of cycles at 35. A
127 bp product was produced with the T47D ARMS primers. Whilst at a low Ta of
55°C, a difference in efficiency of amplification between WT and mutant templates
was seen, this was not specific (i.e., produce no product with WT). Many spurious
products were also visible. As the Ta increased, less product was seen with WT until
64°C when only a faint band is discernable. At higher temperatures, the product with
the mutant template also became much reduced so that the system was useless for
detecting minimal quantities of template (MRD). There was, therefore, a window in
which the Ta was optimal. With T47D, ARMS was still not specific at 64°C and other
factors had to be altered. The 5637 system, on the other hand, appeared much more
robust. Mutant DNA gave a much more intense 104 bp product, and ARMS was
specific across a wide range ofTa's. This system allowed maximum sensitivity and
specificity and was most suited for MRD detection.
3.3.2 MAGNESIUM CONCENTRATION ([Mall
Using the T47D system, the effect of altering [Mg] was investigated. Ta was kept at
64°C (see above), total cycle number at 35 cycles, and [Mg] was increased from a
final concentration in reaction of 1.0 mM, in 0.5 mM steps, to 5.0 mM (Fig. 3.2). The
higher the [Mg], the less specific the system, i.e., the stronger the product amplified
from WT template, and more spurious products were obtained. Specificity was
achieved when [Mg] was 2.0 mM or lower, optimally at 1.75 mM as repeated
experiments showed. Sensitivity was severely compromised with [Mg] of 1.5 mM or
less. The window of specificity with [Mg], therefore, was again very narrow for the
T47D system.
3.3.3 PRESENCE OF GLYCEROL
Some authors report improved specificity ofARMS by the addition of glycerol, when
the quantity ofDNA template is minimal (Cha et al, 1992). The effects of adding 5,
10, 15 or 20% ofmolecular biology grade glycerol to the ARMS reactions were
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LANE123456789101234516789 DNAH20WTMTWTMWT [Mg]mM2.01.52.053..4 0.55. FIG3.2Effectof[Mg]nT47DARMS(Section3 3.2).[ g]of2mMresultedi specificAR Srea tionwi hmu a tDNAly(lanes6and7). <127bpARMSproduct Laneonf rleftis4>X174/Ha IIImolecularw ightm rke .
studied (Fig. 3.3). Five percent glycerol did not have any effect on improving
specificity, while at higher concentrations specificity was improved. Glycerol at
concentrations of up to 20% did not significantly affect reactions using a mutant DNA
template, but higher concentrations did not improve specificity better than lower
concentrations (10%). One major drawback of using glycerol was the viscosity of this
chemical which led to inaccurate pipetting. This was at least partially remedied by
heating an aliquot ofglycerol to 70 - 80°C prior to pipetting. Because of the potential
inaccuracies in pipetting and the slight effect on amplification of the mutant product,
glycerol was not used routinely in ARMS that did not involve radio-nucleotides. It
was reasoned that when 32P-labelled PCR was used, the potential problem of a lower
sensitivity might be solved by increasing exposure time to the X-ray film (see below).
3.3 4 PRESENCE OF FORMAMIDE
Formamide has been used to enhance specificity ofPCR, although not in the context
of ARMS. The effects of formamide in the ARMS reaction was studied by using
2.5%, 5%, 7.5% or 10% in ARMS PCR reactions (Fig. 3.4). The results show that
formamide has a marked suppressive effect on ARMS reactions even at lower
concentrations. Amplification with both WT and mutant was suppressed, even at
2.5% and no product was observed at concentrations higher than 7.5%. Formamide,
therefore, had no apparent role in ARMS reactions as assessed here.
3,3,5 EFFECT OF CYCLE NUMBER
As the intensity of a band corresponding to a PCR product on a polyacrylamide gel is
proportional to the amount of product present, which, in turn, has an exponential
relationship to the number of cycles of amplification performed, both the ability of an
ARMS system to be specific and sensitive may depend on the number of cycles used.
For the T47D system, a relatively non-specific set of conditions - a low Ta of 61 °C
and a [Mg] of 2.0 mM were used to study the effect of reducing cycle number. As
shown in Fig. 3.5, using 30 instead of 35 cycles abolished the WT product, but also
reduced the intensity of the mutant product. Lowering to 25 cycles almost abolished
the mutant product as well. This suggested that lowering the number of cycles of PCR
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LANES 1 2 3 4 5 6 7 8 9 10
DNA WT M WT M WT M WT M WT M
Glycerol(%) 0 0 5 5 10 10 15 15 20 20
Fig. 3.3 Effect of glycerol on T47D ARMS (Section 3.3.3). 10% or more of
glycerol appears to improve specificity ofARMS.
< 127bp ARMS product
Lane in far left is (j)X 174/HaeIII molecular weight marker
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LANES 1 2 3 4 5 6 7 8 9 10 11
DNA H20 WT M WT M WT M WT M WT M
formamide(%) 0 0 2.5 2.5 5 5 7.5 7.5 10 10
Fig. 3.4 Effect of formamide on T47D ARMS (Section 3.3.4). Formamide has
a strong inhibitory effect on ARMS PCR.
< 127bp ARMS product
H20 water control
Lane in far left is <j)X174/HaeIII molecular weight marker
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improved specificity, but at the expense of sensitivity, and again, there was only a
fairly narrow window in which a balance of the two was achieved. Increasing cycle
number under more stringent PCR conditions in which ARMS is normally specific
were also studied. A Ta of 67°C and [Mg] of 2.0 mM were chosen (Fig. 3.6). After
35 cycles, a clear product with mutant DNA but none with WT DNA was seen.
Under the same conditions but increasing the cycle number to 40, produced a clear
product with WT DNA. Increasing further to 45 cycles gave an even stronger product
with other spurious bands appearing as well.
3,3.6 PRIMER CONCENTRATIONS ([PRIMERS!)
The effect reducing the concentrations of both primers in ARMS has on specificity of
the T47D system was studied. Again, a less specific set of conditions, using a Ta of
61 °C, 2.0mM [Mg] and 35 cycles were used. Standard concentration of each primer
in the reaction mixture was 0.25 pM. In addition, concentrations of 0.15, 0.075 and
0.025 pM were used, under otherwise identical conditions. These represented 60%,
30% and 10% of the full concentration, respectively. Fig 3 .7 shows that amplification
efficiency with both WT and mutant template was reduced with decreasing [primers],
and at 0.025 pM the mutant product was too weak. This showed that reducing
[primers] did not differentially affect the WT reaction, and sensitivity could be
compromised.
3 3 7 dNTP CONCENTRATIONS (TdNTPl)
[dNTP] has been reported to be an important parameter in achieving a high
specificity. The effect of 5 other [dNTP] on ARMS specificity in the T47D system
was studied. Standard concentration of each dNTP used was 200 pM. In addition,
[dNTP] of 50, 25, 12.5, 6.25 and 3.125 pM were tested in reaction mixtures (Fig.
3.8). It was clear that, like many of the other parameters above, lowering [dNTP]
reduced amplification ofboth WT and mutant templates, and when full specificity was
achieved, the mutant ARMS product was too weak to be detected.
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LANE 1 2 3 4 5 6 7 8
DNA H20 WT WT M M WT WT M M
CYCLES 30 30 30 30 35 35 35 35
Fig. 3.5 Effect of lower cycle number on T47D ARMS (Section
3.3.5). Less stringent conditions (Ta 61°C, [Mg] 2.0mM) were used
to assess the effect of lowering cycle number.
< 127bp ARMS product
H20 water control
Lane in far left is <|)X174/HaeIII molecular weight marker
108
LANE 123 4 567 8 9 10 11 12
DNA WT WT M M WT WT M M WT WT M M
Cycles 35 35 35 35 40 40 40 40 45 45 45 45
Fig. 3.6 Effect of higher cycle number on T47D ARMS. More stringent
conditions (Ta 67°C, [Mg] 2.0mM) were used to assess the effect of increasing
cycle number.
< 127bp ARMS product
Lane in far left is (})X174/HaeIII molecular weight marker
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LANES 123 456789 10
DNA | H2Q Hp WT WT M M | | WT WT M M |
[PrimersJgM 0.25 0.15
LANES 11 12 13 14 15 16 17 18
DNA I WT WT M M | I WT WT M Ml
[Primers] |iM 0.075 0.025
Fig 3.7 Effect of [primer] on T47D ARMS (Section 3.3.6). Lowering the
[primer] reduces efficiency of bothWT and M amplifications.
< 127bp ARMS product
H20 water control
Lanes in far left are <})X174/HaeIII molecular weight markers
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LANES 12 34 5 67 8 9 10 11 12
DNA WT M WT M WT M WT M WT M WT M
dNTP (mM) 200 200 50 50 25 25 12.5 12.5 6.25 6.25 3.12 3.12
Fig. 3.8 T47D ARMS [dNTP] titration (section 3.3.7). Reducing [dNTP]
appeared to have affected amplification with both WT and mutant DNA
equally. No product was produced with either at the lower extreme of
[dNTP].
< 127bp ARMS product
Lane in far left is <|)X174/HaeIII molecular weight marker
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3.3 8 USE OF 1 VERSUS 2 MISMATCHES AT 3' END OF ARMS PRIMER
The sequence of the ARMS primer (T47D-ARMS1) used above corresponds to the
sense strand, and in PCR, is used with the opposing primer on the anti-sense strand
known as E-Bio. Apart from having thymine in the 3' position, resulting in a T:G
mismatch with WT template, a deliberate mismatch A:A was also introduced in the
penultimate base by substituting adenine for thymine. Hence this primer was
mismatched to WT at the last 2 bases, and mismatched to the mutant sequence in the
penultimate base only, i.e., fully matched in the 3' position and should allow strand
extension to occur during PCR. To determine if it was important for a second
mismatch to be inserted in order to improve ARMS specificity and ease of
optimisation, primer with one- ('ARMS2') or two- ('ARMSl') base mismatches were
compared in the T47D system. PCR conditions were otherwise identical. Fig 3.9
shows that, with Ta of 64°C, [Mg] of 2.0 mM, and 35 cycles of amplification, PCR
with T47D-ARMSl was specific, with no visible product amplified from a WT
template, while a clear product was observed with T47D-ARMS2. Further
optimisation experiments (data not shown) suggested that optimisation with T47D-
ARMS2 was more difficult and more stringent conditions, e.g., higher Ta's, were
required. Therefore, ARMS primers with 2 mismatches to WT were routinely used in
all the ARMS systems in this project.
3,3.9 CONCLUSIONS FROM OPTIMISATION EXPERIMENTS
From optimisation experiments above, assessing the effect of 8 different parameters, it
appeared that the most important parameter to optimise, is the Ta. If an optimal
temperature can be achieved within the range used in PCR, i.e., lower than the
extension temperature (72°C in this case), no further optimisation is required. If full
specificity is not achieved, the next step would be to reduce the [Mg] until no product
is produced with WT template. From these experiments, reducing the [primers] and
[dNTP's] affected the WT and mutant reaction equally, and did not appear to have a
critical role in optimisation. It would appear, therefore, that the third step to achieve
higher specificity was either to add glycerol (10% optimal) or reduce the total number
ofPCR cycles. In this project, as explained above, glycerol was not used routinely in
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LANES 123456 78 9
DNA H20 WT WT M M WT WT M M
Bases mismatched 222221 11 1
Fig. 3.9 Effect of ARMS primer with 1- or 2- base mismatch on T47D ARMS
reaction (section 3.3.8). Under identical conditions, the ARMS primer
mismatched to WT in 2 bases produced a highly specific ARMS system, whilst
the primer with only 1 base mismatched was non-specific.
H20 water control
Lane in far left is ())X174/HaeIII molecular weight marker
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non-radioactive reactions owing to potential errors with pipetting inaccuracies,
although glycerol may have a role in ARMS reactions in which the best conditions
achieved are just not specific enough. As indicated below, the possibility of improving
sensitivity of ARMS by using radio-labelled nucleotides or primers in PCR, or using a
nested system was investigated.
3.4 MIXING TUMOUR CELLS IN DONOR BUFFY COATWHITE CELLS
To investigate the limit of detection ofARMS using p53 point mutations as markers,
cell mixing experiments were performed with the cell lines T47D and 5637, mixed at
varying dilutions in normal blood donors' peripheral blood buffy coat white cells.
These 2 lines were kept in constant culture for the duration of this project. Mixing
experiments were performed by harvesting each cell line fresh, washing them once in
HBSS, and resuspending in PBS, ensuring that single-cell suspensions were achieved,
usually by gentle aspiration up and down with a wide bore glass pipette which
reduced the possibility of lysing the cells. Resuspended cells were temporarily kept on
ice. Blood donors' buffy coats were obtained from the Components Section, SE
Scotland Blood Transfusion Service, Edinburgh, as unwanted fractions after platelets
had been extracted from them, and were between 24 and 48 hr old. Each volume
(typically 10 ml) of bufly coat was red-cell-lysed twice with 4 volumes ofRCLS,
washed once and resuspended in (approximately 5 ml) PBS. Both cell line and bufiy
coat cells were counted with a Coulter STKS counter, and the numbers expressed in
millions per ml. The number of buffy coat cells were invariably several times higher
that those of either cell line, and were diluted down with PBS to the same
concentration as that of the cell line to be spiked in them. Tumour cells were then
spiked in buffy coat cells to a ratio of 1:10, and further 10-fold serially diluted in bufiy
coat cells to 1:100, 1: 10', 1:104, 1:105, 1:106 and 1:107. The total number of cells for
each dilution was between 5xl06 and lxlO7. The cells were centrifuged and
resuspended in 200 pi of PBS. DNA was then extracted from each pellet as per the
Qiagen protocol described in Section 2.1.3. DNA concentration was determined and
cryopreserved at -20°C until required.
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3.5 ARMS MODEL FOR MRP DETECTION
3 5 1 USE OF INTERNAL CONTROL
In these experiments ARMS PCR's were performed on DNA extracted from cell
pellets in which tumour (5637 and T47D lines) cells were spiked in normal buffy coat
DNA prepared above. These DNA samples were also separately amplified, under
identical conditions, by a pair of primers (AAT1 and AAT2) corresponding to a
fragment of exon 3 of the a 1-antitrypsin (AAT) gene giving a product of 360 bp
(Wenham et al, 1991a). Amplification of this product confirmed the absence of factors
inhibitory to PCR in the DNA extracts. Moscinski et al (1994) using P-actin as
internal control in one of the most sensitive systems for detecting cytokeratin 19
message by RT-PCR performed the reactions separately and mixed the product with
CK19 PCR product prior electrophoresis. Separate reactions were performed for the
AAT controls, rather than multiplexing PCRs in the same tube, in order to avoid the
potential risk of the control reaction (which is a far more efficient system) reducing
the detection limit of the ARMS system by competing for reagents and Taq
polymerase. In the experiments below, 20 pi of each ARMS PCR product was mixed
with 2 pi of product from the corresponding AAT control reaction, and 4 pi of 6X
loading buffer, and loaded onto each lane prior to electrophoresis.
3.5.2 LIMITS OF DETECTION
As can be seen above, the ease of achieving a high specificity with ARMS varies even
between cell lines with different point mutations, when good quality, fresh DNA is
used. The efficiency of amplification also varied, and under optimal conditions, a
stronger PCR product was seen on PAGE for the 5637 cell line than for T47D. This
was reflected in the different limits of detection in these 2 systems. Fig. 3.10 illustrates
the titration for 5637. This experiment demonstrated that, when cycling conditions
were optimal, mutant DNA could be detected when one 5637 cell existed amongst
105 normal cells, although on repeated experiments, 1:104 was much more
reproducible. The AAT controls worked equally well with all DNA samples. With
T47D, however, ARMS with mutant DNA appeared less efficient and at optimal
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cycling conditions (Ta 64°C, [Mg] 2.0 mM, 35 cycles) a detection limit of 1 cell in
10" was achieved (Fig. 3.11). These 2 cell lines indicate that, with different point
mutations, there can be at least a one log difference between limits of detection.
3.6 ATTEMPTS AT IMPROVING LIMITS OF DETECTION
3.6.1 USING NESTED PCR
Nested PCR systems involve 2 separate PCR reactions, with the second set of primers
internal to the first set, and an aliquot of product from the first reaction was used as
template for the second reaction. In general terms, nesting improves specificity of
PCR as non-specific products from the first round amplification are unlikely to be
sufficiently complementary to the nested primers to be used as template (Newton and
Graham, 1994). Sensitivity ofPCR is also enhanced as the copy number of template
for the inner nest reaction is much higher. Outer nest PCR was performed on 500 ng
of genomic WT and mutant T47D DNA, and 5 pi (10%) of outer nest PCR product
used as template for the inner nest reaction, under identical cycling conditions (Ta
64°C, [Mg] 1.75 mM, 35 cycles, normally specific for the T47D system). Primers for
the outer nest reaction were E-GC and E-Bio as used for fragment E amplification as
described in Section 2.1.5.3. For the inner nest, a semi-nested system versus a fully
nested system were studied. In the former, primers T47D-ARMS1 and E-Bio were
used, i.e., only one end of the inner nest product was internal to the outer nest
product. In the latter, T47D-ARMS1 and another primer on the anti-sense strand, E-
NB2, were used, and the resulting 100 bp product was fully internal to the first. The







LANES 12 3 4 5 6 7 8
DNA(M:WT) H20 WT 1:10s 1:10s 1:10s 1:102 1:10 1:2 M
Fig. 3.10 5637 cell line ARMS detection limit dilution experiment
(Section 3.5.2). ARMS product visible down to 1 in 105.
< 127bp ARMS product
« 360bp AAT control product
H20 water control
Lane in far left is (j)X174/HaeIII molecular weight marker
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LANES 123 45 67 89
DNA(T47D:WT) H20 WT WT 1:10s LIO4 1:10s 1:102 1:10 M
Fig. 3.11 T47D ARMS detection limit dilution experiments (Section
3.5.2). Detection limit is 1 cell in 103 buffy coat cells.
< 127bp ARMS product
« 360bp AAT control product
H,0 water control
Lane in far left is <))X174/HaeIII molecular weight marker
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The sequence ofE-NB2 was chosen empirically, ensuring similar GC content and Tm
to T47D-ARMS1. As expected, for both systems, a much more intense product was
produced with T47D DNA. However, specificity was completely lost and an intense
product was also produced with WT template. Many spurious products were
amplified on direct transfer of outer nest PCR product to the second reaction, and
diluting the outer nest product 1 in 500 in water removed these products but did not
alter the specificity. Fig. 3.12 illustrates these results.
3.6 2 USING 32P RADIOLABELLED NUCLEOTIDES IN PCR
ARMS PCR incorporating 32P was studied as an alternative means of product
detection to ethidium bromide and UV light. The rationale for this was two-fold: (1) a
small quantity of a PCR product may be made more readiy visible by prolonging the
exposure time of the polyacrylamide gel to the X-ray film, and (2) because of this,
cycling conditions may be made more stringent such that specificity of ARMS is
maximised, and although under these conditions mutant DNA is also less efficiently
amplified, their product may be visualised by increasing film exposure time. PCR
products were radiolabeled by each of two means: (1) using a-32P-labelled dCTP in
the PCR reaction mix such that it was incorporated into multiple positions on the
product where cytosine occurred, and (2) using y-32P-labelled ATP to radio-label the
ARMS primer by means ofT4 polynucleotide kinase, in which case each molecule of
PCR product contained only one label.
3,6,2.1 USING q-32P RADIOLABELLED DCTP
ARMS PCRs were performed along the general principles ofPCR described in
Section 2.1.5, and similar cycling conditions to the corresponding non-radiolabelled
reactions were used. The major difference is a reduced concentration of non-
radiolabelled dCTP in the reaction mix from 200 pM to 20 pM, and 0.5 pi of a-32P-
dCTP (3000 Ci/mmol), or 5 pCi was added to each reaction. Concentration of all
other dNTPs was 200 pM. As explained in Section 3.3.3, 10% glycerol was routinely
included in these reactions to improve specificity. To avoid excessive handling of
radioactive material, the entire 50 pi ofPCR product was mixed with 10 pi of6X
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LANES 12345678 9 10
DNA H20 H20 WT M WT M WT M WT M
Nesting SFSSFFSS FF
Fig 3.12 Effect of nesting on T47D ARMS (Section 3.6.1). ARMS
using WT and tumour DNA were performed both with a semi-nested
(S) system giving a 127bp product and a fully nested system (F)
giving a lOObp product. Outer nest PCRs were performed with
fragment E primers, and the outer nest products were either subject
to inner nest PCR immediately (lanes 3-6) or diluted in water 1:500





Lane in far left is (J)X174/HaeIII molecular weight marker
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loading buffer, and 6 jiil of the mixture loaded onto each lane of a 8% mini
polyacrylamide gel and electrophoresed in a Biorad mini tank for approximately 1 hr.
The gel was placed on blotting paper, wrapped in cling film and exposed to Kodak X-
omat film in a cassette with intensifying screen for 1 to 16 hr at -70°C using counts
from a hand-held Geiger counter as a guide to exposure time. In the T47D system,
while ARMS was specific with Ta of 64°C and [Mg] of 1.75 mM when the ethidium
bromide stained gel was viewed under UV light, with 32P-labelled PCR a product
was readily visible when WT DNA was amplified. Increasing Ta to 67°C significantly
improved specificity, exposure ofX-ray film to the gel for 1 hr 20 min produced no
product with WT template. However, a WT PCR product was evident on exposure
for 8 hr (Fig. 3.13). This high-lights the fact that the heart of ARMS systems used in
this project is the distinction of a PCR product with a mutant template over and above
that with WT, ie, a difference in the efficiencies of the two reactions, and hence when
radio-labelled PCR products are visualised, it is important to adjust the exposure time
to X-ray film (largely empirically) so as to maximise sensitivity of the system.
Two main drawbacks of using 32P were recognised. (1) Previously optimised
conditions based on ethidium bromide staining may no longer be optimal, and cycling
conditions may need to be re-adjusted, as demonstrated here with T47D. (2) 32P-
labelling of PCR products performed as described was much less reproducible than
non-radioactive reactions, and repeated optimisation experiments often yielded
inconsistent results, so much so that some of the systems here became unworkable.
This was the case with the T47D model system. Although optimising 32P-labelled
ARMS appeared relatively straightforward, dilution experiments to determine the new
level of detection using the same set ofDNAs in Section 3.5.2 gave inconsistent
results, showing loss of specificity, poor amplification with T47D DNA, and irregular
amplifications in the series of dilutions. The situation was not remedied by repeated
experiments, taking care to ensure correct pipetting and mixing, and inevitably the




DNA WT WT MM
DNA WT WT M M
Fig. 3.13 a & b T47D ARMS using 32P radiolabeled
dCTR ARMS is specific for mutant DNA but some
products are made with WT DNA which become visible
on prolonged exposure of X-ray film (8 hours). These are
not visible when exposure is 1 hour 20 min.
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3 6 2 2 USING V-32P RADIOLABELLED ARMS PRIMER
An alternative method of radiolabelling PCR products by 32P-labelling the ARMS
primer was attempted. A reason for using this approach was that each molecule of
primer, and hence PCR product, was labelled only once, whilst in PCR using
radiolabeled dCTP multiple radiolabeled nucleotides were inserted into each
molecule of product, and depended on the efficiency of this incorporation and the
relative competition with unlabeled dCTP in the reaction mix. The labelled primer
approach could, therefore, produce a more uniform signal and more consistent results.
This involved 2 separate steps: (1) radiolabelling the ARMS primer, and (2) the PCR
itself. Reagents for step 1 are as follows:
Y-32P-ATP (3000 Ci/mmol)
T4 polynucleotide kinase (10 U/pl)
10X kinase buffer with 700 mM Tris-HCl (pH 7.6), 100 mM MgCl2, 50 mM DTT
T47D-ARMS1 primer (14.5 pmol/pl from manufacturer)
Labelling was performed as follows. Each 10 pi of labelling mix contained:
T47D-ARMS1 primer 5.17 pi (total 75 pmol)
T4 polynucleotide kinase (5 U/pl) 1 pi (total 5 U)
1 OX kinase buffer 1 pi
32P-ATP 1 pi (total 10 pCi)
H20 1.83 ul
Total 10 pi
Volume ofT47D-ARMS1 primer was calculated from the weight per pi and
concentration, based on 1 pg of primer per 10 pi labelling mix. T4 kinase was diluted
1 in 2 with water before use. The labelling mix was incubated at 37°C for 20 min and
heated to 95°C for 5 min to inactivate the enzyme. After brief centrifugation, aliquots
of the labelled primer was used in PCRs which were otherwise performed exactly as
the unlabelled reactions. A volume of 1.66 pi of T47D-ARMS1 primer was used per
50 pi reaction, equivalent to the usual quantity of 12.5 pmol. Because of the lower
signal intensity from each molecule ofPCR product, the entire product was mixed
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with 6X loading buffer and electrophoresed in a standard 1.5 mm thick 6%
polyacrylamide gel. Autoradiography was as in the preceeding section.
In multiple labelling experiments, this approach unfortunately suffered from the same
inconsistency and lack of reproducibility with the radiolabeled dCTP approach, if not
more so, and as each ARMS primer was radiolabeled, background signals were
produced from occasional spurious products and unused primers. This approach also
had to be abandoned.
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3.7 RESULTS OF ARMS OPTIMISATION AND SENSITIVITY IN
CLINICAL SAMPLES
3 71 ARMS IN BREAST CANCER SAMPLES
Base on the conclusions of Section 3.3, attempts were made to systematically
optimise ARMS PCR's for those breast tumours found to contain a point mutation in
p53 (Chapter 2). Of 51 primary breast tumours, 13 (25.5%) were found to contain
mutations in p53. In 2 of these, repeated sequencing was unable to yield a sequence in
the DNA fragment concerned different from the WT. Of the remaining 11 tumours, 2
had an identical missense mutation, CGG > CAG in codon 248. Hence there were 10
ARMS systems to be optimised, all involving a different single base missense mutation
(Table 2.7).
Optimising these ARMS systems proved to be much more difficult in practice than in
theory. Three of them were not able to be optimised (patients B33, B46, B50).
Essentially, amplification with WT and mutant DNA templates behaved similarly and
the ARMS system was unable to differentiate between the two with a single base
difference. ARMS primers for patients B46 and B50 both involved E-NGC as the
opposite primer, and close scrutiny of the GC content and Tm's of these primers
suggests that they are similar and should otherwise be well-matched. Also, the second
mismatch deliberately introduced was a C:T mismatch in each case and, being fairly
high on the Newton and Graham (1994) ranking of destabilising mismatches, should
make WT DNA refractory to amplification. There is also no obvious complementarity
between the primers to enable primer-dimer formation. The ARMS system for patient
B33 involved the use of primers (3 757/94-ARMS 1 and C-NB) with moderately
different Tm's (60.9°C versus 49.6°C) and GC content (56% versus 45%). There is a
run of 6 bases 5' in C-NB, plus 5 isolated bases downstream that are complementary
to 3757/94-ARMS1, and anealing of these primers could potentially occur during
PCR, and might have contributed to the failure of optimisation. This is indicated
below, with the complementary bases in bold.
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C-NB: 3 -A C AT C A AC AT C A CCT ACC AC-5'
3757/94-ARMS1: 5'-GT G AT G A TG GT G A GGATGG GCCTGT-3'
Of the remaining 7 samples, only 5 could be reasonably optimised to be of use in
detecting minority mutant DNA species. Optimisation of the other two, patients B45
(primers 1232/94-ARMS 1 and B-NGC) and B27 (primers 7071/90-ARMS 1 and E-
Bio), was difficult, and WT and mutant PCRs could not be differentiated sufficiently,
such that when specificity was optimised, PCR product from the mutant template was
too weak to be of use in MRD detection. The mutation involved in patient B27 was
subsequently shown to be a germ-line mutation (Chapter 4), which made it unsuitable
as an MRD marker. This mutation was found in all tissues, malignant or normal, from
this patient.
There remained patients B3, B11, B16, B30 and B37 in whom the ARMS systems
were optimised, and could be used to screen PBPCH's. In the account below, the
ARMS systems are identified by the name of the ARMS primer used in each case (see
Table 3.1).
(1) Patient Bll (HB-ARMS1 system). The ARMS system for this patient was
probably the most satisfactorily optimised. Using [Mg] of 1.5 mM, only the Ta needed
to be adjusted. Specificity was achieved at 63°C, but it could be increased to 67°C
without compromising the intensity of the mutant PCR product. Therefore, the
optimised conditions were annealing at 67°C and [Mg] of 1.5 mM, amplified in a total
of 35 cycles (Fig. 3.14). Tumour DNA was then spiked in WT control DNA in serial
dilutions to determine the detection limit of this system (Fig. 3.15). With repeated
experiments, it was shown that 1 part of tumour DNA in 1CF parts ofWT DNA could
be reliably detected using ethidium bromide staining and UV light viewing of the gel.
AAT control PCR indicated that no inhibitory factors were present. It was noted that
the opposing primer used in PCR with HB-ARMS 1 was B-GC, which is the GC-
clamped primer used for initial amplification in DGGE. This primer was a 60-mer with
the 40 bases 5' made up entirely of guanine and cytosine residues. As a result, the
overall GC content of B-GC was much higher than HB-ARMS 1, and the Tm was at
126
LANES 1 2 3 4 5 6 7 8
DNA M WT M WT M WT M WT
Ta(°C) 63 63 65 65 67 67 69 69
Fig. 3.14 Patient B11 ARMS optimisation of annealing
temperature (Ta) (Section 3.7.1). Each pair of lanes
represents PCR with mutant (M) and WT DNA
respectively. ARMS is efficient at a wide range of Ta.
67°C was chosen in this project.
< 140bp ARMS product




DNA(M:WT) Hp WT 1:10' L104 1:10' 1:102 1:10 M
Fig. 3.15 Patient Bll ARMS detection limit dilution experiment
(Section 3.7.1). ARMS product visible only down to 1 in 103.
< 140bp ARMS product
« 360bp AAT control product
R,0 water control
Lane in far left is <|)X174/HaeIII molecular weight marker
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least 30°C higher. The ARMS system using this pair of primers worked surprisingly
well, and paradoxically when the 20 bp equivalent of primer B-GC without the GC-
rich region (B-NGC) was used instead, PCR efficiency was much reduced.
(2) Patient B16 (LB-ARMS1 system). This system was also relatively easily
optimised. With [Mg] of 2.0 mM and Ta of 64°C, 35 cycles ofPCR achieved a high
specificity. Fig. 3.16 indicates the detection limit was also approximately 1 in 10'1
when tumour DNA was serially diluted in WT DNA.
(3) Patient B3 fBD-ARMS 1 system). Optimal conditions were achieved with a Ta of
64°C and [Mg] was 2.0 mM (Fig. 3.17). Dilution experiments, however, indicated
failure of detection beyond 1 in 100, which was surprising, as optimisation was
straightforward and the mutant product appeared relatively intense. Judging by the
above results, the sensitivity would have been expected to be at least another log
higher. Sampling error would be the most likely cause for this, despite considerable
care in ensuring DNAs were thoroughly mixed (Fig. 3.18).
(4) Patient B37 (2477/96-ARMS 1 system). Optimisation was more difficult. The
highest tolerated Ta was 69°C whilst [Mg] was 2.0 mM. When [Mg] was lowered,
specificity did not improve sufficiently before the mutant DNA product became too
weak to be visualised. Hence, with a compromised set of conditions at Ta 69°C and
[Mg] 1.75 mM, cycle number titration was performed (Fig. 3.19) There was a sharp
drop in intensity of the mutant product at 33 cycles or lower, but the WT was no
longer visible. Therefore, with the above Ta and [Mg], 33 cycles were optimal.
Alternatives were tried, by titrating the [dNTP] and [primers], but satisfactory
optimisation could not be achieved. This patient, as patient B11, had a point mutation
in fragment B (exon 5) of p53. The ARMS primers used for both had 65% GC
content and a Tm of 57.8°C. The second mismatch introduced was C:T for both, and
the 3' mismatch was G:T for B11 and A:C for B37. As the GC-clamped B-GC primer
worked well with primer lTB-ARMSl, this was substituted for B-NGC with 2477/96-
ARMS1 for patient B37. Unfortunately, unlike the B11 system, this pair of primers
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LANES 12 3 4 5 6 7 8
DNA(M:WT) H20 WT 1:10' L104 1:10' 1:102 1:10 M
Fig. 3.16 Patient B16 ARMS detection limit dilution experiment
(Section 3.7.1). ARMS product visible only down to 1 in 103.
< 130bp ARMS product
« 360bp AAT control product
H20 water control
Lane in far left is 4>X 174/HaeIII molecular weight marker
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LANES 12 3 45 678 9 10 11
DNA H20 WT M WT M WT M WT M WT M
TEMP (°C) 55 55 61 61 64 64 67 67 69 69
Fig. 3.17 Patient B3 ARMS annealing temperature titration (section 3.7.1). Ta
of 64°C or higher is optimal.
< 87bp ARMS product
H,0 water control
Lane in far left is (j)X 174/HaeIII molecular weight marker
LANES 12 3 4 5 6 7 8
DNA(M:WT) H;0 WT 1:105 L104 1:10' 1:102 1:10 M
Fig. 3.18 Patient B3 ARMS detection limit dilution
experiment (Section 3.7.1). ARMS product visible only down
to 1 in 102.
< 127bp ARMS product
« 360bp AAT control product
H20 water control
Lane in far left is <j)X174/HaeIII molecular weight marker
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LANES 1 23 45 67 89 10 11
DNA H20 WT M WT M WT M WT M WT M
CYCLES 35 35 34 34 33 33 32 32 31 31
Fig. 3.19 Patient B37 ARMS cycle number optimisation (Section 3.7.1).
ARMS is specific with 33 cycles of PCR. At 34 or more cycles, a product is
seen with WT DNA template, and specificity is lost.
< 112bp ARMS product
H,0 water control
Lane in far left is (|>X174/HaeIII molecular weight marker
LANES 12 3 4 5 6 7 8
DNA(M:WT) H,0 WT 105 1 04 1 01 102 1 0 M
Fig. 3.20 Patient B37 ARMS detection limit dilution experiment (Section
3.7.1). ARMS product visible only down to 1 in 103.
< 112bp ARMS product
« 360bp AAT control product
H,0 water control
Lane on far left is ())X 174/HaeIII molecular weight marker.
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did not produce efficient amplification across a wide range of Ta's, and was
abandoned. Serial dilution experiments indicated a detection limit of 1:10" for this
ARMS system (Fig. 3.20).
(5) Patient B30 (2668/96-ARMS1 system). The optimal Ta was much lower than the
rest, at 56°C, [Mg] was 2.0 mM and cycle number was 35 in total. Disappointingly,
DNA spiking and dilution experiments suggested a detection limit of only 1:100 for
this system (Fig. 3.21).
Table 3.2 lists the optimal conditions achieved for all the ARMS systems assessed in
the breast cancer patients, regardless of the intensity of the signal produced with a
mutant template.
For patient B45, in whom optimisation was not possible because ARMS using a
primer with a deliberately mismatched penultimate base was unable to differentiate
WT or mutant DNA, another primer (1232/94-ARMS2) involving 2 instead of 1
additional deliberate mismatches was attempted in order to make ARMS with a WT
template more refractory. In this situation, this primer was mismatched to a WT
template at all of the last 3 bases, whilst fully matched to mutant at the last base but
mismatched at the next two. Fig 3.22 confirms that this approach did improve
specificity even at low Ta's, but not surprisingly, products given with a mutant
template were too weak on ethidium bromide fluorescence to be of value in MRD
detection. Furthermore, many spurious products were also made. Further attempts at
using such a mismatching approach in other tumours were, therefore, not made.
3.7,2 USE OF 32P-LABELLED PCR IN THE 5 OPTIMISED SYSTEMS
The following observations were made with the 5 optimised ARMS systems described
above. For patient B16, the original optimised conditions (Ta 64°C, [Mg] 2.0 mM)
remained optimal, as was the case with patient B11 (Ta 67°C, [Mg] 1.5 mM). For
patient B3, Ta was increased to maintain specificity (Ta 67°C, [Mg] 2.0 mM). In
addition, all had 10% glycerol added. For patient B37, although lowering [Mg] from
1.75 mM to 1.5 mM in initial experiments improved specificity, repeated experiments
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LANES 12 3 4 5 6 7 8
DNA(M:WT) H20 WT 1:10s 1.104 1:103 1:102 1:10 T
Fig. 3.21 Patient B30 ARMS detection limit dilution experiment (Section
3.7.1). ARMS product visible only down to 1 in 102.
< 115bp ARMS product
« 360bp AAT control product
H20 water control
Lane on far left is <j)X174/Hae molecular weight marker
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LANE 1 2 3 4 5 6 7 8 9
DNA h2o WT WT M M WT WT M M
Ta(°C) 47 47 47 47 47 50 50 50 50
Fig. 3.22 Patient B45 ARMS using a primer (1232/94-ARMS2)
which involves 2 additional deliberate mismatches at the penultimate
positions. The primer is mismatched to WT DNA at the two
penultimate bases. PCRs were performed in duplicates at 2 different
annealing temperatures (47°C and 50°C). The reactions are specific
for mutant DNA, giving a 125bp product, but the intensity of the
products is too weak and many spurious products are also obtained.
< 125bp ARMS product
H20 water control
Lane in far left is <[>X 174/HaeIII molecular weight marker
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gave inconsistent results and the system could not in the end be optimised.
Inconsistent results upon repeated experiments were also obtained for patient B30,
and this again had to be abandoned.
3.7.3 ARMS IN ACUTE LEUKAEMIA SAMPLE / CASE REPORT OF PATIENT
LI 1
As indicated in the previous chapter, the incidence of p53 mutations in this cohort of
acute leukaemia patients was disappointingly low. The incidence of over 30% in
relapsed disease (Zhu et al, 1996) was not confirmed here. Apart from 2 patients with
constitutional silent polymorphism in codon 213, only one patient was found to
contain a somatic mutation in fragment D (exon 8) of p53. Interestingly, this patient
had previously been studied in our department by IgH gene and TCRa gene
rearrangement studies and was demonstrated to have 2 separate leukaemic clones
assuming different importance during his disease (Langlands et al, 1993). This 16 year
old male presented with anaemia, fundal haemorrhages and hepatosplenomegaly, and
was found to have a white blood cell count of 151 x 109 /l. TdT, HLA class II and
CD 19 positive pre-B cell ALL was diagnosed. A t(4; 11) translocation was detected.
Remission was achieved with induction chemotherapy, after which PBPC were
collected. A second collection ofPBPC was made after intensification therapy.
Relapse occured soon after, treated with re-induction chemotherapy, followed again
by a third PBPC collection. High dose chemotherapy ensued with PBPC
transplantation. All 3 collections were represented in the reinfusion. Interleukin 2
(IL2) was used to enhance graft-versus-leukaemia effect, but despite all the treatment,
early relapse was observed and he subsequently died.
IgH and TCRa gene rearrangement studies demonstrated 2 separate clones at
presentation and at relapse. Radiolabeled probes corresponding to each of these
clones were designed and used to screen a selection of samples collected during the
course of his disease. Clone A was found at presentation, first remission marrow and
the first and second PBPC collections. Despite first relapse, this clone was not found
in any subsequent sample. Clone B, however, produced an intense signal at final
relapse, but also present in all the samples screened, including marrow at diagnosis,
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albeit less intensely, indicating its presence as a minority clone which became resistant
to therapy, developed into the main clone and caused death of the patient. The p53
data in this study showed the presence of the 8 bp insertion at final relapse (Section
2.7). After searching 2 large p53 databases (Hollstein et al, 1994; Beroud and Soussi,
http://perso.curie.fr/thierry.soussi/p53_database.html), it appeared that this insertion
had not previously been reported. An ARMS primer (2007-ARMS1) was designed
and used in PCR to screen earlier marrow and PBPC samples. Primer design is
described in Section 3.2. Because of the highly specific nature of this insertion and of
the resulting ARMS primer sequence, no specific optimisation of PCR was required.
Standard conditions with Ta of 55°C and [Mg] of 1.5 mM were used. The opposite
primer was D-Bio, and a 94 bp product was produced with a mutant DNA template.
However, a spurious product slightly smaller than the ARMS product was produced
with WT DNA, but this did not interfere with the use of this system as the 94 bp
product was highly specific for mutant DNA sequence. Serial dilutions of leukaemia
DNA collected at final relapse (marrow containing 75% blast cells) in WT control
DNA demonstrated the limit of detection to be of the order of 1 leukaemia cell in up
to 104 normal cells (Fig. 3.23).
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LANES 12 3 4 5 6 7 8 9 10 11 12 13 14
DNA WT WT 1:10' 1:10' 1:10" 1:10' 1:10' 1:10' 1:10' 1:10' 1:10 1:10 M M
(M:WT)
Fig. 3.23 Patient 11 ARMS detection limit dilution experiments (Section
3.7.3). DNA from leukaemia at relapse (75% marrow blasts) spiked in WT
DNA. Detection limit is of the order of 1 part leukaemia DNA in 104 parts
WT DNA.
< 94bp ARMS product
« spurious product serves as internal control
Lane on far left is ())X174/HaeIII molecular weight marker.
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3.8 MRP DETECTION IN BREAST CANCER PATIENTS
Section 3.7.1 described the optimisation ofARMS for 5 patients. Using these
systems, a total of 12 PBPCH's were screened for the presence ofMRD. PBPCH's
were available in the form of cell pellets aliquoted at the time of collection and stored
at -70°C. Each pellet was from PBPCH collected on consecutive days. Genomic DNA
was extracted from each pellet by the Qiagen spin column technique described in
Section 2.1.3. For all MRD screening ofPBPCH's, 1 p.g ofDNA was amplified by
ARMS in triplicates each in a 50 pi reaction mix. Separately, control PCRs were
performed on each DNA sample using AAT gene exon 3 primers (Section 3.5.1).
Two microlitres of the AAT control PCR product was mixed with 20 pi of the ARMS
product and 4 pi of 6X loading buffer, loaded onto each lane of a 1.5 mm 6%
polyacrylamide gel, electrophoresed at constant 45 mA for approximately 1 hr 15 min,
stained with ethidium bromide, destained and viewed under UV light (Section 2.1.4).
Below is a description of the results for each patient in detail, which are summarised
in Table 3.3. Three of 5 patients and 8/12 PBPCHs demonstrated MRD.
(1) Patient Bll (HB-ARMS1 system). Cell pellets from 3 PBPCH's were available
from this patient for study. ARMS PCRs demonstrated that, albeit faint, a product
was produced from each harvest in all triplicate reactions, whilst WT control
remained unequivocally negative (Fig. 3.24). AAT products were present in all
samples. Therefore, there is evidence of tumour cell contamination in all 3 PBPCH's
from this patient. a-32P-labelled ARMS reactions using newly optimised conditions
confirmed the result. Exposure of the polyacrylamide gels over-night showed clear
products with each of the 3 harvests but not with WT (Fig. 3.25).
Clinical Details: Age 41 years at diagnosis. Poorly differentiated breast
adenocarcinoma was diagnosed in October 1992, and treated by right mastectomy.
Many positive axillary nodes were found on both sides. Nodules were found on the
chest wall, around mastectomy scar and in the liver in November 1992. Stage
T2N2M1. She then received 11 courses of adriamycin and 5-flucytosine, associated
with grade 3 mucositis. PBPC mobilisation was performed after treatment with high-
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DNA H20 WT WT HI HI HI H2 H2 H2 H3 H3 H3 M M
Fig. 3.24 Patient B11 ARMS screening of PBPC harvest (section 3.8). Faint
bands across all 3 PBPC harvests in triplicates indicate the presence of MRD.
< 140bp ARMS product
« 360bp AAT control product
H20 water control
Lane in far left is t(>X 174/HaeIII molecular weight marker
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LANES 1 2 3 4 5 6 7
DNA M HI HI HI H2 H2 H2
DNA H3 H3 H3 WT WT WT
FIG. 3.25 Screening of PBPC harvests (HI, H2, H3)
from patient Bll using 32P radiolabelled ARMS. A
strong signal is produced with tumour DNA (M) and
weak signals from each of 3 harvests in triplicates.
One of 3 reactions using WT DNA produced a
product (lane 13) but overloading of the well may
have contributed.
< 140bp ARMS product
LANES 8 9 10 11 12 13
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dose cyclophosphamide and G-CSF, following which she was conditioned with high-
dose etopide and melphalan and received PBPC rescue in April 1993. Consolidative
radiotherapy was given in June 1993. By January 1994, a cerebral metastasis was
diagnosed, causing left hemiparesis and disturbance of balance. This was surgically
excised and she was given cranial radiotherapy. In February 1994, further metastatic
deposits were found in the thoracic spine in the ribs, both treated with radiotherapy,
and CMF chemotherapy with cyclophosphamide, methotrexate and fluorouracil.
Further spinal and liver metastases developed and jaudice and confusion ensued,
leading rapidly to death. Disease-free survival was 9 months.
(2) Patient B16 (LB-ARMS 1 system). 3 PBPCH's were studied, and at the detection
limit possible, no evidence ofMRD was detected (Figure 3.26). Again this finding
was confirmed with a-32P-labelled ARMS. With this latter technique, ARMS
appeared very specific, and on prolonged exposure to X-ray film, no product was
visible with WT DNA or any of the 3 PBPCH's (results not shown).
Clinical Details: Age 31 at diagnosis. T2N0M0, oestrogen receptor negative right
breast carcinoma was diagnosed in November 1992 and treated with wide local
excision and axillary node sampling which was negative. She was given radical
radiotherapy post-operatively. A right axillary nodule developed in December 1993
and axillary node clearance was carried out, showing one positive node out of 12. Six
courses of cyclophosphamide, adriamycin and fluorouracil were given from March to
June 1994 with good response. This was followed by PBPCH and transplantation in
July 1994, which achieved complete remission. On follow-up in January 1998, she
was still well and remained in CR. At the time of this follow-up, disease-free survival
was 3.5 years.
(3) Patient B3 (BP-ARMSI system). 3 PBPCH's were studied. Despite screening
these harvests with ARMS at a higher Ta (67°C) than optimal (64°C), repeated
experiments showed that 2 of 3 reactions using WT DNA had very faint products
visible. However, all triplicate samples of all 3 harvests had slightly more intense
products visible, especially one of 3 reactions with Harvest 1 and Harvest 3 (Fig.
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LANES 1 2 3 4 5 6 7 8 9 10 11 12 13 14
DNA H.O WT WT HI HI HI H2 H2 H2 H3 H3 H3 MM
Fig. 3.26 Patient B16 ARMS screening of PBPC harvests (section 3.8). No
evidence of MRD is seen in all 3 harvests in triplicates.
< 130bp ARMS product
« 360bp AAT control product
H20 water control
Lane in far left is <j)X 174/HaeIII molecular weight marker
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3.27, lanes 6 and 10). a-32P-labelled reactions were less ambiguous regarding
specificity of ARMS - all 3 WT reactions were clearly negative. With prolonged over¬
night exposure, one of 3 reactions from each of the 3 harvests yielded a clear product.
This suggests that all 3 harvests may contain MRD, although at such a low level as to
be present in only one of 3 samples (total 3 pg DNA) by random chance (Fig. 3.28).
Clinical Details: Age 34 at diagnosis. A right breast carcinoma was treated in June
1988 with mastectomy and axillary node clearance followed by tamoxifen. Stage
T2N0M0. In July 1989 metastases were found in the right axilla and she received
bilateral oophorectomy and radiotherapy to the right chest wall and shoulder area. A
hot spot was noted on bone scan in January 1992 for which radiotherapy was given.
By October 1992, widespread metastases were clinically noted in the liver, skin and
axilla. Eleven courses of adriamycin and fluorouracil were given, and in February
1993, PBPC mobilisation was performed with cyclophosphamide and G-CSF. PBPC
transplant was performed in April 1993 following high-dose chemotherapy
conditioning with etoposide and melphalan. Maintainance with Megace was started in
May 1993. A complete remission was achieved after transplant, but by October, she
had relapsed with liver metastases. Three courses ofCMF chemotherapy were given,
but her disease progressed, leading to her death in December 1993. Disease-free
survival after transplant was 6 months.
(4) Patient B37 (2477/96-ARMS1 system). Two PBPCH's were available. Using
optimised conditions, both harvests produced weak products with ARMS in
triplicates, detected with ethidium bromide (Fig. 3.29). It would appear that this
patient also had tumour contamination ofboth harvests. Unfortunately, radiolabelled
ARMS was unable to be optimised to confirm this.
Clinical Details: Age 34 years at diagnosis. She was found in February 1996 to have a
5 cm right breast mass, and wide local excision and axillary node clearance confirmed
oestrogen receptor negative carcinoma. Clinical stage was T2N0M0. Six of 11
axillary nodes were positive with visible lymphatic invasion. She fulfilled the criteria
for and was randomised on the ACCOG study to subsequently receive high dose
therapy and PBPCT. She was first treated with 4 courses of adriamycin, to June 1996.
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LANES 1 2 3 4 5 6 7 8 9 10 11 12 13
DNA WT WT WT HI HI HI H2 H2 H2 H3 H3 H3 M
Fig. 3.27 Patient B3 ARMS screening of PBPCHs (HI, H2, H3) (section
3.8). Unexpectedly, despite prior optimisation, very faint hint of a product
was seen in 2 of 3 WT DNA.
< 87bp ARMS product
« 360bp AAT control product
Lane in far left is (|)X174/HaeIII molecular weight marker
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LANES 1 234567
DNA WT WT WT HI HI HI M
LANES 8 9 10 11 12 13 14 15
DNA H2 H2 H2 H3 H3 H3 H20 M
Fig. 3.28 Screening PBPCHs (HI, H2, H3) from patients B3
using 32P radiolabelled ARMS. A strong signal is produced
with tumour DNA (M) and moderate signals in one of each set
of triplicates from the 3 harvests. No signal is seen with WT
DNA.
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LANES 1 23456789 10
DNA WT WT WT HI HI HI H2 H2 H2 M
Fig. 3.29 Patient B37 ARMS screening of PBPCHs (HI,
H2)(Section 3.8). A faint product corresponding to the presence of
MRD is seen in triplicates in each harvest.
< 112bp ARMS product
« 360bp AAT control product
Lane in far left is ())X174/HaeIII molecular weight marker
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The following month, PBPC were successfully mobilised with cyclophosphamide and
G-CSF. High dose chemotherapy with cyclophosphamide and thiotepa followed, with
PBPC rescue. Consolidative radiotherapy was given to the chest wall in August 1996.
Over a year later, in September 1997, routine mammogram showed micro-
calcification in the right breast and mastectomy was carried out. She had remained in
CR on follow-up in February 1998. However, in May 1998, disease relapse was
observed on the skin, on the chest wall within a previously irradiated area. Outlook
was therefore extremely poor, and palliative chemotherapy was offered in the form of
infusional fluorouracil and vinorelbine. Disease-free survival after transplant was 14
months.
(5) Patient B30 (2668/96-ARMS1 system!. Only one harvest was performed in this
patient, and it appeared that this was unequivocally negative for MRD as detected by
this optimised ARMS system. Again, radiolabeled ARMS could not be optimised to
confirm this finding.
Clinical Details: Age 35 years at diagnosis. She presented in March 1996 with a large
right breast mass confirmed on fine needle aspiration to be malignant. She underwent
wide local excision and axillary node clearance which showed that 8 of 28 nodes were
positive and there was extensive replacement by malignant cells. A mastectomy was
performed. Clinical stage was T2N0M0. She was treated on the ACCOG study and
after 4 courses of induction chemotherapy with adriamycin between May and August
1996, cyclophosphamide and G-CSF mobilisation ofPBPC was carried out in
September 1996, followed immediately by high dose cyclophosphamide and thiotepa
conditioning and PBPCT. Consolidative radiotherapy was also given between
December 1996 and January 1997 and initial follow-up confirmed CR. In March
1998, she presented with 3 weeks of cough and breathlessness. Chest X-ray showed
diffuse extensive mottling in mid and lower lung fields, suggestive of lymphangitis.
Liver function tests were also found at the same time to be abnormal, with the liver
palpable 4 finger-breadths below the costal margin. The clinical picture was of
extensive disease relapse, and histological confirmation was not possible because of
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her poor clinical condition. She died rapidly following this event. Disease-free survival
after transplant was 16 months.
Table 3.3 Summary of the screening of PBPCH's of the 5 patients described using
ARMS. The detection sensitivity of each system is indicated. The numbers against
each PBPCH for each patient represent the number of positive reactions out of
triplicate tests.
Patient Bi t Patient B16 Patient B3
'
Patient 37 Patient B30
MRD
detection 1:1000 1:1000 1:100 1:1000 1:100
sensitivity
PBPCH 1 3 0 1 3 0
PBPCH 2 3 0 1 3 --
PBPCH 3 3 0 1 — —
3.9 MRP DETECTION IN ACUTE LEUKAEMIA PATIENT
For patient LI 1 described in Section 3.7.3, primer 2007-ARMS1 was used to screen
BM and PBPCH's taken at various time points during his disease (Fig. 3.30). At final
relapse just prior to death, the BM contained 75% blast cells, and ARMS produced an
intense 94 bp specific product associated with this clone. This signal was also noted in
the BM 2 weeks previously when the sample was unsatisfactory for morphology, but
relapse was evident on the basis of this ARMS product, albeit less intense presumably
reflecting a smaller population of blasts. A BM sample at first relapse several months
previously also gave this product, but when BM at diagnosis was screened, only a
very faint band was noted. Consistent with the IgH and TCRct studies described
above, the data here indicates that the chemoresistant leukaemic clone which led to
death of the patient was present at diagnosis as a minority, but was responsible for the
first and second relapses. Comparing the intensity of the ARMS product at diagnosis
and the dilution experiment, the proportion of the resistent clone might be as low as 1
cell in 104. ARMS also indicated the presence ofMRD in the third PBPCH and in BM
subsequent to this procedure, although the first and second harvests appeared free of
this clone (Figure 3.30). High dose therapy appeared to have eradicated detectable
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leukaemia from the marrow temporarily as the post-PBPCT BM was negative for
MRD. His subsequent relapse may therefore be due either to re-infused malignant
cells during PBPCT or to residual disease in the bone marrow occuring in minute
quantities beyond the detection limit of this ARMS system.
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LANES 1 2 3 4 5 6 7 8 9 10 11 12
Fig. 3.30 Allele-specific PCR screening of index patient's samples. Note
that a 94bp product is produced with mutant allele (<) and a slightly smaller
spurious product produced with wild type allele. lane 1, wild type control
DNA; lane 2, presentation peripheral blood; lane 3, first PBPCH; lane 4,
bone marrow after induction chemotherapy; lane 5, second PBPCH; lane 6,
first relapse marrow; lane 7, third PBPCH; lane 8, pre-PBPCT marrow;
lane 9, immediately post-PBPC transplant marrow; lane 10, 4 weeks
post-PBPCT marrow; lanes 11 and 12, 6 weeks post-PBPCT marrow (75%
blasts). Evidence of minimal quantities of the mutant clone are detected in
lanes 2,4,7 and 8, indicating the presence of this clone at diagnosis and in
the 3rd PBPCH.
> 94bp PCR product
Lane in far left is (J)X174/HaeIII molecular weight marker
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3.10 SUMMARY
This chapter has described my experience in optimising ARMS for 2 tumour cell lines,
a cohort of breast cancers carrying point mutations in the p53 gene, and the one case
ofALL with a novel 8 bp insertion. Used as potential markers in detecting minority
clones, p53 mutations appears to be a relatively insensitive and unreliable marker. Cell
line systems were easier to work with and produced more consistent results. It is clear
that optimising a set of reaction conditions for ARMS is multi-factorial. The key
parameters to be optimised as determined using the T47D cell line model are
annealing temperature and magnesium concentration. Although altering most other
conditions influence the amplification efficiency in ARMS, reactions with both WT
and mutant DNA appear to be affected more or less equally. Also crucial is the use of
an addtional deliberate mismatch near the 3' end of the primer which enhanced
specificity substantially. The work-up for each individual point mutation suggests that
optimisation ofARMS primers for such a heterogeneous system is very difficult, and
here, only about halfof the available systems could be optimised with a degree of
satisfaction, using the guidelines in Section 3.3, albeit more difficult for some of them
such as patient B37 where the cycle number had to be dropped to achieve specificity.
Of 10 point mutations in this breast cancer cohort, 3 could not be optimised at all as
the intensity of the mutant and WT products were too similar under all conditions. Of
the remaining 7, 5 could be optimised with a degree of satisfaction. In the other two,
ARMS was unable to distinguish between WT and mutant DNA sufficiently to enable
the systems to be used for MRD detection - in each of these, the band produced with
mutant DNA was too faint such that further dilutions with WT DNA in the MRD
setting would make the system unworkable. One of these was subsequently found to
be a germ-line mutation (see Chapter 4) which would, in any case, make it unsuitable
as a tumour marker for MRD studies.
Detection limit is very poor by current standards using other markers, and although
capable of studying the phenomenon of clonal evolution in certain malignancies, is
unlikely to be useful in detecting MRD in tissues such as PBPCH's where the level of
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contamination by tumour cells is often much lower. Using ethidium bromide staining
of the polyacrylamide gels, the level of detection in the best ARMS systems is of the
order of 1 cell in 104. This was achieved here with the 5637 cell line and a highly
specific alteration like the insertion in patient LI 1. In most other systems, the limit is
probably of the order of 1 in 100 to 10\ 32P radiolabeled ARMS did not work
consistently in this project, but results from 3 of the 5 optimised patients confirmed
the findings of the non-radiolabelled assessment. It was not possible to demonstrate
an improvement in detection sensitivity by using radiolabeled PCR.
Of the 5 optimised ARMS systems, 3 patients were in the 'metastatic' group (B3,
B11, B16), and 2 given PBPCT as adjuvant therapy (B30, B37). Two of the
metastatic group had evidence ofMRD in all 3 PBPCH's (6 of 9 harvests, 66.7%),
and one of the adjuvant (ACCOG) group had MRD in both harvests (2 of 3 harvests,
66.7%). It is notable that, on studying the clinical details of patient B16 in the
metastatic group, she did not in fact have metastatic disease, but was considered to be
at high risk of systemic relapse on the basis that she had axillary node relapse despite
radical radiotherpy, and that her tumour was oestrogen receptor negative. She was
also young and thought to be a good candidate for high dose therapy. Both patients
who were transplanted because of known metastatic disease (B3, B11), had evidence
ofMRD in the PBSCH, and despite achieving CR, both had short DFS of 6 and 9
months, respectively. On the other hand both patients treated on the ACCOG study
and given PBPCT as adjuvant therapy also had adverse outcomes despite achieving
CR. Patient B37 had evidence ofMRD in both harvests, and had DFS of 14 months,
whilst patient B30 had no evidence ofMRD in her single harvest, and had DFS of 17
months.
The situation with patient LI 1 is more straightforward, because of the relatively
higher sensitivity of detection (1:104) and specificity, and that serial samples were
available at various time points. This enabled the demonstration of the phenomenon of
clonal evolution of the second (chemo-resistant) leukaemic clone, and its presence in
2 or the 3 different sets ofPBPCH's albeit as a minority.
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CHAPTER 4
RESTRICTION SITE-GENERATING POLYMERASE CHAIN
REACTION (RG-PCR) APPROACH
4.1 INTRODUCTION
The ARMS approach described in Chapter 3 is based on allele-specific PCRs in which
reactions with an ARMS primer are dependent on the higher efficiency of
amplification using a mutant DNA template compared to a WT one. As noted, this
relative difference in amplification efficiencies is variable and varies from one mutation
to another. In this study, the ARMS systems for almost half of the mutations studied
could either not be optimised at all or not sufficiently to be of any value in detecting
MRD. Therefore, a lack of specificity and sensitivity are major drawbacks. For this
reason, I attempted to examine a PCR approach in which a deliberate mismatch
positioned in up to several bases 5' to the mutation is introduced during PCR by using
a 'mutagenic' primer containing this mismatch, such that an artificial restriction
enzyme recognition site is generated for the WT but not the mutant (tumour)
sequence (Haliassos, et al, 1989a and b; Mullen et al, 1997; Ng et al, 1991, Gasparini
et al, 1992). Because the mismatch introduced is not adjacent to the 3' end of the
primer, strand extension is allowed at the same efficiency with WT and mutant
templates. With this, a PCR product is made with both templates, to be distinguished
from each other by the ability of a restriction enzyme to specifically recognise the
unique sequence to allow digestion of the DNA. Therefore, 2 separate steps, PCR and
restriction enzyme digestion, are required. The main advantages of this approach are
that (1) a PCR product is always available and the issue is not of the presence or
absence of a product, (2) unlike ARMS, no laborious optimisation is needed, and (3)
the recognition sequence for a particular restriction enzyme is highly specific and is
conceivably much more reliable than the relative non-specificity of ARMS.
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4.2 DESIGN OF MUTAGENIC PRIMERS
A mutagenic primer introduces a recognition site by incoporating the 3' portion of its
own sequence and the first couple of bases 3' to it in the template, where the base
change in question is positioned. Two approaches are available. The mutagenic primer
may introduce a recognition site in which the WT sequence is digested, leaving the
mutant sequence intact, or it may introduce a recognition site for the mutant
sequence, leaving the WT intact. Of these two, I chose the former approach. The
reason for this is that it is dependent on the disappearance of a product (WT) with
restriciton enzyme digestion, when any remaining product is mutant, while the latter
approach is dependent on the appearance of one or more smaller products resulting
from digestion of the mutant sequence, and can potentially suffer from the same
problem as ARMS in that, in the MRD setting, the bands on PAGE gel may be so
faint as to cause difficulty in determining if they are really present.
Mutagenic primers are designed according to the following principles:
(1) WT sequence around the point mutation is compared with recognition sequences
of a list of restriction enzymes. If a recognition site is already lost as a result of the
point mutation, no further mutagenic primer is required, and the appropriate enzyme
may be used to digest PCR products of the exon amplified with primers described in
Table 2.3;
(2) mutagenic primers are approximately 20 bp, stopping just short of the point
mutation in question, such that the artificial recognition site generated encompasses
the WT base at the position of the mutation;
(3) a mutagenic primer may stop just 1 base short of the mutation, but the 3' base of
the primer should not be chosen to be the mismatch as this reduces amplification
efficiency;
(4) not more than one mismatch is to be introduced if possible, as this may make
amplification refractory;
(5) the DNA strand on which the primer is designed is chosen in order to produce a
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Table 4.1 lists the sequences of such primers for each point mutation in this project,
the corresponding restriction enzyme used and its recognition sequence, and
characteristics of the products and fragments resulting from digestion. All mutagenic
primers are suffixed 'MP' after the respective sample identity. T47D again was used
as the model system, and it can be seen that, for each of the mutations in question, it
was possible to design a mutagenic primer for PCR, to be used with a restriction
enzyme identified from a collection of scientific companies' catalogues. Three of the
mutations naturally result in loss of recognition sites, and no mutagenic primers are
required for these. Some of the systems contain more than one recognition site for the
enzyme and generate more than one fragment.
4.3 USE OF RG-PCR IN THE T47D MODEL
The T47D system was used to assess if this approach would be feasible, and also to




where A represents the restriction site. Incubations ofPCR products with restriction
enzymes were carried out along manufacturer's guidelines. In general, 20 pi ofPCR
product was mixed with 3 pi 1 OX enzyme buffer, 3 pi 1:10 diluted bovine serum
albumin, 3 pi distilled water and 1 pi restriction enzyme (10 U/pl) (total 30 pi). The
mixture was incubated at 37°C for a minimum of 3 hr, at the end ofwhich time the
mixture was heated to 60°C for 5 to 10 min prior to loading onto polyacrylamide gel
for electrophoresis. For the size of the fragment concerned, 12.5% acrylamide was
used to improve resolution.
The 127 bp PCR product from primers T47D-MP and E-Bio using WT DNA as
template was digested to 111 bp and 16 bp fragments, easily visible on PAGE. If the
enzyme-treated sample was subject to electrophoresis immediately, a weak residual
product of 127 bp remained, indicating incomplete digestion. However, increasing the
number of units ofMbol per 30 pi digestion mix from 4 U to 12 U, or increasing
incubation time (at 37°C) from 3.5 hr to over-night did not produce any improvement.
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The problem was resolved when the digestion mix was heated to 60°C or higher for 5
to 10 min after digestion, just prior to loading and electrophoresis, and the most likely
reason was that the staggered ends of the digestion fragments with a 4-base single
strand had allowed the fragments to re-anneal. The Mbol digestion is also specific, as
no evidence of digestion of the product made with mutant DNA was observed,
regardless of enzyme dose and time of incubation.
The most significant limitation of the RG-PCR technique is the lack of sensitivity
when mutant DNA is dispersed among WT. Fig. 4.1 shows that the T47D-MP PCR
reaction itself is efficient, and a product is visible when T47D DNA is diluted serially
in distilled water down to 1:105, or 10 pg of genomic DNA. However, when T47D
DNA is likewise mixed in serial dilutions with WT DNA, amplified by PCR and
digested with Mbol, a product can barely be seen beyond 1 in 10 (100 ng DNA) (Fig.
4.2). This was confirmed with repeated experiments, and although sensitivity of other
systems may be better (1 in 100 for patient B11), it would appear to be unsuitable for
MRD detection. It is unclear what the cause of the discrepancy may be. Preferential
amplification ofWT DNA over mutant could account for it but as the mutated base is
not involved in the annealing of the mutagenic primer onto template, this would seem
unlikely to be the explanation.
A potential solution to the lack of sensitivity is to enrich the mutant DNA species
from a mixed WT / mutant population by using a restriction enzyme to remove the
WT species by cleavage, followed by PCR amplification, which should only amplify
the mutant species (Pourzand and Cerutti, 1993; Kahn et al, 1991). An attempt was
made with the T47D model and Mbol enzyme. As described above, standard RG-
PCR was performed on genomic T47D DNA using primers T47D-MP and E-Bio
(Table 4 .1). 20 pi of the PCR product was digested with 10 U ofMbol, and an
aliquot of 5 pi was reamplified with the same primers, and electrophoresed in a
polyacrylamide gel. Fig. 4.3 shows the result of such second-round PCR reactions,
using 2 different Ta's ( 64°C and 67°C) and for each, 2 different [Mg], As in the
attempts with nested ARMS PCR (Chapter 3), many spurious products were
produced in all reactions, and disappointingly, a correct product (127 bp) was
161
LANES 1 2 3 4 5 6 7 8
Dilution H,0 M 1:2 1:10 1:102 1:10' L104 1:10s
Fig. 4.1 Efficiency of T47D RG-PCR. lp.g of T47D DNA
was serially diluted in water and amplified by RG-PCR. A
PCR product is visible down to 1:105 (1 Opg) indicating a
very efficient PCR system.
M neat tumour (mutant) DNA
H90 water control
Lane in far left is <])X174/HaeIII molecular weight marker
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LANES 1234567 89 10
DNA H20 M 1:2 1:10 1:10-' 1:10' 1:10' 1:10' WT uT
(T47D:WT)
Fig. 4.2 RG-PCR detection limit (Section 4.3) using T47D cell
line. PCR products in lanes 2 to 9 had been digested by Mbol
enzyme, lane 10 was untreated. A 127bp product with a mutant
sequence would be uncut by Mbol (<), whilstWT sequence would
be cut to 16 + 111bp(«). This experiment indicates that the
RG-PCR approach is insensitive to the presence of tumour DNA
which has been mixed with WT DNA and 1 tumour cell in 10




Lane in far left is (f>X174/HaeIII molecular weight marker
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LANE 1 2 3 4 5 6 7 8 9
DNA h2o wt M wt M wt M wt M
[Mg]mM 1.5 1.5 1.5 2.0 2.0 1.5 1.5 2.0 2.0
Ta(°C) 64 64 64 64 64 67 67 67 67
Fig. 4.3 Mutant enriched RG-PCR using T47D model. RG-PCR was
performed using primers T47D-MP and E-Bio. An aliquot was digested
with Mbol enzyme and then subjected to the same RG-PCR for 35
cycles. This shows a lack of specificity as a visible 127bp product (<) is
still obtained with WT template. Reactions were performed at two
different [Mg] and Ta.
< 127bp ARMS product
h2o water control
Lane in far left is (|)X174/HaeIII molecular weight marker
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observed even with WT templates after digestion with Mbol. The fact that a product
was yielded with WT DNA template would suggest that the DNA was not completely
digested with the restriction enzyme. Alternatively, the multi-step process ofPCR -
enzyme digestion - second PCR opened up considerable risk for contamination. It
would be expected that 10 U ofMbol should fully cleave the first round WT PCR
product in 3 hr of incubation, and at least when visualised with ethidium bromide and
UV light, 10 U ofMbol appeared to be as effective as higher doses in cleaving WT
PCR products in the one-step RG-PCR (work-up results not shown). Unfortunately,
owing to time constraint, I was unable to further investigate the possibility of
increasing the dose of enzyme for mutant enrichment or alternative strategies.
4.4 USE OF RG-PCR IN BREAST CANCER SAMPLES
Breast tumour DNAs from 5 patients (B3, B11, B27, B37, B45) were analysed by
RG-PCR.
In 4/5 of these patients, RG-PCR as used in this manner lacked specificity as
undigested product always resulted from digestion ofWT PCR product. In these
cases, higher enzyme dose or heating the digestion mix to 60°C did not produce any
improvement. Fig. 4.4 shows the example of patient B11, whose ARMS system was
optimised. RG-PCR was disappointing as a weak residual 131 bp product was visible
on PAGE gel which made it unsuitable forMRD detection, which relies on 100%
digestion of the WT. Fig 4.4 also indicates that despite an efficient PCR in amplifying
the template, detection sensitivity is poor when mutant DNA is the minor population
with WT.
The main value ofRG-PCR used in this project is that it facilitated the detection of a
germ-line mutation in patient B27. Previous sequencing detected a point mutation in
codon 267 (CGG > CAG) which resulted in an arginine to glutamine amino acid
change, but unfortunately, ARMS could not be adequately optimised forMRD
detection. RG-PCR using a mutagenic primer generated 2 recognition sites on WT for
enzyme Hpall but 1 site for the mutant sequence. The appearance of a 64 bp product
on PAGE suggested the presence ofmutant sequence (Fig. 4.5). Although such a
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LANES 12 3 456 78 9 10 11
DNA M M/H.O M/H,0 M/H20 M/H.O M/H.O M M/WT MAVT MAVT MAVT
Dilution - 1:2 1:10 1:10= 1:10' 1:10' - 1:2 1:10 1:10' 1:10'
Fig. 4.4 Comparison of sensitivity of Patient B11 RG-PCR with detection
limit using Hpall digestion (Section 4.4). All PCR reactions contained 1 pig of
DNA. With dilutions of tumour DNA in water, a 131 bp PCR product can just
be seen at 1:104 (lanes 1 - 6). When tumour DNA was diluted in WT DNA and
the product digested with Hpall, a digestion product can be reliably
distinguished from WT control only down to dilution of 1:10 (lanes 7-11).
< 131 bp ARMS product
Lane in far left is <])X174/HaeIII molecular weight marker
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LANES 1 234 5678 9
DNA M HI HI HI H2 H2 H2 WT WT
Fig. 4.5 Germline mutation in codon 267 (CGG>CAG)
demonstrated by Hpall restriction enzyme digestion of primary
tumour (M), PBPCHs (HI, H2) and WT control DNA (Section
4.4). After PCR using the 7071/91-MP mutagenic primer a mutant
PCR product is characterised by the failure of Hpall digestion of a
64bp product (<) owing to loss of a recognition site.
Lane in far left is (j)X174/HaeIII molecular weight marker
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band was also present as a weak band with WT control, when tumour DNA and DNA
from each of the 2 PBPC harvests were studied, all samples showed a pattern
indicative of mutant sequence. The intensity of the 64 bp band excludes tumour
contamination being the cause, and a germ-line mutation was the most likely
explanation. When DNA from these tissues were re-amplified and screened by DGGE,
positive results were obtained (not shown), confirming that the mutation was in the
germ-line. Of interest in this case is that a search of the EMBL p53 database revealed
that a germline mutation in codon 267 has been reported only once, by Prosser et al
(1991) of the MRC Human Genetics Unit, Edinburgh. They reported an identical
mutation to that found here in patient B27, in a non-Li-Fraumeni cancer family. The
proband was a 53 year-old woman with breast cancer. Four cancer deaths were
reported in the 5-generation pedigree: breast cancer at age 53 (proband's maternal
grandmother), breast cancer at age 67 (sister ofgrandmother), lung cancer at age 66
(proband's mother) and ovarian cancer at age 63. Materials were not available from
these 4 relatives, but the same constitutional mutation was found in the proband's 37
year-old sister and a 74 year-old first cousin of the proband's mother, both ofwhom
were unaffected by cancer. The authors argued that, owing to the late onset of
cancers in members of this family, and the fact that the 74 year-old carrier was still
cancer free, the mutation was a 'weak' one from the cell's point of view, not
conferring a particularly strong growth advantage. A pedigree for patient B27 was
kindly composed by Mrs. Alison Fordyce of the Registry Office, MRC Human
Genetics Unit, Edinburgh (Fig. 4.6). This shows that B27 also was one of a breast
cancer family. The 'weakness' or low penetrance of the codon 267 mutation was
again demonstrated by the late onset of cancer; breast cancer deaths were recorded at
the age of 63 (mother) and 87 (great-grandmother), the age characteristically
becoming progressively younger with successive generations. Study of tumours from
these individuals was beyond the scope of this project, although it would not be
surprising to find these tissues also contain the same codon 267 mutation. Of even
greater interest is that both patient B27's family and that described by Prosser et al
(1991) originated from Fife, and with the rarity of codon 267 germ line mutations, the
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obvious link between the families was made. Potentially, the use of polymorphic
markers for this region of chromosome 17p may help to link these families.
4.5 SUMMARY
In contrast to the optimism inspired by the report of Haliassos et al (1989b) on the
sensitivity of RG-PCR, my work here has not demonstrated any usefulness of this
approach in the detection ofMRD, at least when ethidium bromide was used to
visualise PCR products. The first major problem was the lack of specificity when a
system involving restriction of the WT allele was used. This was not due to
incomplete digestion ofPCR products by restriction enzymes but may be due to re-
annealing of cut ends especially where over-hanging bases exist. With hind-sight, the
opposite approach, creating recognition sites for the mutant allele may have been
preferable. The other problem is the lack of sensitivity. The figure of 10% found here
is consistent with the comment ofHaliassos (> 5%), and the use of radio-labelled
nucleotides in PCR or the use of Southern blotting may improve this situation. With
the brief attempts at enriching the mutant DNA species using restriction enzymes,
production of a PCR product with WT template was a major disappointment, and the




The key purpose of this project was to assess the feasibility of using single-base
mutations, specifically in the p53 tumour suppressor gene, as molecular markers for
MRD detection. Rather than exclusively advocating p53 as a potential marker for this
purpose, I set out to use p53 simply as a model, and the findings of this project could
potentially be applied to other genes in which subtle alterations are present in
malignant cells, and which may be the only markers available to distinguish these cells
from normal ones. As outlined in Chapter 1, in both the diseases studied in this
project, other markers are available, achieving high levels of sensitivities and
specificities, and the usefulness as MRD markers of small alterations in cancer-
associated genes would therefore have to be set against the gold standards set by
these techniques. The purpose of this project is not to find an alternative ultra¬
sensitive technique to supercede those available, for instance as outline in Section
1.2.3, but to attempt to answer the question ofwhether, with the remarkable ability of
PCR to amplify DNA, one can take advantage of certain relatively common genetic
changes in malignancies to serve as tumour- and patient-specific markers ofMRD. In
a disease such as AML where often no consistent marker is available, this may
potentially be of greatest interest.
p53 was chosen to be studied in this project for 3 main reasons:
(1) It is the single most frequently mutated gene in human cancers. Although in most
cancers, p53 alterations are still found in only a minority of cases, one can expect to
find abnormal p53 in one fifth or more of sporadic breast cancers (Bergh et al, 1995 -
21.8%; Saitoh et al, 1994 - 39.6%; Blaszyk et al - 34%, 1994; Sommer et al, 1992a -
32.6%; Coles et al, 1992 - 40%; Andersen et al, 1993 - 21%; Mazars et al, 1992 -
18.7%; Osborne et al, 1991 - 46%; Prosser et al, 1990 - 13%), and up to one third of
relapsed acute leukaemias (Zhu et al, 1996), but in less than 10-15% of acute
leukaemias at diagnosis. The incidence in AML at diagnosis is uniformly low (Pignon
et al, 1995 - 5%; Fenaux et al, 1992 - 7.1%, Wattel et al, 1994 - 15%; Preudhomme
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et al, 1994 - 11%) whilst that ofALL seeems slightly more variable, and is
particularly high in FAB subtype L3 in adults (Fenaux et al, 1992 - 22%; Gaidano et
al, 1991 - 55.5%; Wada et al, 1993 - 25%). With the sample size used in this project,
It was expected that approximately 12 positive breast tumours and 5 or more acute
leukaemia samples would be found and make a reasonable platform on which to
assess the key aim.
(2) In significant subgroups of the cohort of patients studied, the process of selection
meant that they were already in an adverse prognostic group or had demonstrated
aggressive or extensive disease, so that the likelihood of finding p53 mutations
(themselves an adverse prognostic marker) might be higher. For example, because
PBPC harvests were the main 'tissue' to be assessed for the presence ofMRD,
patients were selected because they were known to have had PBPC harvested. This
included a large number of patients with metastatic breast cancer (38 of 51 patients
studied). In the ACCOG patient group, as the choice ofPBPCT was made by
randomisation, this rationale would obviously not apply. In contrast, for patients with
acute leukaemia, it was customary in our department at the Royal Infirmary to carry
out back-up harvests as a matter of routine, and furthermore, the selection of patients
was made simply on the basis that we had prospective DNA samples stored and they
were, therefore, more or less consecutive patients treated at our department.
Nonetheless, 16 of29 patients studied had samples taken at relapse, and carried a
higher likelihood of a p53 mutation (Zhu et al, 1996; Hsiao et al, 1994).
(3) p53 mutations are heterogeneous in location and nature. The majority (79%) of
mutations are single-base missense mutations (Greenblatt et al, 1994), and scattered
amongst much of the exonic and intronic sequences of the gene, although hot-spot
regions, roughly corresponding to exons 5-8, have been identified. 87% ofmutations
are located within these exons (Greenblatt et al, 1994), and the conserved domains II
to V contain approximately 2/3 of all mutations (Levine et al, 1995; see Section
1.4.2). Both transversions and transitions are represented (Hollstein et al, 1997) with
very different neighbouring base sequences and probably secondary and tertiary DNA
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structures. This heterogeneity posed a major challenge in this project, as the basis for
using p53 (missense) mutations is the use of allele-specific PCR or ARMS, and it can
be anticipated that the design of primers and the optimisation process to achieve a
high degree of specificity are likely to be very difficult, and very different from one
mutation to another. Paradoxically, because of these potential difficulties, p53 is
actually a 'good' system to test the feasibility ofusing such subtle alterations as
markers to detect MRD. This contrasts with ras oncogenes where the codons in
which mutations can take place in malignancies are much more limited and
theoretically may be a more robust system.
5.1 USE OF p53 AS DISEASE MARKER
p53 mutations have often been used for the study ofminority tumour clones in the
areas of clonal expansion or evolution of these tumours (Pollock et al, 1996;
Sidransky et al, 1992; Wada et al, 1993). Using p53 and allele-specific PCR to detect
MRD within other non-tumour tissues has been much less often performed and even
more uncommonly on a relatively large scale (Hayashi et al, 1995). The ras oncogene
family has been more often used in this context, but nevertheless, examples of the use
of p53 in this way are available (Mao et al, 1994; Hayashi et al, 1995; Rhodes et al,
1995). To utilise p53 as a tumour and MRD marker, bearing in mind the very subtle
alterations in question in the majority of cases, the allele-specific PCR (or ARMS)
must be both specific and sensitive, i.e., being able to amplify only the mutant but not
the WT DNA template, and to have a high detection limit for minority mutant species
amongst a large excess ofWT species. There would be many steps and hurdles
involved, but I felt that this system was achievable. Here I shall discuss the many
issues raised throughout the stages of this project.
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5.2 MUTATION DETECTION
5.2,1 CHOICE OF TECHNIQUE
After obtaining the appropriate clinical materials, the first objective was to determine
which primary breast tumour or leukaemia had a mutation in p53 to be used as
markers. Because the location of p53 mutations are diverse, a screening method was
required to identify samples to be sequenced. As outlined in Section 1.5, there is a
wide selection of techniques available. The choice of detection technique would have
to fulfill several criteria: (1) it should be widely used and accepted as a hallmark of its
efficacy; (2) it should be sensitive and is capable of detecting the great majority of
mutations present in the fragments ofDNA studied; (3) it should be able to detect the
presence of a mutation even if the malignant cells are a relative minority amongst
normal tissues; (4) it should be relatively simple to set up using materials readily
obtainable within financial constraints; (5) it should be relatively easy to learn to use.
A review of the available options identified 3 feasible methodologies, namely, SSCP,
DGGE and HA. Most of the other techniques were either not in popular use (such as
carbodiimide modification, Ganguly et al, 1990), or involved hazardous chemicals
(such as HOT, Cotton et al, 1988).
HA may be slightly less sensitive than the other two, with figures of around 80%
reported (Cotton, 1993). The sensitivity, however, is dependent on the nature of the
substitution, and for some, there may be little or no difference in the mobility between
WT and mutant. The type of gel matrix may help to improve this and the use of
Hydrolink and MDE (Soto and Sukumar, 1992) gels have been described to this end.
There is no theoretical basis to predict the behaviour and property of heteroduplexes,
and HA is very much dependent on the ionic strength, concentration, and type of
buffer used (Glavac and Dean, 1995). One advantage ofHA is that it may be used
without radioisotopes, and furthermore, manoeuvres such as hybridisation with an
artificial deletion-mutant instead ofWT DNA may improve sensitivity (van den Akker
et al, 1992). Of the other 2, SSCP is said to be easy to use in most reports (Prosser,
1993), and has a high level of sensitivity (Moyret et al, 1994; Condie et al, 1993). The
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sensitivity ofDGGE is even higher, near 100% in most cases (Macek et al, 1997;
Beck et al, 1993) when properly optimised. Both are popular techniques, perhaps
more so with the former, and apart from the slight edge DGGE has in sensitivity, a
number of factors influenced my decision to choose DGGE. SSCP requires the use of
radioisotopes which, though not prohibitory, adds to the inconvenience, relative
hazard and expense. Once a mutation is identified by SSCP, the isolation of the
mutant DNA strand for sequencing requires the extra step of further autoradiography
to identify the position of the correct band to be cut from the gel (H.A.Phillips,
personal communication). On the contrary, mutant bands on DGGE can be visualised
directly by UV light illumination of ethidium bromide-stained gel, hence isolation of
the mutant species is achieved more rapidly. Like HA, there is no theoretical model to
predict the 3-dimensional structure of single-stranded DNA, and all optimisation steps
are largely empirical. Usually, not only does the gel matrix need to be optimised, for
example, the addition of glycerol, electrophoretic temperature may have to vary
between 4°C and room temperature, necessitating electrophoresis in the cold room
and pre-cooling of the gel. In general, electrophoresis at room temperature with 5-
10% glycerol or at 4°C without glycerol are good starting points (Hayashi and
Yandell, 1993).
Although the optimisation and the set-up ofDGGE are not by any means less
laborious, there are key advantages.
(1) Sensitivity may be higher as has been mentioned. One of the mechanisms for this is
that DGGE can take advantage of the formation of heteroduplexes between a mutant
strand and a WT strand during the later cycles ofPCR. Because of their reduced
stability, heteroduplexes tend to have lower melting temperatures than homoduplexes
formed by WT or mutant sequences, and hence bands that are far removed from the
homoduplexes, making visualisation easier. Destabilisation by up to 6°C is possible by
a single base mismatch (Myers et al, 1988). In the context of screening tumour
samples, WT strands are derived either from the opposite allele within the same
tumour cell, or from contaminating normal tissues which are almost invariably
present.
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(2) DGGE is non-radioactive, thus reducing the hazards of chemical handling and
costs.
(3) DGGE enables the separation of pure mutant species ofDNA which are usually
easily distinguished from species containing WT, making it straightforward to re-
amplify and sequence the mutant sequence without any confusion caused by WT
strands.
(4) As the melting property of a double-stranded piece ofDNA of known sequence
can be calculated, computer programmes are available to predict the melting map,
optimal gel running time, and the expected effects of any base change on the Tm.
(Fodde and Losekoot, 1994). Programmes such as SQHTX can even predict the
expected separation distance between bands on the gel (Hamelin et al, 1993). I have
not taken advantage of this last factor during this project largely because of the
expense involved in obtaining such programmes, when balanced against the fact that
the fragments of p53 studied here are already well known and investigated, and it
would be much easier to use published parameters and primer sequences. There are
also a number of disadvantages with DGGE. Setting up the apparatus was labour-
intensive, and much time had to be spent on learning to use it to be proficient
(especially, for example, casting linear denaturing gradient gels). Again, custom-made
apparatus is available from Biorad, but the cost is prohibitive. I improvised using
equipment already available (such as the Hoefer SE600 electrophoresis tank, water
bath and heat exchanger) which worked out to be quite satisfactory (Myers et al,
1988).
5,2,2 PROPORTION OF TUMOUR TISSUE REQUIRED
Unlike cell line models, the study of clinical materials almost always involves the
presence of contaminating normal tissue, whether the primary tissue is frozen section
ofbreast tumours, paraffin-embedded sections or bone marrow at the time of
diagnosis of leukaemia. As can be expected, the higher the proportion of tumour
tissue, the higher the copy number of amplicons of the mutant sequence after PCR,
and the corresponding band on DGGE may be expected to be more intense. Mutation
screening techniques are not ultra-sensitive in this regard, and for most techniques, the
176
proportion ofmutant tissue require is of the order of 5-20% (Prosser, 1993). For
example, SSCP can detect a mutant when tumour makes up 5-10% (H.A.Phillips,
personal communication), DGGE 12.5% (Beck et al, 1993) and TGGE 10% (Ke et
al, 1993). Section 2.2.2 describes the use of 5637 bladder carcinoma cell line in serial
dilutions with normal blood white cells to determine this sensitivity. This cell line
contains a AGA to ACA missense mutation in codon 280 (exon 8, 'fragment D'). By
mixing experiments, I was able to demonstrate that DGGE as used in the way
described, is able to demonstrate the presence of the mutation down to 5% of tumour
cells by the appearance of heteroduplexes. Although I did not study the other 4 p53
fragments, all 4 positive controls were clearly demonstrable and there was no reason
to suspect that the sensitivity should be significantly different from the 5% noted here.
However it must be noted that below 40%, the mutant homoduplex band had faded so
much that it was not possible to cut this out for reamplification. For practical
purposes, therefore, samples containing more that 50% tumour content were used in
this project. For the acute leukaemia diagnostic samples, this was easier to ensure, as
a blast count was routinely given in the bone marrow reports. For the paraffin-
embedded breast tumours, many were checked by colleagues in the Pathology
departments to contain a substantial amount of tumour before being sectioned for
DNA extraction. The frozen sections, however, were not studied by microscopy.
5 2 3 CHOICE OF PRIMERS AND DGGE CONDITIONS
Because of the fact that the great majority of p53 mutations are known to exist in hot-
spot regions which correspond to the conserved domains of the gene, roughly
representing exons 5-8, most studies concentrate on these exons (Beck et al, 1993;
Nigro et al, 1989). For studies that describe the use ofDGGE in p53 screening, there
are a host of different conditions and primer sequences used. In this project, I selected
the technique used by Borresen et al (1991) in their original description ofCDGE as
there was local experience with the use of this system which had proved to be
efficient. Modifications were made, however, as the Borresen primers did not cover
exon 6 which also contained mutations though not one of the 5 domains (Caron de
Fromentel and Soussi, 1992). I empirically added primers to cover this exon
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(fragment E), which turned out to be quite satisfactory. A second modification was a
change in the primers that covered fragment A (exon 5) as the Borresen primers did
not consistently amplify and in fact, the authors had changed to a new primer set more
recently (S.Lystad, personal communication). Owing to time constraints, I was unable
to screen the leukaemic samples using these fragment A primers. Therefore, all acute
leukaemic samples were screened for mutations in fragments B, C, D and E only.
In order for a particular DGGE system to achieve the highest sensitivity of detecting
all possible point mutations within the particular DNA fragment studied, the specific
set of conditions ought to be optimised. This enables the separation between mutant
and WT species to be as great as possible. Ideally the denaturant concentrations in the
gel should represent approximately 10°C round the Tm of the studied fragment, ie,
5°C on either side (Myers et al, 1989). Each degree Celsius in Tm is represented by
approximately 3% in denaturant concentration. The denaturants have, therefore, to
make up the deficit in Tm between the desired range of temperature and the
temperature at which the gel is run in the electrophoresis tank.. Higher running
temperatures mean lower denaturant concentrations are required. Given the
manufacturer's highest recommended temperature for the Hoefer tank is 55°C, I
attempted a maximum running temperature of 60°C which did not produce any
adverse effect on the apparatus, but conveniently shortened the electrophoresis time
to enable gel run and staining to be performed within the same working day. 60°C,
therefore, became the routine temperature used. In order to detect all possible
mutations in a DNA fragment, it is important that the fragment melts as a single low-
melting domain when attached to a GC-clamp. The presence ofmore that one such
domain would mean that only the one with the lowest Tm is studied. Ensuring that
this is the case may be achieved either by using computer programmes to plot the
melting map, or by running a perpendicular DGGE which should show a simple
sigmoid curve, the steep slope ofwhich represents the optimal range of denaturant
concentrations. The latter can be estimated by measuring the distance between each
end of the slope and the left or right edge of the gel, and knowing the lowest and
highest denaturant concentrations, assuming the gradient is linear. Section 2.2.7 and
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the accompanying figure describe such a gel in which p53 fragment B (exon 5) PCR
products are electrophoresed. Fragment B melts as a single domain, and the 2 lines at
the slope of the sigmoid represent WT and mutant (H69 cell line) sequences co-
electrophoresed. For this fragment, a denaturant range of 50 to 70% seems most
appropriate, with 64.4% being the central point of the sigmoid. This differs from the
original description (Borresen et al, 1991) in which 50% denaturants was optimal.
The likely reason for this is the inconsistency of obtaining a perfect linear gradient gel
in which concentrations along the gradient can be estimated. As noted in Section
2.1.6.2, outflow from the gravitational gel caster is variable, largely dependent on the
smooth operation of the 3-way tap, and the time spent varies between 3 to 10 minutes
or longer. For this reason, I elected to use a broad gradient of 30-80% which, with
the relatively high electrophoresis temperature of 60°C, should enable detection of all
point mutations in the studied fragment (Busby-Earle et al, 1994). For the same
reason, I did not feel that perpendicular DGGE assessment of the remaining 4
fragments was worthwhile and applied these same conditions to them.
The use ofDATD as cross-linker is unique to Borresen's description ofCDGE and
Busby-Earle's report (1994) which followed the Borresen protocol, and all other
reports identified described the use ofbisacrylamide as cross-linker, with an
acrylamide: bis ratio of 37.5:1. This contrasts with the 19:1 ratio which I used for
ordinary PAGE, which seems to require a higher degree of cross-linking than DGGE.
As seen in Section 2.2.4, the polymerised DGGE gel with acrylamide:bis of 37.5:1
was unable to demonstrate the presence ofmutations in positive controls. Gels with
the lower ratio of 19:1 were also ineffective (data not shown). Furthermore, gels
cross-linked with bis also appeared not to retard migration of the DNA fragments as
shown in the travel schedule gels. One possible explanation might be that the highl¬
and low-concentration denaturants in the gradient were allowed to mix between the
plates prior to polymerisation, resulting in a uniform denaturant concentration
throughout the gel with an equivalent Tm lower than that of the DNA fragment
studied. I felt this was unlikely as meticulous care was taken to ensure that the gel
was poured at such a speed that the acrylamide was not allowed to stand in liquid
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phase for too long before it polymerised, and the optimal gel-pouring time was 8 to
10 minutes. It would seem, therefore, that under the electrophoretic conditions and
primer sequences used here, DATD somehow provided a unique molecular
environment for the retardation ofmigration of denatured double-stranded DNA
fragments.
5,2.4 COVERAGE OF POSSIBLE MUTATIONS
In Borresen's description ofCDGE (1991) from which my primer sequences were
derived, it was remarked that the regions screened covered over 80% ofmutations
reported. This study did not cover exon 6 which, although not within the conserved
domains, is known to contain a significant proportion ofmutations (14.5% for breast
cancer, see below). I have, therefore, empirically added a set of primers for exon 6
(fragment E) containing some 5' intronic sequences, which improved the coverage of
possible mutations to 90.6% (Table 5.1). This figure is derived from a database of p53
mutations as described by De Vries et al (1996). In this database, 1965 p53 mutations
are listed. These were reported in the English world literature up to September 1993.
From the abbreviated listing ofmutations, a total of 145 missense, nonsense, silent
and complex exonic point mutations are identified for breast cancer. The hot-spot
codons 175, 245, 248, 249, 273 and 282 cover 30.3% of all reports for this disease.
Codons 175 and 248 cover 9% each. The merits of adding the exon 6 primers can be
seen in my cohort of cases, as p53 mutations in exon 6 (fragment E) are found in 4/13
tumours. Table 5 .1 compares the regions covered by the conserved domains where
most mutations of p53 are clustered around domains II to V, and the regions screened
in this project. For each of the 5 fragments (A - E) and 5 domains (I - V), the
proportion ofmutations in breast cancer likely to be found in it is listed (De Vries et
al, 1996). It is noted that the p53 fragments covered by the primers used in this
project are likely to contain a larger proportion ofmutations than the conserved
domains themselves. In this project, the incidence of non-polymorphic mutations in
breast cancer is 13/51, or 25.5%. If this represents 90.6% of all mutations likely to be
present in the cohort of breast cancers studied, the total incidence here is 28.1%,
within the accepted range for this disease.
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Table 5.1 Calculations based on p53 database ofDe Vries et al (1996). See Section
5.2.4.
Domain Codons Exon Proportion of all
mutations in breast cancer
I 13 - 19 2 0%
II 117-142 4 and 5 6.9%
III 171 - 181 5 12.4%
IV 234 - 258 7 29.6%
V 270 - 286 8 17.9%
66.8% total
Fragment Codons Exon Proportion of all
mutations in breast cancer
A 124 - 148 5 9.6%
B 155 - 185 5 20%
E 187-222 6 14.5%
C 237 - 253 7 26.2%
D 264 - 301 8 20%
90.6% total
5.2,5 PRESENCE OF p53 MUTATIONS IN CLINICAL SAMPLES
As noted in the above section, the incidence of p53 mutations in the studied breast
cancer population is within expected limits, including 4 cases (of 11 sequenced)
whose mutations are in the hot-spot codons (codon 175 - patient B11, codon 248 -
patients B28 and B33, codon 273 - patient B45). The pattern ofmutations in the
breast cancer cohort, therefore, conforms to what is known and implies that the
patients and tumours studied are representative of sporadic breast cancers generally.
Of the 11 sequenced tumours, only 5 could be optimised adequately to be used in
ARMS. It is suspicious, therefore, if the other 6 tumours had been correctly
sequenced. If the mutations did occur elsewhere, the ARMS PCR would not be
expected to amplify WT sequences whether tumour or control template was used. I
surveyed the EMBL p53 database (Hollstein et al, 1994) to confirm that each of the 5
un-optimisable sequences (1 sequence occurred in 2 tumours) had been reported in
breast or other cancers. The following is a list of these mutations and the tumours in






Cancers in which mutations reported
Breast, gastric.
216 GTG > ATG Breast (many reports), head and neck, lung,
liver, oesophageal, leiomyosarcoma, MDS,
ovarian.
248 CGG > CAG Endometrial, CLL, bladder, nasopharyngeal,
glioma, NHL, colorectal, head and neck,
gastric, Burkitt's lymphoma, ALL, breast,
oesophageal, urothelial, ovarian, plasma cell
leukaemia.
267 CGG > CAG Breast, prostate, Li-Fraumeni syndrome.
273 CGT > TGT Breast, bladder, thyroid, head and neck,
glioblastoma, astrocytoma, basal cell, liver,
cervix, uterine, colorectal.
It would seem that the sequences obtained are believable. Moreover, the
chromatograph appearances at these mutations are always unequivocal (Fig. 2.10). It
must be admitted, however, that the fact that these mutations have been reported in
association with cancers and in particular breast cancer would not necessarily confirm
that they are correct for the samples whose ARMS were not optimisable. The only
means of confirming would be to sequence the opposite strand which, with hind-sight
would certainly have been worthwhile had it not been for time constraints.
The incidence ofmutations in the leukaemia samples, on the other hand, is
disappointingly low. Because of the reported higher incidence of such mutations in
relapsed disease (Zhu et al, 1996), of 16 samples taken at relapse, approximately 5
could be expected. Of the remaining 18 patients, 1 or 2 would be present. Instead,
one single mutation was detected (excluding the 2 constitutional polymorphisms in
codon 213) in a relapse sample. This low incidence may be due to the fact that
fragment A (5' portion of exon 5) was not screened in any of the leukaemia samples
because of initial technical difficulties with PCR amplification. However, a study of
the EMBL database shows that only approximately 6% of reports of acute leukaemias
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fall within this fragment, and hence unlikely to contribute to the number of mutations
detected here.Technical factors might be involved, but care was taken to ensure that
materials studied contained a high proportion of leukaemic blasts, and a positive
control was alway run on the same gel, so these would also seem unlikely. It remains
possible that the incidence of p53 mutations in this cohort of patients is genuinely low.
The 8 bp insertion (5'-CCGGGGGG-3') between the second and third bases of codon
281 of the ALL patient (LI 1) is novel and not previously been reported. A survey of
the EMBL database, that ofDe Vries et al (1996) and that of Beroud and Soussi of
the Curie Institute (http://perso/curie.fr/thierry.soussi/p53_database.html) did not
reveal this insertion in any malignancy. In this patient, clonal evolution is implicated.
As described in Section 3.7.3, a previous study of this patient (Langlands et al, 1993)
confirmed the presence of 2 leukaemic clones. The major clone at diagnosis appeared
to have responded to chemotherapy such that there was no molecular evidence of it
after therapy, but the more aggressive clone, which was a minority at diagnosis and
which contained the 8 bp insertion in p53, ultimately resulted in death of the patient.
This comes as no surprise, as it is now widely recognised that in many human
malignancies, the presence of a p53 mutation carries adverse prognostic implication in
terms of survival and resistance of the tumour to cytotoxic chemotherapy (Aas et al,
1996). In acute leukaemias, blast cells carrying p53 mutations are more resistant to
both high dose chemotherapy and low dose cytosine arabinoside (Wattel et al, 1994).
Clonal evolution in such leukaemias over a background of blasts not containing p53
mutations has also been implicated (Wada et al, 1994; Zhu et al, 1996), and this
phenomenon is also recognised in lung cancer (Mao et al, 1994), malignant brain
tumours (Sidransky et al, 1992) and soft tissue sarcomas (Pollock et al, 1996). Patient
LI 1 again confirms this. Although the great majority of p53 alterations are missense
mutations leading to conformation changes and often increased half-life of the p53
protein, over 280 short insertions or deletions have been reported to the EMBL
database (Greenblatt et al, 1994). 90% are monotonic runs of 2 or more identical
bases in tandem or with a short intervening sequence, and codons, 151-159 are most
frequently involved. Although our mutation occurs in codon 281, it is adjacent to a
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short run of G and C repeats, and the mechanism of slipped mispairing, or template
misalignment, may be involved. There is no identifiable mutagen in this young patient
of 16 years that may be implicated. From this case, it can be seen that as well as
missense mutations, frameshift mutations of p53 may also be associated with a more
aggressive phenotype, leading to therapy resistance and clonal evolution of acute
leukaemias. Unlike single-base mutations, the specific nature of this insertion makes
allele-specific PCR to detect MRD much more feasible.
5.3 AMPLIFICATION REFRACTORY MUTATION SYSTEM (ARMS)
5.3.1 USE OF ARMS IN THE DETECTION OF MINORITY CLONES
ARMS-based techniques (in their various synonyms) have frequently been used to
distinguish one allele from another in inherited conditions, and in the analysis and
characterisation of acquired mutations associated with a disease process, as outlined
in Section 1.5.8. Prior to the introduction of such techniques in the late 1980's, PCR
techniques coupled with dot-blot and allele-specific oligonucleotide hybridisation had
been used but sensitivity was relatively low, approximately 5% (Flalliassos et al,
1989b). ARMS has the advantage of being rapid; potentially highy sensitive (Kirby et
al, 1996); non-radioactive and does not require hybridisation; amenable to
manoeuvres such as multiplexing (Patel et al, 1993), detection with fluorochromes
(Chehab and Kan, 1989), and use of oligonucleotide or peptide nucleic acid blockers
(Seyama et al, 1992; Rhodes et al, 1997) to enhance sensitivity; and applicable to sites
across a wide variety of genes (Bottema and Sommer, 1993). Because of the highly
subtle nature (often a single base change) of the genetic alterations studied by ARMS,
considerable optimisation of the PCR system was required to achieve the best cycling
conditions for each site (Sommer et al, 1992b; Cha et al, 1992; Rychlik, 1995; Rhodes
et al, 1997). All the studies that describe the optimisation process or the use ofARMS
to detect minority clones of cells have one feature in common - they have all used
models of one or a small number of single-base genetic changes. The ras oncogenes
have often been studied along these lines with ARMS, but ras differs from p53 in that
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mutations of this family of genes largely occur in a small number of codons, primarily
codons 12, 13 and 61 (Takeda et al, 1993), such that it has even been possible to use
a mixture of primers corresponding to mutations of the first or second nucleotide of
codon 12 in the MASA technique (Takeda et al, 1993). This approach is clearly not
applicable to p53 whose mutations are scattered over a large number of codons. A
very small number of studies are available where heterogeneous disease markers such
as p53 mutations are used in a large scale for detecting minority clones (Hayashi et al,
1995; Mao et al, 1994). Both of these studies used a combination of p53 and K-ras
mutations as markers. Neither study described the optimisation procedure. Whilst
Mao et al achieved a sensitivity of 1 tumour cell in 104 normal cells by cloning the
PCR products and hybridising with a radio-labelled ASO probe, Hayashi et al did not
use probes but then did not specify the sensitivity of their technique. In order for
heterogeneous markers to be employed in MRD detection in an already multi-step
protocol, steps should be simplified as much as possible and individual hybridisation
and probing is likely to be too cumbersome. Hence I hoped to assess the feasibility of
a PCR-based technique that did not require Southern hybridisation. Radio-labelling of
either primers or dCTP was tried in an attempt to improve sensitivity, however.
5 3 2 OPTIMISATION OF ARMS
The principle ofARMS lies with the different efficiencies in which matched and
mismatched primer-template pairs are amplified. Because of the large number of times
a piece ofDNA is amplified, differences in such efficiencies are magnified, to produce
a detectable difference between the templates. For instance, if the amplification
efficiency of a matched pair is 90% and a mismatched pair is 60%, after 25 cycles of
amplification, there will be 73 times more product from the matched than the
mismatched reactions (Wu et al, 1989). Optimisation is still required, however, to
ensure that the difference in amplification efficiencies is maximal. Such differences are
most important in the initial cycles ofPCR as, once a product has been formed,
subsequent cycles will produce perfectly matched products. Unlike the use ofARMS
in screening inherited conditions or determining tissue types, in which the allele in
question is in the germ-line and present in all cells studied, MRD detection has the
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additional requirements of absolute specificity (no detectable PCR product with WT
template) and a reasonably intense specific ARMS product such as to be visible when
mutant DNA species are heavily out-numbered by WT species. Whilst a minor degree
of non-specificity may be tolerated when ARMS is used for other applications, it is
imperative that no detectable product is obtained with WT DNA when ARMS is used
in the study ofMRD. Therefore, the aim of the optimisation work-up for any
mutation site in this project is not simply to ensure that PCR products are not
produced with a WT template, but also to avoid reducing the intensity of the product
with the mutant template. Much effort in this project was spent in determining the
factors which would make an ARMS reaction specific and sensitive, using DNA from
the cell lines T47D and 5637. Such optimisations were along the lines suggested by
previous published work.
Because of the requirement of a lack of 3' to 5' exonuclease activity, Taq polymerase
is usually used. Similar results can also be obtained with the Stoffel fragment of Taq
(Rhodes et al, 1997). Apart from the choice of Taq which is not in dispute, numerous
factors associated with PCR have been studied in optimisation experiments by various
authors. In this project, the parameters assessed individually whilst keeping other
variables constant were: annealing temperature, magnesium concentration, dNTP
concentration, primer concentration, the presence of glycerol and of formamide, cycle
number, and the use of an ARMS primer with the 3' base corresponding to the mutant
sequence versus one in which the penultimate base was also deliberately mismatched.
5 3 2 1 ADDITION OF A DELIBERATE MISMATCH
As indicated in Chapter 3, using DNA from the breast cancer cell line T47D which
contains a missense mutation CTT to TTT in codon 194, the first conclusion was that,
as well as replacing the 3' base of the ARMS primer with the mutation, deliberately
introducing a mismatch in the penultimate base did improve specificity, and at least in
the T47D model, did not significantly compromise sensitivity. Based on this finding,
all ARMS systems studied in this project used ARMS primers which mismatched a
WT template at the 2 bases 3', and mismatched a mutant template at the penultimate
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3' base only. The mismatch was chosen according to the destabilisation ranking as
determined by Newton et al (1989). In descending order of destabilisation,
mismatches are: CC > CT > GG = AA = AC > GT. For each ARMS system, the most
destabilising mismatch was chosen, with the assumption that any other single base
mismatch introduced would not improve specificity greater. The further from the 3'
end of a primer the deliberate mismatch is introduced, the lower the destabilising
effect, and the more likely for a product to result with a WT template (Newton et al,
1989; Newton and Graham, 1994), hence all mismatches were introduced in the
penultimate base only. Internal mismatches are often very well tolerated, even with
lower Ta's (Christopherson et al, 1997). Obviously, introducing 2 deliberate
mismatches (first and second penultimate bases) would be even more destabilising for
the WT template and improve specificity, and this was attempted with patient B45
(using primer 1232/94-ARMS2). The result was that, though no specific product was
obtained with WT template, little amplification was obtained with the mutant template
even at the lower Ta's of47 and 50°C, and none at all at the higher Ta's (Section
3.7.1). Furthermore, a lot of spurious products were amplified. From this, it can
therefore be concluded that, for certain ARMS systems, mismatching strategy may
either produce too little or too much destabilisation of primer-template annealing,
with nothing to bridge the gap to produce an operable system. Several mutation sites
could not be optimised (patients B27, B28, B33, B45, B46, B50). Invariably, in each
of these the intensity of the WT and mutant products were too similar, and any
alterations in PCR conditions affected both to a similar degree.
5.3,2.2 ALTERATIONS OF OTHER PARAMETERS
Reviewing available literature on the optimisation ofARMS identified a number of
studies in which PCR conditions were adjusted to make ARMS specific. Bottema and
Sommer (1993) reviewed their experience of using ARMS at 41 different sites (69
allele-specific assays) for a variety of applications including population screening for
variants of the coagulation factor IX gene, haplotyping of the transthyretin gene and
carrier testing for genetic conditions. In the majority of cases, magnesium
concentration (1.5 - 4.5 mM) and primer concentration (0.05 - 1.0 pM) titrations
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were adequate in producing a robust and specific system. Using a G to A missense
mutation of the factor IX gene as a model, [Mg] of< 3.5 mM and [primers] of around
0.05 pM produced specific reactions (Sommer et al, 1992b). It is widely known that
specificity of a PCR reaction improves with lower [Mg]. Magnesium ions form a
soluble complex with dNTPs, essential for their incorporation in a PCR. Magnesium
also has the effect of stimulating DNA polymerase activity and increasing the melting
temperature of the primer-template structure (Newton and Graham, 1994). The
benefit of lowering [Mg] was demonstrated in this project and was in fact a key
parameter to be optimised. The main issue here is that amplification of a doubly
mismatched primer-template pair (i.e. WT template) was more susceptible to the
effect of lower [Mg] than if the 3' bases were perfectly matched (mutant template), a
feature much utilised in this project. On the other hand, the effect of lowering
[primers] was not obvious, as amplifications with both WT and mutant DNA were
affected simultaneously.
Increasing Ta can improve specificity and prevents priming ofmismatches (Rychlik,
1995), although not found to be important by some authors (Sommer et al, 1992b).
Ta was a most important condition to be optimised in this project. Because of the
relatively higher melting temperature and stability of a matched (or less mismatched)
primer-template pair (Huang et al, 1992), a higher Ta allows preferential annealing of
matched primer to template and hence more efficient amplification. Generally, a high
Ta of 64 - 67°C was required for optimal specificity, and the experience here is that
Ta should be the first parameter optimised, and other factors may then be adjusted
after the best Ta is selected. All other factors previously reported to enhance
specificity, in particular [dNTP], were not found to contribute significantly. The main
problem with all these factors appeared to be that they simultaneously reduced
amplification with both WT and mutant templates. This was the case with [dNTP]
which at 25 - 50 pM has been found to decrease spurious products (Bottema and
Sommer, 1993), and very low concentrations of around 6 pM enhanced specificity,
giving 10-20 fold less products than reactions at higher [dNTP] (Kwok et al, 1990).
The discrimination between extension efficiencies ofmatched and mismatched
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sequences is maximum when the concentration of the next correct dNTP is low
(Huang et al, 1992). Although the range tested in this project (3.125 - 200 pM)
covered these concentrations, amplification with the mismatched WT template was
not preferentially inhibited by low [dNTP]. Some authors have found that extension of
certain mismatches (C:T, A:C, C:C) were susceptible to even lower [dNTP], as low
as 2 pM (Ehlen and Dubeau, 1989). Addition of other solvents have been found to be
of some benefit to ARMS. Formamide at 2 - 5% increases signal strength, eliminates
spurious bands and enhances allele specificity (Bottema and Sommer, 1993). Here,
the addition of formamide was strongly inhibitory to amplification. The 2.5% of
formamide used here produced a significant reduction of intensity ofmutant product.
Conceivably, a lower concentration might have produced less inhibition and might
have been worth trying in sites where ARMS was difficult to optimise. Glycerol at 5 -
10% enhances specificity (Cha et al, 1992; Rychlik, 1995). This was tested here. 10 -
20% glycerol added to the ARMS reaction produced slight benefit by reducing the
signal from the amplicon of the WT template. 5% did not make a difference. The main
drawback ofglycerol was the difficulty of accurate pipetting owing to its viscosity,
but this was improved by prior warming. For this reason glycerol was not routinely
used here.
Various other manoeuvres have also been reported in the optimisation ofARMS
reactions. For example, a shorter ARMS primer enhances the difference with which
extension takes place on a WT or mutant template (Huang et al, 1992) as the
destabilising effects of mismatches are relatively greater. Primers as short as 14
nucleotides may be successfully used (Wu et al, 1989). Other authors advocate longer
primers of around 30 nucleotides (Newton and Graham, 1994). As a compromise and
in line with most reports of ARMS, I selected 20 nucleotides as the standard length.
Sometimes, even though the design of an ARMS primer from the physico-chemical
point of view appears optimal, the nature of the opposite (non-specific) primer may
have bearing on the success of the reaction. Surprisingly, replacing the opposite
primer with a different non-specific primer at another location, keeping the product
size between 300 and 600 bp, has been reported to be beneficial in difficult cases
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(Sommer et al, 1992b). In this project, 1 was reluctant to attempt this approach for
various reasons. (1) There is no formula to help predict which sequence should be
chosen, other than generally accepted guidelines for choosing primer sequences for
PCR (Newton and Graham, 1994). Efforts in trying out various non-specific
sequences randomly may well not pay off, and certainly if halfof all systems require
such optimisation as is the case here, the whole approach of using point mutations as
MRD markers would be much too inefficient for clinical or even research application.
It might be that some ARMS systems here were unoptimisable because of primers
having different characteristics. On close scrutiny of the characteristics of the various
ARMS / non-specific primer pairs (Table 3.2), 3 of the 5 unoptimisable systems
(patients B45, B46, B50) are comparable within their primer pairs in terms of GC
content and melting temperature (Tm). The other 2 systems have rather larger
differences: Tm's for ARMS and non-specific primers for patient B27 are 48.4°C and
53.7°C, respectively, and for patient B33 are 60.9°C and 49.6°C, respectively.
However, of the 5 optimised systems, large Tm differences are also observed. Patient
B30's primers have Tm's 49.6°C and 56.6°C, and more remarkably, ARMS for
patient B11 was very successfully optimised with the original GC-clamped primer
used in DGGE (Section 2.1.5.3). (2) using p53 as a marker for MRD is already quite
laborious and involves numerous steps, and I was keen to restrict the number of
primers used and to take advantage of sequences already available.
5.3 2.3 NATURE OF PRIMER-TEMPLATE MISMATCHES
A number of studies have looked at the ability ofmismatched sequences to extend in
PCR. Although perfectly matched bases at the 3' end of a primer enables maximum
efficiency of extension, mismatched bases may extend more or less efficiently
depending on the nature of the mismatch. Studying the thermodynamics of
mismatching to thymine, Petruska et al (1988) reported that a matched A:T terminus
extended 200 times faster than a G:T mismatch, 1400 times faster than C:T, and 2500
times faster than T:T, using purified Drosophila DNA polymerase a. Contrasting
results were reported by Kwok et al (1990) who found that any 3' mismatch involving
T was extended efficiently, even at low [dNTP] and when coupled with an additional
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deliberate mismatch. A:A mismatch reduced yield by 20 fold, whilst A:G, G:A and
C:C mismatches reduced yield by 100 fold. Of note is that these authors used
relatively long primers (30 bp), and the destabilising effects of these mismatches might
be greater if the primers were much shorter. Another detailed studied by Huang et al
(1992) showed that A:A, G:G, G:A, A:G, C:C mismatches were the most difficult to
extend, whilst other mismatches could be extended slightly more efficiently but 100 -
10000 fold less than perfect matches. Overall, it seems clear that purine:purine or
pyrimidine: pyrimidine mismatches are extended much less efficiently than
purine:pyrimidine or pyrimidine:purine mismatches.
With this information in mind, a study of the 5 optimised ARMS systems here shows
that the 3' mismatches are A:G, G:T, G:G, T:C and A:C, for patients B3, B11, B16,
B30 and B37, respectively (Table 3.1). Only 2/5 of these are mismatches from the
same class of nucleotide. On the other hand, the unoptimisable ones are A:C, G:T,
T:G, A:G and G:T, for patients B27, B33, B45, B46 and B50, respectively. Only 1/5
are mismatches from the same class. In conclusion, although it is useful to have
theoretical guidelines to help design ARMS primers or to assess the likelihood of
success (Petruska et al, 1988; Ikuta et al, 1987), each system needs to be optimised
individually and in practice, ARMS may work quite differently from what one might
expect in theory. Apart from considerations at the 3' end of a primer, ARMS
specificity is also influenced by the overall sequence context (Cha et al, 1992; Kwok
et al, 1989).
5 3 2.4 SENSITIVITY OF ARMS
With a degree of heterogeneity of assay systems and optimisation criteria, a range of
sensitivities have been reported for the use of ARMS in detecting minority DNA
species. Many applications ofARMS are not for MRD detection (Section 1.5 .8) and
so a high sensitivity, or the ability to detect minority sequences is not important. In the
application ofARMS in MRD detection, it is the 'discrimination sensitivity' between
WT and mutant that is most important. The ARMS PCR itselfmay well detect a small
quantity ofmutant DNA, but much of this sensitivity is of no significance when the
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system is optimised sufficiently to remove any trace of product with the WT template.
For instance, Horikoshi et al (1994) reported that allele-specific PCR with the ras
gene was capable of detecting 55 molecules ofDNA, but the discrimination sensitivity
was only 1:500. Other reported sensitivities range from 1:100 (Stork et al, 1991) to
1:1000 (Wada et al, 1993), 1:104 (Cha et al, 1994) or 1:105 (Ehlen and Dubeau,
1989) when radioisotopes are used, or glycerol added. In this project, my range of
sensitivities also fall within this broad bracket, from 1:100 - 1000 in patient samples,
to 1:1000 - 104 with cell line models (5637 and T47D). The lower sensitivities with
patient samples may be due at least in part to the quality ofDNA extracted from
paraffin embedded sections, and that these are highly likely to be contaminated with
normal surrounding tissues whilst cell lines provide a pure source of tumour DNA.
Sensitivity is much more easily achieved in situations where the alteration is less subtle
than a single base change, as in the leukaemia patient LI 1, in which system the
mutation was an 8 bp insertion. This makes ARMS primer design and optimisation
much easier as there is virtually no chance of a specific product of the correct size to
be produced from a WT template. Indeed, here no optimisation was required, and
simply standard PCR conditions were used and a moderately high sensitivity of 1:104
was achieved.
Thus far discussed, all ARMS products were visualised by ethidium bromide staining
of polyacrylamide gels. As described in Section 3.6, attempts were made to improve
the detection sensitivity, based on the T47D breast cancer cell line model. The first
attempt was to use a nested PCR, employing primer sequences with which the
individual exons were amplified. It rapidly became apparent that a loss of specificity
was limiting to this approach, owing to the much larger number of template molecules
available for the inner nest (ARMS) reaction. This was not improved by diluting the
product from the outer nest reaction 500 fold. I next attempted to use 32P
radiolabelled dCTP, with the quantity of the non-radioactive dCTP counterpart
reduced. This approach produced a slightly different set of optimised conditions from
the non-radioactive ARMS, but it was perfectly feasible to have the system optimised.
For reasons not apparent, attempts at obtaining detection sensitivity by serial dilutions
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ofmutant in WT DNA were unfortunately unsuccessful. The main difficulties
appeared to be inconsistencies in the generation of products for each dilution. Despite
repeated experiments, it was not unusual for higher dilutions to yield a product when
lower dilutions did not, and loss of specificity was also observed. These problems
could not be remedied and this approach had to be abandoned. Further attempts were
made by 32P-radiolabelling the ARMS primer instead of dCTP in the hope of
obtaining products with a more consistent signal as each molecule of the PCR product
would contain one radiolabel, whilst the former dCTP approach would yield products
with signal strength dependent on the number of C's incorporated. Unfortunately, the
same inconsistencies were observed, and this too had to be abandoned. A possible
explanation for the inconsistencies in the dilution experiments was of course sampling
error, but it is to be noted that aliquots of these dilutions were also used in
experiments with the non-radioactive approach which did not suffer the same
difficulties. Since the initial optimisation using WT and mutant DNA only had not
suffered these problems, I would imagine technical or sampling errors were still the
likely reasons for failure of these experiments.
One limitation of detection sensitivity is obviously the quantity ofDNA used in an
ARMS reaction. In this project 1 pg of genomic DNA was used in each 50 pi reaction
mixture as standard. Each 1 pg ofmammalian genomic DNA contains approximately
3x105 copies of an autosomal gene (Cha et al, 1992). p53 alterations in malignancies
may occur either as a heterozygous phenomenon (i.e. on one of two alleles) or, more
commonly, in a hemizygous state in which the normal allele is deleted (loss of
heterozygosity). Hence, 1 pg of tumour DNA should contain 1.5x10s copies of
mutated p53. Even assuming that ARMS can amplify one single molecule of mutated
p53 within 1 pg of template, the maximum sensitivity, whatever the visualisation
method, should be of the order of 1 cell in 105, and probably much lower. I would,
therefore, be satisfied with a sensitivity of around 1: 104. To increase the detection
sensitivity one order of magnitude would require 10 pg ofDNA, or 10 separate
reaction tubes. Even then, with one tube out of 10 yielding a product, it would be
impossible to conclude that MRD was present. Furthermore, the amount ofDNA
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required might well be prohibitive, depending on the source and quantity of study
clinical material available. When compared to ultra-sensitive RT-PCR techniques
using RNA as starting material (Datta et al, 1994; Gerhard et al, 1994; Fields et al,
1996) in which weight for weight many more copies of nucleic acids are examined, it
would appear from here that methods using DNA may well not have a significant role
in the detection ofMRD, at least in the context ofbreast cancer in which RNA-based
technologies are increasingly available.
5.4 RESTRICTION SITE-GENERATING POLYMERASE CHAIN
REACTION (RG-PCR)
The short Chapter 4 describes my attempts at using the RG-PCR approach as an
alternative to ARMS in detecting MRD. PCR is a powerful technique and as well as
amplifying DNA with a specific defined sequence, can modify the sequence of the
product one wishes to obtain by deliberately changing the primer sequence. This has
already been described in the design ofARMS primers to enhance specificity. In RG-
PCR, whilst the 3' end of the primer is perfectly matched both to WT and mutant (and
stops short of the mutation itself), the deliberate mismatch is slightly further upstream
such that an artificial restriction enzyme recognition site is generated for the WT
sequence as seen here, or for the mutant sequence if desired. RG-PCR has more often
been used for indications other than MRD detection. Examples include mutations in
the CFTR cystic fibrosis gene such as the AF508 deletion of 3 bp, and 2 other
relatively common mutations (Friedman et al, 1991); population studies of the
5382insC mutation of the BRCA1 gene using the enzyme BstOl; and detection of ras
oncogene mutations (Jiang et al, 1989).
There are key advantages ofRG-PCR over ARMS. A PCR product is always
available, whetherWT or mutant DNA is used, and internal control with another gene
is not required. Because the mismatched base is slightly further upstream, extension of
primer should not be impaired and amplification is efficient as a result. Optimisation of
PCR should, therefore, be relatively straightforward. Also, recognition sequences of
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restriction enzymes are usually highly specific and should reliably cleave double-
stranded WT DNA only, leaving mutant DNA intact (or vice versa). This compares
with the relatively non-specific nature of ARMS which is totally dependent on the
discrimination sensitivity between WT and mutant (Section 5.3.2.4 above). RG-PCR
has a wide applicability, as a restriction enzyme site can be generated for all 10
mutations detected in the breast cancer samples, 3 ofwhich already altered restriction
sites on their own (Table 4.1). With these positive features, I thought RG-PCR would
be well worth assessing as an alternative to ARMS.
As with any technique used to detect minimal quantities of abnormal DNA amongst a
large excess of normal DNA, sensitivity is a key requirement. In this project, RG-
PCR, in which visualisation ofPCR products was by ethidium bromide and UV light,
has failed in this important regard. Serial dilution experiments showed that the mutant
could barely be detected if it existed in less than 1:10 mixture. This is, however, not
dissimilar to the sensitivities previously reported as determined by serial dilutions of
mutant in WT DNA. Using K- and H-ras oncogene models, dilution experiments of
Jiang et al (1989) obtained sensitivities of 1:16 and 1:9, respectively. Other earlier
studies (Haliassos et al, 1989a and 1989b) gave a sensitivity of approximately 5%.
These reports all involved the use of ethidium bromide and UV light to visualised
products. The sensitivity was improved dramatically to 1: 2.5x104 when the PCR
product was blotted onto a solid phase support and visualised with an internal radio-
labelled ASO probe not corresponding to the mutation (Haliassos et al, 1989b). With
the reasoning in the Section 5.3.2.4 above, this is bordering on the theoretical limit of
detection when 1 pg of genomic DNA is used, although these authors did not specify
the quanitity ofDNA used in each reaction. This method was obviously worth
attempting here, but because of time and resource constraints, was considered outwith
the scope of this project.
Another method of potentially improving the detection sensitivity of RG-PCR is to
use restriction enzyme to enrich the mutant DNA selectively for PCR. Kahn et al
(1991) described this approach in the detection of codon 12 mutations in K-ras,
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achieving a sensitivity of identifying one copy of the mutation amongst 104 copies of
WT. This 'enriched' PCR was based on the use of a mutagenic primer which created a
restriction site for the enzyme BstNl if the template was WT. After first round PCR
and enzyme digestion, another mutagenic primer also creating a BstNl site further
downstream was used for the second round PCR and this served as a control for the
enzyme action. Because of cleavage of the WT DNA, only mutant DNA remained to
be amplified in the second round of PCR. As a result of these 3 steps, products of
different sizes representing WT and mutant species were obtained. Dilution
experiments confirmed the marked improvement in sensitivity, and this was with non¬
radioactive reagents and visualisation by ethidium bromide staining. One drawback of
using multiple steps is the risk of contamination, but some restriction enzymes, though
active at lower temperatures, may withstand the high temperatures ofPCR for short
periods, and it may be possible to have a one-step procedure in which the enzyme is
added at the outset (Huber et al, 1998). This is the case with BstNl, but obviously for
different mutations, each enzyme needs to be evaluated for this individually, and with
a heterogeneous set of mutations as with p53, this may not be feasible. Attempts here
in using enriched RG-PCR were not successful (Section 4.3) because, despite enzyme
digestion which should remove all WT DNA, a product was still produced after the
second round PCR. Although 10 U ofMbol enzyme would be expected to digest to
completion after 3 hours of incubation, residual WT strands were likely to have
remained. Time and resource constraints prevented a more complete evaluation of this
technique, but probable avenues would include (1) using a higher dose of enzyme, (2)
digesting for longer, or (3) reducing the number of cycles in the first round of PCR
such that enough template molecules are available for the second round, whilst the
smaller number ofWT DNA to be digested by the enzyme means more complete
digestion.
As described above, screening genomic DNA for MRD usually means that the limit of
detection is of the order of 1: 105, if 1 pg ofDNA is examined. This assumes the
amplification and subsequent product detection of 1 copy of the mutation. In practice
the actual detection limit is likely to be much lower, and figures from the techniques
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described by both Haliassos et al (1989b) and by Kahn et al (1991) would suggest that
they were approaching what was theoretically possible. When compared with the
sensitivities reported for RT-PCR techniques used in MRD detection of breast cancer
(Tables 1.2a and 1.2b), this high-lights the insensitivity of using DNA as study
material.
5.5 CLINICAL RELEVANCE OF MRD IN PBPC HARVESTS OF BREAST
CANCER PATIENTS
For epithelial tumours such as breast cancer, immunocytochemistry (ICC) was
traditionally the method of choice for MRD detection (Mansi et al, 1987; Molino et
al, 1991). Attempts have also been made to use ICC in the liquid phase, i.e., by flow
cytometry (Leslie et al, 1990; Simpson et al, 1995) but this does not seem to have
gained as much popular appeal. With the advent of the PCR in the 1980's (Saiki et al,
1988), naturally much interest was generated in the use of this technique as a ultra¬
sensitive means ofMRD detection. Momentum in this development gathered only
relatively recently (Datta et al, 1994; Gerhard et al, 1994) with the use ofCK19, and
perhap CEA as markers, and since that time a significant body of literature has
gathered, both describing the laboratory development of such techniques (Traystman
et al, 1997; Moscinski et al, 1996) and their actual clinical application, correlating the
presence ofMRD with clinical outcome (Fields et al, 1996). To date, ICC using
immunostained cells visualised on fixed slides with a fluorescent microscope (Cooper
et al, 1998) and RT-PCR detecting the CK19 message remain the 2 most sensitive
'gold standards' most widely employed.
Very few controlled studies have examined the contribution ofMRD in PBPC
harvests to clinical outcome. Sharp et al (1992) studied MRD using a cell culture
technique with a sensitivity of 1 cell in 104 normal cells, and found that in patients
with stage IV breast cancer at 10 to 28 months of follow-up, only 1 of 6 paitents who
received contaminated PBPCs remained alive, which contrasted with 7 of 8 patients
who received culture-negative collections. The fact that culture techniques were used
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could mean that any malignant cells detected were more likely to grow and
metastasise in vivo, unlike other techniques which are unable to distinguish between
live and dead cells. The only other large study on PBPC (Cooper et al, 1998) in breast
cancer came to a very different conclusion. Using a sensitive ICC technique capable of
detecting 1 cell in 5x105 cells, these authors reported no significant difference in the
outcome of patients with stage IV breast cancer who received MRD-positive or
negative PBPCs. If the tumour dose received was > 2/105 tumour cells (which
occurred in only 6 patients), there was reduced survival but not time to disease
progression. Similar studies have also been performed for BM harvests, with results
suggestive of favourable outcome if patients were transplanted with MRD-free
products (Fields et al, 1996; Brockstein et al, 1996).
In this current project, overall results are hard to interpret. (1) Firstly, the number of
patients in whom a disease marker is available is very small, and in even fewer could
the ARMS systems be optimised sufficiently for MRD detection. No meaningful
statistics could be performed on such a sample. Of the 5 patients described in detail in
Section 3.8, 2 were known to have metastatic disease (B11, B3), 2 had high risk stage
II/III disease on the basis of 4 or more axillary nodes (B30, B37), and the remainder
(B16) was considered to have poor prognosis because of relapse after radical
radiotherapy. After PBPCT, patients B11 and B30 relapsed in new sites, while B3 and
B37 relapsed in previous sites of disease. Relapsing in new sites may potentially imply
a role for re-infused tumour cells contaminating PBPCs. Here, patient B30 had no
evidence ofMRD determined by ARMS, whilst both B3 and B37 did. The fact that
the latter 2 patients relapsed in previous sites indicate failure of disease eradication,
and patient B30 relapsing with widespread lymphangitis may represent re-infused
disease at a concentration of less than 1 cell in 1000. Cooper et al (1998), however,
concluded that regardless of the incidence and quantities of tumour cells re-infused,
the majority of patients did relapse in previously involved sites. (2) Another, more
serious, difficulty in results interpretation is the level at which MRD was detected. Of
the 3 patients whose PBPCH had evidence ofMRD (B11, B3, B37), the
corresponding detection sensitivities by ARMS were 1:1000, 1:100 and 1:1000,
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respectively. It is somewhat doubtful ifMRD can really exist in PBPCH in such high
concentrations. These levels contrast with those reported in a number of studies in
which the highest recorded level ofMRD is in the region of 1:2xl04 (Cooper et al,
1998) and 1:2.3xl04 (Ross et al, 1993). With the ARMS system, as noted before, a
major problem is with specificity and difficulties with optimisation. MRD is said to be
present when there is a clear difference between the amplification ofDNA extracted
from the harvests and that from control WTcells (normal tonsils). This usually means
no detectable product with WT, although as described in Section 3 .8, some difficulty
was encountered with the screening of PBPCHs from patient B3. Because each set of
PBSCH screening was performed with WT negative control and tumour positive
control, and each in triplicates (except positive control which was performed once), I
can only conclude that using this ARMS approach, under given conditions and
sensitivity as determined by serial dilution of tumour DNA in WT DNA, that MRD
was present in these samples in at least those concentrations. A potential source of
error is, of course, in the serial dilution of tumour in WT DNA. Dilutions were made
in factors of 10, such that if the first dilution was inaccurate, this would be
exaggerated 10-fold with each dilution. Against this explanation are the observations
that, firstly, all 5 sets of serial dilutions for the 5 patients produced sensitivities from
1:100 to 1:1000, and secondly, Stork et al (1991) also reported a sensitivity of 1:100
when PCR products were visualised with ethidium bromide fluorescence. Another
possibility may be that the sensitivities were under-estimated because the original
tumour sections had significant amounts of surrounding normal tissues. This also
seems unlikely because, in order for the mutation to be sequenced, the mutant
homoduplex band had to be cut from the DGGE gel and as demonstrated by the study
ofDGGE sensitivity (Section 2.2.2), a significant proportion of cells (in the region of
20 - 40%) had to be mutant. Therefore, low fraction of tumour cells in the tissue
section would not be expected to account for a one log reduction in the detection
sensitivity ofARMS.
Whether directly re-infusing tumour cells accounted for the relapse of the 3 patients
here is not possible to determine. The 2 patients who had metastatic disease relapsed
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much faster (6 and 9 months) than the 2 with stage IL/III disease (14 and 17 months),
and this difference may well simply reflect the natural history of the disease itself at
different stages.
5.6 CLINICAL RELEVANCE OF MRP IN PBPC HARVESTS OF
LEUKAEMIA PATIENTS
In this project the MRD study on patients with acute leukaemias was much more
straightforward than on breast cancer patients, except for the extremely low incidence
of p53 mutations amongst these patients. Apart from 2 patients with a known
constitutional polymorphism in codon 213, only 1 other patient had a genuine somatic
mutation associated with clonal evolution of his leukaemia as already discussed
(Section 3.7.3). Because of the specific nature of this 8 bp insertion, optimisation and
screening were easier and a reasonable sensitivity of 1:104was achieved. During the
course of his treatment, PBPCs were harvested on 3 separate occasions after courses
of chemotherapy. One of these 3 harvests had evidence ofMRD, and his PBPCT
involved re-infusion of all of the 3 harvests. It is likely that his disease relapse was
partly caused by leukaemia re-infusion, but equally likely is failure of eradication as his
leukaemia was extremely aggressive, being refractory to a number of courses of
chemotherapy.
5.7 CONCLUSIONS - ARE p53 MUTATIONS USEFUL AS MARKERS OF
MRD?
The primary aim of this project was to assess the feasibility ofusing subtle genetic
alterations, e.g., single base changes, as markers forMRD detection, and along with
this aim several secondary aims arose (Section 1.6). The answer to the title question
of this section may be arrived at by sequentially looking at the steps required in using
p53 as an MRD marker. The theoretical basis of using a tumour-specific marker to
study MRD is sound. If a cell containing a copy of the mutant gene found in the
original tumour is present in another tissue such as PBPCH, tumour contamination is
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present within that tissue. What cannot be concluded is that the cell is viable, which is
also a drawback ofmost other MRD techniques except those using cell culture (Sharp
et al, 1992). The advantage of tumour-specific markers over lineage-related markers
is that false positives arising from other tissues expressing the marker do not occur.
For example, RT-PCR for CK19 which is now commonly used may give false positive
results in chronic myeloid leukaemia bone marrow (Moscinski et al, 1996) or even
healthy controls (Krismann et al, 1995). But the main problem here is the lack of
universal application of a single marker. Whilst CK19 can be used as a disease marker
for all breast cancers, p53 mutations can only be found in a minority, approximately a
quarter in this project. Because the mutations in different tumours are likely to be
different, in the main each marker can only be used for the patient in whom it is found.
The identification ofmutations is also laborious, because 5 different DNA fragments
(4 exons) of the gene have to be screened in order to cover over 90% of possible
mutations. Although the successful use of a universal gradient of 30 - 80%
denaturants does help to simplify the procedure, further steps involving direct
sequencing are required to determine the exact nature of each mutation before ARMS
primers can be designed to be used in a sensitive MRD assay. This again contrasts
with CK19 in which one set of techniques can be applied to all patients studied,
without the need for 'tailor-made' conditions for each patient.
The disadvantages of using a multi-step approach aside, ARMS as used in this project
suffers badly from a lack of sensitivity and specificity. Optimisation is difficult, on
account of the subtlety of the genetic alteration, resulting in the successful
optimisation of only 5 of 10 missense mutations. Using ethidium bromide fluorescence
to visualise PCR products, sensitivity is poor - in the region of 1:100 to 1:1000. Here,
attempts at improving the sensitivity with 32P radiolabelled ARMS or nesting were
not successful, but such alternative methods as using radiolabelled internal probes may
improve the sensitivity 2 logs (Ehlen and Dubeau, 1989). With the already complex
methods, I felt that the addition of dot-blot and probing techniques were unacceptably
cumbersome in such a heterogeneous system. The question of sensitivity also throws
into some doubt the reliability of the positive MRD results. With the very small
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number of patients with a optimisable marker, it is not possible to comment on any
correlation between positive MRD screens in PBPCH and survival.
Taken in all, therefore, p53 (single base) mutations are not of value as markers to be
used in MRD detection, at least not with the level of tumour contamination one can
expect to encounter in PBPC harvests of breast cancer patients. On the other hand,
what this project has high-lighted also is that there are situations, such as with the 8
bp insertion of leukaemia patient LI 1, where less subtle p53 changes can be used as
disease markers with a very reasonable degree of sensitivity and specificity. ARMS or
allele-specific PCR used in this way can be a very useful technique in the study of
cancer biology where ultra-sensitivity is not crucial. Meanwhile, as far as molecular
detection ofMRD is concerned, the keys to success appear to remain with techniques
using large DNA changes or gene rearrangements, or those using RNA as starting




Aas T., Borresen A-L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E.,
Akslen L.A. and Lonning P.E. (1996) Specific p53 mutations are associated with de
novo resistance to doxorubicin in breast cancer patients. Nature Medicine 2: 811-814.
Adamson D.J.A., Dawson A.A., Bennett B., King D.J. and Haites N.E. (1995) p53
mutation in the myelodysplastic syndromes. British Journal of Haematology 89: bi¬
bb.
Allred D.C., Clark G.M., Elledge R., Fuqua S.A.W., Brown R.W., Chamness G.C.,
Osborne C.K. and McGuire W.L. (1993) Association of p53 protein expression with
tumor cell proiferation rate and clinical outcome in node-negative breast cancer.
Journal of the National Cancer Institute 85: 200-206.
Andersen T.I., Holm R., Nesland J.M., Heimdal K.R., Ottestad L. and Borresen A-L.
(1993) Prognostic significance of TP53 alterations in breast carcinoma. British
Journal ofCancer 68: 540-548.
Anglo-Celtic Cooperative Oncology Group clinical trial protocol. Intensive
Chemotherapy for High Risk Breast Cancer. (1994)
Antman K.H., Rowlings P.A., Vaughan W.P., Pelz C.J., Fay J.W., Fields K.K.,
Freytes C O., Gale R.P., Hillner B E, Holland H.K., Kennedy M.J., Klein J.P.,
Lazarus H.M., McCarthy Jr. P.L., Saez R., Spitzer G., Stadmauer E.A., Williams
S.F., WolffS., Sobocinski K.A., Armitage JO. and Horowitz M.M. (1997) High dose
chemotherapy with autologous hematopoietic stem-cell support for breast cancer in
North America. Journal of Clinical Oncology 15: 1870-1879.
Ayash L.J. (1994) High dose chemotherapy with autologous stem cell support for the
treatment ofmetastatic breast cancer. Cancer 74: 532-535.
Barrett A.J., Horowitz M M., Pollock B.H., Zhang M.-J., Bortin M M., Buchanan
G.R., Camitta B.M., Ochs J., Graham-Pole J., Rowlings P.A., Rimm A.A., Klein J.P.,
Shuster J.J., Sobocinski K.A. and Gale R.P. (1994) Bone marrow transplants from
HLA-identical siblings as compared with chemotherapy for children with acute
lymphoblastic leukemia in a second remission. New England Journal ofMedicine 331:
1253-1258.
Bartek J., Iggo R., Gannon J. and Lane D P. (1990) Genetic and immunochemical
analysis ofmutant p53 in human breast cancer cell lines. Oncogene 5: 893-899.
Bartram C.R. (1993) Detection ofminimal residual leukemia by the polymerase chain
reaction: potential implications for therapy. Clinica Chimca Acta 217:75-83.
Bearman S.I., Overmoyer B.A., Bolwell B.J., Taylor C.W., Shpall E.J., Cagnoni P.J.,
Mechling B E, Ronk B., Baron A.E., Purdy M.H., Ross M. and Jones R.B. (1997)
203
High-dose chemotherapy with autologous peripheral blood progenitor cell support for
primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone
Marrow Transplantation 20: 931-937.
Beck J.S., Kwitek A.E., Cogen P H., Metzger A.K., Duyk G.M. and Sheffield V.C.
(1993) A denautring gradient gel electrophoresis assay for sensitive detection of p53
mutations. Human Genetics 91: 25-30.
Bergh J., Norberg T., Sjogren S., Lindgren A. and Holmberg L. (1995) Complete
sequencing of the p53 gene provides prognostic information in breast cancer patients,
particularly in relation to adjuvant therapy and radiotherapy. Nature Medicine 1:
1029-1034.
Bezwoda W.R., Seymour L. and Dansey R.D. (1995) High-dose chemotherapy with
hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized
trial. Journal of Clinical Oncology 13: 2483-2489.
Bezwoda W.R. (1997) High-dose chemotherapy with hematopoietic rescue I breast
cancer: from theory to practice. Cancer Chemotherapy and Pharmacology 40
(Suppl ): S79-S87.
Blaszyk H., Vaughn C.B., Hartmann A., McGovern R.M., Schroeder J.J.,
Cunningham J., Schaid D., Sommer S.S. and Kovach J.S. (1994) Novel pattern of
p53 gene mutations in an American black cohort with high mortality from breast
cancer. Lancet 343: 1195-1197.
Borresen A-L., Andersen T.I., Eyfjord J.E., Cornelis R.S., Thorlacius S., Borg A.,
Johansson U., Theillet C., Scherneck S., Hartman S., Cornelisse C.J., Hovig E. and
Devilee P. (1995) TP53 mutations and breast cancer prognosis: particularly poor
survival rates for cases with mutations in the zinc-binding domains. Genes,
Chromosomes and Cancer 14: 71-75.
Borresen A-L., Hovig E., Smith-Sorensen B., Malkin D., Lystad S., Andersen T.I.,
Nesland J.M., Isselbacher K.J. and Reiend S.H. (1991) Constant denaturant gel
electrophoresis as a rapid screening technique for p53 mutations. Proceedings of the
National Academy of Science U.S.A. 88: 8405-8409.
Bottema C.D.K. and Sommer S.S. (1993) PCR amplification of specific alleles: Rapid
detection of known mutations and polymorphisms. Mutation Research 288: 93-102.
Brockstein B E., Ross A. A., Moss T.J., kahn D.G., Hollingsworth K. and Williams
S.F. (1996) Tumor cell contamination of bone marrow harvest products: clinical
consequences in a cohort of advanced-stage breast cancer patients undergoing high-
dose chemotherapy. Journal ofHematotherapy 5: 617-624.
204
Brugger W., Bross K.J., Glatt M., Mertelsmann R. and Kanz L. (1994) Mobilisation
of tumor cells and hematopoietic progenitor cells into peripheral blood of patients
with solid tumors. Blood 83: 636-640.
Burnett A.K., Goldstone A.H., Stevens R.M.F., Hann I.M., Rees J.K.H., Gray R.G.
and Wheatley K. (1998) Randomised comparison of addition of autologous bone-
marrow transplantation ot intensive chemotherapy for acute myeloid leukaemia in first
remission : results ofMRC AML 10 trial. Lancet 351: 700-708.
Busby-Earle R.M.C., Steel C.M., Williams A.R.W. Cohen B. and Bird C.C. (1994)
p53 mutations in cervical carcinogenesis - low frequency and lack of correlation with
human papillomavirus status. British Journal of Cancer 69: 732-737.
Cagnoni P.J., Shpall E.J., Bearman S.I., Ross M. and Jones R.B. (1996) High-dose
chemotherapy with AHPCS for the treatment ofbreast cancer. The University of
Colorado results. Bone Marrow Transplantation 18 (Suppl.l): S26-S29.
Cameron D.A., Craig J., Gabra H., Lee L., Mackay J., Parker A C. and Leonard
R.C.F. (1996) High-dose chemotherapy supported by peripheral blood progenitor
cells in poor prognosis metastatic breast cancer - a phse I/II study. British Journal of
Cancer 74: 2013-2017.
Campana D. and Pui C-H. (1995) Detection of minimal residual disease in acute
leukemia: methodologic advances and clinical significance. Blood 85: 1416-1434.
Campana D., Coustan-Smith E. and Janossy G. (1990) The immunologic detection of
minimal residual disease in acute leukemia. Blood 76: 163-171.
Carbone D., Chiba I. and Mitsudomi T. (1991) Polymorphism at codon 213 within the
p53 gene. Oncogene 6: 1691-1692.
Caron de Fromentel C. and Soussi T. (1992) TP53 tumor suppressor gene: a model
for investigating human mutagenesis. Genes, Chromosomes and Cancer 4: 1-15.
Cassileth P.A., Harrington D P., Appelbaum F.R., Lazarus H.M., Rowe J.M., Paietta
E., Willman C., Hurd D.D., Bennett J.M., Blume K G., Head D R. and Wiernik P H.
(1998) Chemotherapy compared with autologous or allogeneic bone marrow
transplantation in the management of acute myeloid leukemia in first remission. New
England Journal ofMedicine 339: 1649-1656.
Cattoretti G., Rilke F., Andreola S., D'Amato L. and Delia D. (1988) p53 expression
in breast cancer. International Journal ofCancer 41: 178-183.
Cave H., Guidal C., Rohrlich P., Delfau M.H., Broyart A., Lescoeur B., Rahimy C.,
Fenneteau O., Monplaisir N., d'Auriol L., Elion J., Vilmer E. and Grandchamp B.
(1994) Prospecitve monitoring and quantitation of residual balsts in childhood acute
205
lymphoblastic leukemia by polymerase chain reaction study of o and y T-cell receptor
genes. Blood 83: 1892-1902.
Cebula T.A., Payne W.L. and Feng P. (1995) Simultaneous identification of strains of
Escherichia coli serotype 0157:H7 and their shiga-like toxin by mismatch
amplification mutation assay-muliplex PCR. Journal of Clinical Microbiology 33: 248-
250.
Cha R.S., Zarbl H., Keohavong P. and Thilly W.G. (1992) Mismatch amplification
mutation assay (MAMA): application to the c-H-ras gene. PCR Methods and
Applications 2: 14-20.
Chehab F. and Kan Y.W. (1989) Detection of specific DNA sequences by
fluorescence amplification: a color complimentation assay. Prooceedings of the
National Academy of Science of the USA. 86: 9178-9182.
Chessells J.M., Bailey C., Wheeler K. and Richards S.M. (1992) Bone marrow
transplantation for high-risk childhood lymphoblastic leukaemia in first remission :
experience in MRC UKALL X. Lancet 340: 565-568.
Chessells J.M., Bailey C. and Richards S.M. (1995) Intensification of treatment and
survival in all children with acute lymphoblastic leukaemia: results ofUK Medical
Research Council trial UKALL X. Lancet 345: 143-148.
Christopherson C., Sninsky J. and Kwok S. (1997) The effects of internal primer-
template mismatches on RT-PCR: HIV-1 model studies. Nucleic Acids Research 25:
645-648.
Coles C., Condie A., Chetty U., Steel C.M., Evans H.J. and Prosser J. (1992) p53
mutations in breast cancer. Cancer Research 52: 5291-5298.
Coles C., Thompson A.M., Elder P. A., Cohen B.B., Mackenzie I.M., Cranston G.,
Chetty U., Mackay J., Macdonald M., Nakamura Y., Hoyheim B. and Steel C M.
(1990) Evidence implicating at least two genes on chromosome 17p in breast
carcinogenesis. Lancet 336: 761-763.
Condie A., Eeles R., Borresen A-L., Coles C., Cooper C. and Prosser J. (1993)
Detection of point mutations in the p53 gene: comparison of single-strand
conformation polymorphism, constant denaturant gel electrophoresis, and
hydroxylamine and osmium tetroxide techniques. Human Mutations 2: 58-66.
Cooper B.W., Moss T.J., Ross A.A., Ybanez J. and Lazarus H.M. (1998) Occult
tumor contamination of hematopoietic stem-cell products does not affect clinical
outcome of autologous transplantation in patients with metastatic breast cancer.
Journal of Clinical Oncology 16: 3509-3517.
206
Cote R.J., Rosen P.P., Lesser M.L., Old L.J. and Osborne M.P. (1991) Prediction of
early relapse in patients with operable breast cancer by detection of occult bone
marrow micrometastases. Journal of Clinical Oncology 9: 1749-1756.
Cotton R.G.H. (1993) Current methods ofmutation detection. Mutation Research
285: 125-144.
Cotton R.G.H., Rodrigues N.R. and Campbell R.D. (1988) Reactivity of cytosine and
thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and
its application to the study ofmutations. Proceedings of the National Academy of
Science U.S.A. 85: 4397-4401.
Coustan-Smith E., Behm F.G., Sanchez J., Boyett J.M., Hancock M.L., Raimondi
S.C., Rubnitz J.E., Rivera G.K., Sandlund J.T., Pui C-H. and Campana D. (1998)
Immunological detection ofminimal residual disease in children with acute
lymphoblastic leukaemia. Lancet 351: 550-554.
Datta Y.H., Adams P.T., Drobyski W.R., Ethier S.P., Terry V.H. and Roth M.S.
(1994) Sensitive detection of occult breast cancer by the reverse-transcriptase
polymerase chain reaction. Journal ofClinical Oncology 12: 475-482.
DavidoffA.M., Humphrey P.A., Iglehart J.D. and Marks J.R. (1991) Genetic basis for
p53 overexpression in human breast cancer. Proceedings of the National Academy of
Sciences U.S.A. 88: 5006-5010.
De Leo A.B., Jay G., Appella E., Dubois G.C., Law L.W. and Old L.J. (1979)
Detection of a transformation-related antigen in chemically induced sarcomas and
other transformed cells the mouse. Proceedings of the National Academy of Sciences
U.S.A. 76: 2420-2424.
Deane M. and Norton J.D. (1990) Detection of immunoglobulin gene rearrangement
in B lymphoid malignancies by polymerase chain reaction gene amplification. British
Journal ofHaematology 74: 251-256.
Dumaz N., Stary A., Soussi T., Daya-Grosjean L. and Sarasin A. (1994) Can we
predict solar ultraviolet radiation as the causal event in human tumours by analysing
the mutation spectra of the p53 gene? Mutation Research 307: 375-386.
Easton M.C., Hardingham J.E., Kotasek D. and Dobrovic A. (1997) Immunobead
RT-PCR: a sensitive method for detection of circulating tumor cells. BioTechniques
21: 100-105.
Eddy D.M. (1992) High-dose chemotherapy with autologous bone marrow
transplantation for the treatment ofmetastatic breast cancer. Journal ofClinical
Oncology 10: 657-670.
207
Ehlen T. and Dubeau L. (1989) Detectin of ras point mutations by polymerase chain
reaction using mutation-specific inosine-containing oligonucleotide primers.
Biochemical and Biophysical Research Communications 160: 441-447.
Eliyahu D., Michalovitz D., Eliyahu S., Pinhasi-Kimhi O. and Oren M. (1989) Wild-
type p53 can inhibit oncogene-mediated focus formation. Proceedings of the National
Academy of Sciences U.S.A. 86: 8763-8767.
Eliyahu D., Raz A., Gruss P., Givol D. and Oren M. (1984) Participation of p53
cellular tumour antigen in transformation of normal embryonic cells. Nature 312: 646-
649.
Elledge R.M., Fuqua S.A.W., Clark G.M., Pujol P. and Allred D.C. (1993) The role
and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer
Research and Treatment 27: 95-102.
Fenaux P., Jonveauz P., Quiquandon I., Preudhomme C., Lai J-L., Vanrumbeke M.,
Loucheux-Lefebvre M.H., Bauters F., Berger R. and Kerckaert J.P. (1992a)
Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60
cases. Leukemia 6: 42-46.
Fenaux P., Preudhomme C., Quiquandon I., Jonveaux P., Lai J-L., Vanrumbeke M.,
Loucheux-Lefebvre M.H., Bauters F., Berger R. and Kerckaert J.P. (1992b)
Mutations of the p53 gene in acute myeloid leukaemia. British Journal of
Haematology 80: 178-183.
Fields K.K., Elfenbein G.J., Trudeau W.L., Perkins J.B., Janssen W.E. and Moscinski
L.C. (1996) Clinical significance ofbone marrow metastases as detected using the
polymerase chain reaction in patients with breast cancer undergoing high-dose
chemotherapy and autologous bone marrow transplantation. Journal of Clinical
Oncology 14: 1868-1876.
Finlay C., Hinds P.W. and Levine A.J. (1989) The p53 proto-oncogene can act as a
suppressor of transformation. Cell 57: 1083-1093.
Fischer S.G. and Lerman L.S. (1983) DNA fragments differing by single base-pair
substitutions are separated in denaturing gradient gels: correspondence with melting
theory. Proceedings of the National Academy of Sciences U.S.A. 80: 1579-1583.
Fodde R. and Losekoot M. (1994) Mutation detection by denaturing gradient gel
electrophoresis (DGGE). Human Mutation 3: 83-94.
Franklin W.A., Shpall E.J., Archer P., Johnston C.S., Garza-Williams S., Hami L.,
Bitter M.A., Bast R.C. and Jones R.B. (1996) Immunocytochemical detection of
breast cancer cells in marrow and peripheral blood of patients undergoing high dose
chemotherapy with autologous stem cell support. Breast Cancer Research and
Treatment 41: 1-13.
208
Friedman K.J., Highsmith W.E. Jr. and Silverman L.M. (1991) Detecting multiple
cystic fibrosis mutations by polymerase chain reaction-mediated site-directed
mutagensis. Clinical Chemistry 37: 753-755.
Fritsche M., Haessler C. and Brandner G. (1993) Induction ofnuclear accumulation
of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-
318.
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath
I.T., Knowles D.M. and Dalla-Favera R. (1991) p53 mutations in human lymphoid
malignancies: association with Burkitt's lymphoma and chronic lymphocytic leukemia.
Proceedings of the National Academy of Sciences U.S.A. 88: 5413-5417.
Ganguly A. and Prockop D.J. (1990) Detection of single-base mutations by reaction
ofDNA heteroduplexes with a water-soluble carbodiimide followed by primer
extension : application to products from the polymerase chain reaction. Nucleic Acids
Research 18: 3933-3939.
Gasparini P., Bonizzato A., Dognino M. and Pignatti P.F. (1992) Restriction site
generating-polymerase chain reaction (RG-PCR) for the probe-less detection of
hidden genetic variation: application to the study of some common cystic fibrosis
mutations. Molecular and Cellular Probes 6: 1-7.
Gerhard M., Juhl EL, KalthoffBL, Schreiber H.W., Wagener C. and Neumaier M.
(1994) Specific detection of carcinoembryonic antigen-expressing tumor cells in bone
marrow aspirates by polymerase chain reaction. Journal of Clinical Oncology 12: 725-
729.
Glavac D. and Dean M. (1995) Application of heteroduplex analysis for mutation
detection in disease genes. Human Mutation 6: 281-287.
Goulden N.J., Knechtli C.J.C., Garland R.J., Langlands K., Hancock J.P., Potter
M.N., Steward C.G. and Oakhill A. (1998) Minimal residual disease analysis for the
prediction of relapse in children with standard-risk acute lymphoblastic leukaemia.
British Journal ofHaematology 100: 235-244.
Gray J.W., Kuo W.L., Liang J., Pinkel D., van den Engh G., Trask B., Tkachuk D.,
Waldman F. and Westbrook C. (1990) Analytical approaches to detection and
characterisation of diesease-linked chromosome abberations. Bone Marrow
Transplantation 6 (Suppl. 1): 14-19.
Greenblatt M.S., Bennett W.P., Hollstein M. and Harris C.C. (1994) Mutations in the
p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis.
Cancer Research 54: 4855-4878.
209
Haines D.S. (1997) The mdm-2 proto-oncogene. Leukemia and Lymphoma 26: 227-
238.
Haliassos A., Chomel J.C., Tesson L., Baudis M., Kruh J., Kaplan J.C. and Kitzis A.
(1989a) Modification of enzymatically amplified DNA for the detection of point
mutations. Nucleic Acids Research 17: 3606.
Haliassos A., Chomel J.C., Grandjouan S., Kruh J., Kaplan J.C. and Kitzis A. (1989b)
Detection ofminority point mutations by modified PCR technique: a new approach
for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Research 17:
8093-8099.
Hamelin R., Jego N., Laurent-Puig P., Vidaud M. and Thomas G. (1993) Efficient
screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal
tumors. Oncogene 8: 2213-2220.
Harousseau J.L., Pignon B., Witz F., Linassier P., Lioure B., Le Prise P.Y., Cahn
J.Y., Desablens B., Caillot D., Ifrah N., Abgrall J.F., Sadoun A., Guyotat D., Mors
A., Casassus P., Briere J., Polin V., Berthaud P. and Hurteloup P. (1994) Prospective
comparison of allogeneic bone marrow transplantation (allo-BMT), intensive
consolidation chemotherapy (ICC) and unrpurged autologous bone marrow
transplantation (ABMT) as post remission therapy in adult acute myeloid leukemia
(AML). Blood 84 (Suppl 1): 251.
Harris C.C. and Hollstein M. (1993) Clinical implications of the p53 tumor-suppressor
gene. New England Journal ofMedicine 329: 1318-1327.
Hartmann A., Blaszyk H., Saitoh S., Tsushima K., Tamura Y., Cunningham J.M.,
McGovern R.M., Schroeder J.J., Sommer S.S. and Kovach J.S. (1996) High
frequency of p53 mutationsin primary breast cancers in Japanese women, a low-
incidence population. British Journal ofCancer 73: 896-901.
Hayashi K. and Yandell D.W. (1993) How sensitive is PCR-SSCP? Human Mutation
2: 338-346.
Hayashi N., Ito I., Yanagisawa A., Kato Y., Nakamori S., Imaoka S., Watanabe H.,
Ogawa M. and Nakamura Y. (1995) Genetic diagnosis of lymph-node metastasis in
colorectal cancer. Lancet 345: 1257-1259.
Hollstein M., Sidransky D., Vogelstein B. nd Harris C.C. (1991) p53 mutations in
human canacers. Science 253: 49-53.
Hollstein M., Rice K., Greenblatt M.S., Soussi T., Fuchs R., Sorlie T., Hovig E.,
Smith-Sorensen B., Montesano R. and Harris C.C. (1994) Database of p53 gene
somatic mutations in human tumors and cell lines. Nucleic Acids Research 22: 3551-
3555.
210
Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R. and
Harris C.C. (1996) Somatic point mutations in the p53 gene of human tumors and cell
lines: updated compilation. Nucleic Acids Research 24: 141-146.
Hollstein M., Soussi T., Thomas G., von Brevern M-C. and Bartsch H. (1997) p53
gene alterations in human tumors: perspective for cancer control. Resent Results in
Cancer Research 143: 369-389.
Horikoshi T., Lenz H-J., Danenberg K., Koch O.M., Bertino J.R. and Danenberg P.V.
(1994) Quantitative determination of the ratio ofmutated to normal ras genes in the
blood of leukemia patients by allele-specific PCR. Leukemia Research 18: 693-702.
Hsiao M.H., Yu A.L., Yeargin J., Ku D. and Haas M. (1994) Nonhereditary p53
mutations in T-cell acute lymphoblastic leukemia are associated with the relapse
phase. Blood 83: 2922-2930.
Huang M-M., Arnhein N. and Goodman M.F. (1992) Extension of base mispairs by
Taq DNA polymerase: implications for single nucleotide discrimination in PCR.
Nucleic Acids Research 20: 4567-4573.
Huber K.R., Bittner J., Bauer K., Trumper L., Sek A., Sebesta C., Rosen H. and
Tragi K.-H. (1998) Restriction digest PCR (RD-PCR) for the analysis of gene
mutations. Application to Ki-ras. Clinical Chemical and Laboratory Medicine 36: 593-
595.
Ikuta S., Takagi K., Wallace R.B. and Itakura K. (1987) Dissociation kinetics of 19
base paired oligonucleotide-DNA duplexes containing different single mismatched
base pairs. Nucleic Acids Research 15: 797-811.
Jiang W., Kahn S.M., Guillem J.G., Lu S.-H. and Weinstein I.B. (1989) Rapid
detection of ras oncogenes in human tumors: applications to colon, esophageal, and
gastric cancer. Oncogene 4: 923-928.
Johnson F.L., Thomas E.D., Clark B.S., Chard R.L., Hartmann J.R. and Storb R.
(1981) A comparison ofmarrow transplantation with chemotherapy for children with
acute lymphoblastic leukemia in second or subsequent remission. New England
Journal ofMedicine 305: 846-851.
Jones P.A., Buckley J.D., Henderson B.E., Ross R.K. and Pike M.C. (1991) From
gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer
Research 51: 3617-3620.
Jonveaux P., Fenaux P., Quiquandon I., Pignon J.M., Lai J-L., Loucheux-Lefebvre
M.H., Goossens M., Bauters F. and Berger R. (1991) Mutations in the p53 gene in
myelodysplastic syndromes. Oncogene 6: 2243-2247.
211
Joshi S.S., Novak D.J., Messbarger L., Maitreyan V., Weisenburger D.D. and Sharp
J.G. (1990) Levels of detection of tumor cells in human bone marow with or without
prior culture. Bone Marrow Transplantation 6: 179-183.
Kahn S.M., Jiang W., Culbertson T.A., Weinstein I.B., Williams G.M., Tomita N. and
Ronai Z. (1991) Rapid and sensitive nonradioactive detection ofmutant K-ras genes
via 'enriched' PCR amplification. Oncogene 6: 1079-1083.
Ke S.H., Keely P.J., Wartell R.M., Hunter S. and varma V.A. (1993) Selecting DNA
fragments for mutation detection by temperature gradient gel electrophoresis:
application to the p53 gene cDNA. Electrophoresis 14: 561-565.
Keith F.J. and Russell N.H. (1996) The role of p53 in malignancy. Cancer Treatment
and Research 84: 113-137.
Kennedy M.J. (1995) High-dose chemotherapy of breast cancer: Is the question
answered? Journal ofClinical Oncology 13: 2477-2479.
Kirby G.M., Batist G., Fotouhi-Ardakani N., Nakazawa H., Yamasaki H., Kew M.,
Cameron R.G. and Alaoui-Jamali M.A. (1996) Allele-specific PCR analysis of p53
codon 249 AGT transversion in liver tissues from patients with viral hepatitis.
International Journal ofCancer 68: 21-25.
Karlic H.I., Muhlberger H., Pavlova B.G., Pfeilstocker M., Salamon J., Pittermann E.,
Heinz R. and Koller E. (1995) Analysis of peripheral blood progenitor cells
demonstrates limitations ofminimal residual disease diagnosis in a case of acute
promyelocytic leukemia. Bone Marrow Transplantation 15: 999-1000.
Knechtli C.J.C., Goulden N.J., Hancock J.P., Harris E.L., Garland R.J., Jones C.G.,
Grandage V.L.G., Rowbottom A.W., Green A.F., Clarke E., Lankester A.W., Potter
M.N., Cornish J.M., Pamphilon D.H., Steward C.G. and Oakhill A. (1998) Minimal
residual disease status as a predictor of relapse after allogeneic bone marrow
transplantation for children with acute lymphoblastic leukaemia. British Journal of
Haematology 102: 860-871.
Krismann M., Todt B., Schroder J., Gareis D., Muller K.-M., Seeber S. and Schutte J.
(1995) Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain
reaction analyses for detection of hematogenous lung cancer dissemination. Journal of
Clinical Oncology 13: 2769-2775.
Kwok S., Kellogg D.E., McKinney N., Spasic D., Goda L., Levenson C. and Sninsky
J.J. (1990) Effects of primer-template mismatches on the polymerase chain reaction:
human immunodeficiency virus type 1 model studies. Nucleic Acids Research 18:
999-1005.
212
Lampel K.A., Keasler S.P. and Hanes D.E. (1996) Specific detection of Salmonella
enterica serotype enteritidis using the polymerase chain reaction. Epidemiology and
Infection 116: 137-145.
Lane D.P. (1992) p53, guardian of the genome. Nature 358: 15-16.
Lane D.P. and Crawford L.V. (1979) T antigen is bound to a host protein in SV40-
transformed cells. Nature 278: 261-263.
Langlands K., Craig J.I.O., Anthony R.S. and Parker A.C. (1993) Clonal selection in
acute lymphoblastic leukaemia demonstrated by polymearase chain reaction analysis
of immunological heavy chain and T-cell receptor a chain rearrangements. Leukemia
7: 1066-1070.
Langlands K., Goulden N.J., Steward C.G., Potter M.N. and Oakhill A. (1995) Solid-
phase sequencing ofmultiple PCR products resolved by polyacrylamide gel
electrophoresis. BioTechniques 18: 618-620.
Leonard R.C.F. (1998) High-dose chemotherapy in solid tumours: breast cancer. In
Reiffers J., Goldman J.M. and Armitage J.O., ed. Blood Stem Cell Transplantation:
147-156, Martin Dunitz.
Leonard R.C.F., Rodger A and Dixon J.M. (1994) Metastatic breast cancer. British
Medical Journal 309: 1501-1504.
Lerman L.S. and Silverstein K. (1987) Computational simulation ofDNA melting and
its application to denaturing gradient gel electrophoresis. Methods in Enzymology,
Ed. Wu R. 155: 482-501. Academic Press.
Leslie D.S., Johnston W.W., Daly L., Ring D.B., Shpall E.J., Peters W.P. and Bast Jr.
R.C. (1990) Detection ofbreast carcinoma cells in human bone marrow using
fluorescence-activated cell sorting and conventional cytology. American Journal of
Clinical Pathology 94: 8-13.
Levine A. J., Momand J. and Finlay C.A. (1991) The p53 tumour supressor gene.
Nature 351: 453-456.
Lin F. and Cross N.C.P. (1995) Molecular methods for monitoring malignant disease
after bone marrow transplantation. Current Opinion in Hematology 2: 460-467.
Lo Coco F., Diverio D., Pandolfi P.P., Biondi A., Rossi V., Awisati G., Rambaldi A,
Arcese W., Petti M.C., Meloni G., Mandelli F., Grignani F., Masera G., Barbui T. and
Pelicci P.G. (1992) Molecular evaluation of residual disease as a predictor of relapse
in acute promyelocytic leukaemia. Lancet 340: 1437-1438.
213
Lo Y-M.D., Patel P., Newton C.R., Markham A.F., Fleming K.A. and Wainscoat J.S.
(1991) Direct haplotype determination by double ARMS: specificity, sensitivity and
genetic applications. Nucleic Acids Research 19: 3561-3567.
Lo Y-M.D., Roux E., Jeannet M., Chapuis B., Fleming K.A. and Wainscoat J.S.
(1993) Detection of chimaerism after bone marrow transplantation using the double
amplification refractory mutation system. British Journal ofHaematology 85: 223-
226.
Macek Jr. M., Mercier B., Mackova A., Miller P.W., Hamosh A., Ferec C. and
Cutting G.R. (1997) Sensitivity of the denaturing gradient gel electrophoresis
technique in detection of known mutations and novel Asian mutations in the CFTR
gene. Human Mutation 9: 136-147.
Malkin D., Li F.P., Strong L.C., Fraumeni Jr. J.F., Nelson C.E., Kim D.H., Kassel J.,
Gryka M.A., BischofFF.Z., Tainsky M.A. and Friend S.H. (1990) Germ line p53
mutations in a familial syndrome ofbreast cancer, sarcomas, and other neoplasms.
Science 250: 1233-1238.
Maltzman W. and Czyzyk L. (1984) UV irradiation stimulates levels of p53 cellular
tumor antigen in non-transformed mouse cells. Molecular and Cellular Biology 4:
1689-1694.
Mansi J.L., Berger U., Easton D., McDonnell T., Redding W.H., Gazet J-C.,
McKinna A., Powles T.J. and Coombes R.C. (1987) Micrometastases in bone marrow
in patients with primary breast cancer: evaluation as an early predictor ofbone
metastases. British Medical Journal 295: 1093-1096.
Mansi J.L., Berger U., McDonnell T., Pople A., Rayter Z., Gazet J.C. and Coombes
R.C. (1989) The fate of bone marrow micrometastases in patients with primary breast
cancer. Journal ofClinical Oncology 4: 445-449.
Mansi J.L., Easton D., Berger U., Gazet J-C., Ford H.T., Dearnaley D. and Coombes
R.C. (1991) Bone marrow micrometastases in primary breast cancer: prognostic
significance after 6 years follow-up. European Journal ofCancer 12: 1552-1555.
Mao L., Hruban R.H., Boyle J.O., Tockman M. and Sidransky D. (1994) Detection of
oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Research
54: 1634-1637.
Marasca R., Luppi M., Barozzi P., Ferrari M.G., Morselli M. and Torelli G. (1996)
p53 gene mutations in chronic myelogenous leukemia medullary and extramedullary
blast crisis. Leukemia and Lymphoma 24: 175-182.
Marks D.L, Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J., Brodsky I. and
Haines D.S. (1996) High incidence of potential p53 inactivation in poor outcome
childhood acute lymphoblastic leukemia at diagnosis. Blood 87: 1155-1161.
214
Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J., Carroll D.,
Brodsky I. and Haines D.S. (1997) Altered expression of p53 and mdm-2 proteins at
diagnosis is associated with early treatment failure in childhood acute lymphoblastic
leukemia. Journal of Clinical Oncology 15: 1158-1162.
Mazars G-R., Jeanteur P., Lynch H.T., Lenoir G. and Theillet C. (1992) Nucleotide
sequence polymorphism in a hotspot mutation region of the p53 gene. Oncogene 7:
781-782.
Mercer W.E., Avignolo C. and Baserga R. (1984) Role of the p53 protein in cell
proliferation as studied by microinjection ofmonoclonal antibodies. Molecular and
Cellular Biology 4: 276-281.
Metcalfe P. and Waters A.H. (1993) HPA-1 typing by PCR amplification with
sequence-specific primers (PCR-SSP): a rapid and simple technique. British Journal of
Haematology 85: 227-229.
Miller W.H., Levine K., DeBlasio A., Franker S.R., Dmitrovsky E. and Warrell R.P.
(1993) Detection ofminimal residual disease in acute promyelocytic leukemia by a
reverse transcription polymerase chain reaction assay for the PML/RAR-a fusion
mRNA. Blood 82: 1689-1694.
Misawa S. and Horiike S. (1996) TP53 mutations in myelodysplastic syndrome.
Leukemia and Lymphoma 23: 417-422.
Miyashita T., Krajewski S., Krajewski M., Wang H.G., Line H.K., Liebermann D.A.,
Hoffman B. and Reed J.C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and
bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805.
Molino A., Colombatti M., Bonetti F., Zardini M., Pasini F., Perini A., Pelosi G.,
Tridente G., Veneri D. and Cetto G.L. (1991) A comparative analysis of three
different techniques for the detection of breast cancer cells in bone marrow. Cancer
67: 1033-1036.
Mori N., Hidai H., Yokota J., Okada M., Motoji T., Oshimi K. and Mizoguchi H.
(1995) Mutations of the p53 gene in myelodysplastic syndrome and overt leukaemia.
Leukemia Research 19: 869-875.
Mori N., Wada M., Yokota J., terada M., Okada M., Teramura M., Masuda M.,
Hoshino S., Motoji T., Oshimi K. and Mizoguchi H. (1992) Mutations of the p53
tumour suppressor gene in haematologic neoplasms. British Journal ofHaematology
81:235-240.
Moscinski L.C., Trudeau W.L., Fields K.K. and Elfenbein G.J. (1996) High-sensitivity
detection ofminimal residual breast carcinoma using the polymerase chain reaction
and primers for cytokeratin 19. Diagnostic Molecular Pathology 5: 173-180.
215
Mowat M., Cheng A., KimuraN., Bernstein A. and Benchimol S. (1985)
Rearrangement of the cellular p53 gene in erythroleukaemic cells transformed by
Friend virus. Nature 314: 633-636.
Moyret C., Theillet C., Laurent-Puig P., Moles J-P., Thomas G. and Hamelin R.
(1994) Relative efficiency of denaturing gradient gel electrophoresis and single strand
conformation polymorphism in the detection ofmutations in exons 5 to 8 of the p53
gene. Oncogene 9: 1739-1743.
Mullen P., MillerW.R., Mackay J., Fitzpatrick D.R., Langdon S.P. and Warner J.P.
(1997) BRCA1 5382insC mutation in sporadic and familial breast and ovarian
carcinoma in Scotland. British Journal ofCancer 75: 1377-1380.
Munroe D.G., Rovinski B., Bernstein A. and Benchimol S. (1988) Loss of a highly
conserved domain on p53 as a result of gene deletion during Friend virus-induced
erythroleukemia. Oncogene 2: 621-624.
Myers R.M., Fischer S.G., Maniatis T. and Lerman L.S. (1985a) Modification of the
melting properties of duplex DNA by attachment a GC-rich DNA sequence as
determined by denaturing gradient gel electrophoresis. Nucleic Acids Research 13:
3111-3129.
Myers R.M., Fischer S.G., Lerman L.S. and Maniatis T. (1985b) Nearly all single
base substitutions in DNA fragments joined to a GC-clamp can be detected by
denaturing gradient gel electrophoresis. Nucleic Acids Research 13: 3131-3145.
Myers R.M., Sheffield V.C. and Cox D.R. (1988) Detection of single base changes in
DNA: ribonuclease cleavage and denaturing gradient gel electrophoresis. In Davies K.
ed., Genome Analysis: a Practical Approach. IRL Press.
Myers R.M., Sheffield V.C. and Cox D.R. (1989) Mutation detection by PCR, GC-
clamps and denaturing gradient gel electrophoresis. In Erlich H.A. ed., PCR
technology: Principles and applications for DNA amplification. Stockton Press.
Naume B., Borgen E., Beiske K., Herstad T-K., Ravnas G., Renolen A., Trachsel S.,
Thrane-Steen K., Funderud S. and Kvalheim G. (1997) Immunomagnetic techniques
for the enrichment and detection of isolated breast carcinoma cells in bone marrow
and peripheral blood. Journal ofHematotherapy 6: 103-114.
Newton C.R. and Graham A. (1994) PCR. Bios Scientific Publishers.
Newton C.R., Graham A., Heptinstall L.E., Powell S.J., Summers C., Kalshwker N.,
Smith J.C. and Markham A.F. (1989a) Analysis of any point mutation in DNA. The
amplification refractory mutation system (ARMS). Nucleic Acids Research 17: 2503-
2516.
216
Newton C.R., Summers C., Schawrz M., Graham A., Heptinstall L.E., Super M.,
Anwar R., Smith J.C., and Markham J.C. (1989b) Amplification refractory mutation
system for prenatal diagnosis and carrier assessment in cystic fibrosis. Lancet i: 1481-
1483.
Ng I.S.L., Pace R., Richard M.V., Kobayashi K., Kerem B., Tsui L-C., Beaudet A.L.
(1991) Methods of analysis of multiple cystic fibrosis mutations. Human Genetics 87:
613-617.
Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner
S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali
R., Harris C.C. and Vogelstein B. (1989) Mutations in the p53 gene occur in diverse
human tumour types. Nature 342: 705-708.
Oltvai Z.N., Milliman C.L. and Korsmeyer S.J. (1993) Bcl-2 heterodimerizes in vivo
with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:
609-619.
Orita M., Iwahana H., Kanazawa H., Hayashi K. and Sekiya T. (1989a) Detection of
polymorphisms of human DNA by gel electrophoresis as single-strand conformation
polymorphisms. Proceedings of the National Academy of Sciences U.S.A. 86: 2766-
2770.
Orita M., Suzuki Y., Sekiya T. and Hayashi K. (1989b) Rapid and sensitive detection
ofpoint mutations and DNA polymorphisms using the polymerase chain reaction.
Genomics 5: 874-879.
Osborne R.J., Merlo G.R., Mitsudomi T., Venesio T., Liscia D.S., Cappa A.P.M.,
Chiba I., Takahashi T., Nau M.M., Callahan R. and Minna J.D. (1991) Mutations in
the p53 gene in primary human breast cancers. Cancer Research 51: 6194-6198.
Ouspenskaia M.V., Johnston D.A., Roberts W.M., Estrov Z. and ZipfT.F. (1995)
Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by
limiting dilution and a PCR-based detection system: a description of the method and
the principles involved. Leukemia 9: 321-328.
Owen R.G., Johnson R.J., Evans P.A., Smith G.M., Child J.A. and Morgan G.J.
(1995) Detection of clonal immunoglobulin gene rearrangements in the PBPC
harvests of patients with acute lymphoblastic leukemia. Bone Marrow Transplantation
16:831-834.
Owen R.G., Goulden N.J., Oakhill A., Shiach C., Evans P.A., Potter M.N. and
Morgan G.J. (1997) Comparison of fluorescent consensus IgH PCR and allele-
specific oligonucleotide probing in the detection ofminimal residual disease in
childhood ALL. British Journal ofHaematology 97: 457-459.
217
Pantel K., Felber E. and Schlimok G. (1994a) Detection and characterisation of
residual disease in breast cancer. Journal ofHematotherapy 3: 315-322.
Pantel K., Schlimok G., Angstwurm M., Weckermann D., Schmaus W., Gath H.,
Passlick B., Izbicki J.R. and Riethmuller G. (1994b) Methodological analysis of
immunocytochemical screening for disseminated epithelial tumor cells in bone
marrow. Journal ofHematotherapy 3: 165-173.
Patel P., Lo Y-M.D., Bell J.I. and Wainscoat J.S. (1993) Rapid HLA typing by
multiplex amplification refractory mutation system. Journal of Clinical Pathology 46:
1105-1108.
Peters W.P., Ross M., Vredenburgh J.J., Meisenberg B., Marks L.B., Winer E.,
Kutzberg J., Bast Jr. R.C., Jones R., Shpall E., Wu K., Rosner G., Gilbert C., Bathias
B., Coniglio D., Petros W., Henderson I.C., Norton L., Weiss R.B., Budman D. and
Hurd D. (1993) High-dose chemotherapy and autologous bone marow support as
consolidation after standard-dose adjuvant therapy for high-risk primary breast
cancer. Journal of Clinical Oncology 11:1132-1143.
Peters W.P. (1995a) High-dose chemotherapy with autologous bone marrow
transplantation for the treatment ofbreast cancer: Yes. Important Advances in
Oncology 215-230.
Peters W.P., Fay J.W., Holland H.K., Ahmed T., Bolwell B.J., Wolf J., Damon L.,
Long G., Schwartzberg L.S., Goldberg S.L., Friedman D.J., Lynch J.P., Weinberger
B.B., Taylor R.F., Stadtmauer E., Rifkin R.M., Broun E.R., McCarthy P.L., Zamkoff
K., Petersen F.B., Reed E.C., Mills L., Schuster M.W., Larzarus H.H., Fruchtman
S.M., Hesdorffer C.S., Douer D., Flomenberg J., Guarino M.J., Maziarz R.T.,
Elfenbein G.J., LeMaistre C.F., Akard L. and Cirrincione C. (1995b) Autologous
bone marrow transplantation in primary breat cancer: the American experience. Bone
Marrow Transplantation 15 (Suppl.l): S254-S259.
Peters W.P., Jones R.B., Vredenburgh J., Shpall E.J., Hussein A., Elkorily M., Rubin
P., Ross M. and Berry D. (1996) A large prospective randomised trial of high dose
combination alkylating agents (CPB) with autologous cellular support (ABMS) as
consolidation for patients with metastatic breast cancer achieving complete remission
after intensive doxorubicin-based induction therapy (AFM) (abstract) Proceedings of
the American Society of Clinical Oncologists 15:121.
Peters W.P. and Dansey R. (1997) New concepts in the treatment ofbreast cancer
using high-dose chemotherapy. Cancer Chemotherapy and Pharmacology 40 (Suppl.):
S88-S93.
Petruska J., Goodman M.F., Boosalis M.S., Sowers L.C., Cheong C. and Tinoco I.
(1988) Comparison between DNA melting thermodynamics and DNA polymerase
fidelity. Proceedings of the National Academy of Sciences U.S.A. 85: 6252-6256.
218
Pignon J.M., Vinatier I., Fanen P., Jonveauzz P., Tournilhac O., Imbert M., Rochant
H. and Goossens M. (1994) Exhaustive analysis of the p53 gene coding sequence by
denaturing gradient gel electrophoresis: application to the detection of point
mutations in acute leukemias. Human Mutation 3: 126-132.
Poirel H., Radford-Weiss I., Rack K., Troussard X., Veil A., Valensi F., Picard F.,
Guesnu M., LeboeufD. and Melle J. (1995) Detection of the chromosome 16 CBF(3-
MYH11 fusion transcript in myelomonocytic leukemias. Blood 85: 1313-1322.
Pollock R.E., Lang A., Luo J., El-Naggar A.K. and Yu D. (1996) Soft tissue sarcoma
metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 12: 2035-
2039.
Pourzand C. and Cerutti P. (1993) Genotypic mutation analysis by RFLP / PCR.
Mutation Research 288: 113-121.
Preudhomme C., Lubin R., Lepelley P., Vanumbeke M. and Fenaux P. (1994)
Detection of serum anti-p53 antibodies and their correlation with p53 mutations in
myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8: 1589-1591.
Prosser J. (1993) Detecting single-base mutations. Trends in Biotechnology 11: 238-
246.
Prosser J., Porter D., Coles C., Condie A., Thompson A.M., Chetty U., Steel C.M.
and Evans H.J. (1991) Constitutional p53 mutation in a non-Li-Fraumeni cancer
family. British Journal of Cancer 65: 527-528.
Prosser J., Thompson A.M., Cranston G. and Evans H.J. (1990) Evidence that p53
behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5: 1573-
1579.
Racila E., Euhus D., Weiss A.J., Rao C., McConnell J., Terstappen L.W.M.M. and
Uhr J.W. (1998) Detection and characterization of carcinoma cells in the blood.
Proceedings of the National Academy of Sciences U.S.A. 95: 4589-4594.
Ravindranath Y., Yeager A.M., Chang M.N., Steuber C.P., Krischer J., Graham-Pole
J., Carroll A., Inoue S., Camitta B., and Weinstein H. (1996) Autologous bone
marrow transplantation versus intensive consolidation chemotherapy for acute
myeloid leukemia in childhood. New England Journal ofMedicine 334: 1428-1434.
Reading C.L., Estey E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen
L.W.M.M., O'Brien M.C., Baron S. and Deisseroth A.B. (1993) Expression of
unusual immunophenotype combinations in acute myelogenous leukemia. Blood 81:
3083-3090.
Reich N.C. and Levine A.J. (1984) Growth regulation of a cellular tumour antigen,
p53, in nontransformed cells. Nature 308: 199-201.
219
Rhodes C.H., Honsinger C. and Sorenson G.D. (1995) PCR-detection of tumor-
derived p53 DNA in cerebrospinal fluid. American Journal of Clinical Pathology 103:
404-408.
Rhodes C.H., Honsinger C., Porter D.M. and Sorenson G.D. (1997) Analysis of the
allele-specific PCR method for the detection of neoplastic disease. Diagnostic
Molecular Pathology 6: 49-57. >
Rill D.R., Santana V.M., Roberts W.M., Nilson T., Bowman L.C., Krance R.A.,
Heslop H.E., Moen R.C., Ihle J.N. and Brenner M.K. (1994) Direct demonstration
that autologous bone marrow transplantation for solid tumors can return a multiplicity
of tumorigenic cells. Blood 84: 380-383.
Rosenbaum V. and Riesner D. (1987) Temperature-gradient gel electrophoresis.
Thermodynamic analysis of nucleic acids and proteins in purified form and in cellular
extracts. Biophysical Chemistry 26: 235-246.
Ross A.A., Cooper B.W., Lazarus H.M., Mackay W., Moss T.J., Ciobanu N.,
Tallman M.S., Kennedy M.J., Davidson N.E., Sweet D., Winter C.,.Akard L., Jansen
J., Copelan E., Meagher R.C., Herzig R.H., Klumpp T.R., Kahn D.G. and Warner
N.E. (1993) Detection and viability of tumor cells in peripheral blood stem cell
collections from breast cancer patients using immunocytochemical and clonogenic
assay techniques. Blood 82: 2605-2610.
Ross A.A., Miller G.W., Moss T.J., Kahn N.E., Warner N.E., Sweet D.L., Louie
K.G., Schneidermann E., Pecora A.L., Meagher R.C., Herzig R.H., Collins R.H. and
Fay J.W. (1995) Immunocytochemical detection of tumor cells in bone marrow and
peripheral blood stem cell collections from patients with ovarian cancer. Bone
Marrow Transplantation 15: 929-933.
Ross A.A. (1998) Minimal residual disease in solid tumor malignancies. Journal of
Hematotherapy 7: 9-18.
Rychlik W. (1995) Priming efficency in PCR. BioTechniques 18: 84-90.
Saiki R.K., Gelfand D.H., Stoffel S„ Scharf S.J., Higuchi R„ Horn G.T., Mullis K.B.
and Erlich H.A. (1988) Primer-directed enzymatic amplification ofDNA with a
thermostable DNA polymerase. Science 239: 487-491.
Sainsbury J.R.C., Anderson T.J., Morgan D.A.L. and Dixon J.M. (1994) Breast
Cancer. British Medical Journal 309: 1150-1153.
Saitoh S., Cunningham J., De Vries E.M.G., McGovern R.M., Schroeder J.J.,
Hartmann A., Blaszyk H., Wold L.E., Schaid D., Sommer S.S. and Kovach J.S.
(1994) p53 gene mutations in breast cancers in midwestern US women: null as well as
missense-type mutations are associated with poor prognosis. Oncogene 9: 2869-2875.
220
Sarkar G., Yoon H.-S. and Sommer S.S. (1992) Screening for mutations by RNA
single-strand conformation polymorphism (rSSCP): comparison with DNA -SSCP.
Nucleic Acids Research 20: 871-878.
Sebban C, Lepage E., Vernant J.P., Gluckman E., Attal M., Reiffers J., Sutton L.,
Racadot E., Michallet M. and Maraninchi D. (1994) Allogeneic bone marrow
transplantation in adult acute lymphoblastic leukemia in first complete remission : a
comparative study. French Group of Therapy ofAdult Acute Lymphoblastic
Leukemia. Journal of Clinical Oncology 12: 2580-2587.
Seyama T., Ito T., Hayashi T., Mizuno T., Nakamura N. and Akiyama M. (1992) A
novel blocker-PCR method for detection of rare mutant alleles in the presence of an
excess amount of normal DNA. Nucleic Acids Research 20: 2493-2496.
Sharp J.G., Kessinger A., Vaughan W.P., Mann S., Crouse D.A., Dicke K., Masih A.
and Weisenburger D.D. (1992) Detection and clinical significance ofminimal tumor
cell contamination of peripheral stem cell harvests. International Journal ofCell
Cloning 10 (Suppl 1): 92-94.
Sharp J.G., Bishop M., Chan W.C., Greiner T., Joshi S.S., Kessinger A., Reed E.,
Sanger W., TarantoloS., Traystman M. and Vose J. (1995a) Detection ofminimal
residual disease in hematopoietic tissues. Annals of the New York Academy of
Sciences 770: 242-261.
Sharp J.G., Mann S.L., Murphy B. and Weekes C. (1995b) Culture methods for the
detection ofminimal tumor contamination of hematopoietic harvests: a review.
Journal ofHematotherapy 4: 141-148.
Sheffield V.C., Cox D.R., Lerman L.S. and Myers R.M. (1989) Attachment of a 40-
base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the
polymerase chain reaction results in improved detection of single-base changes.
Proceedings of the National Academy of Sciences U.S.A. 86: 232-236.
Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M.L., Cavanee W. and
Vogelstein B. (1992) Clonal expansion of p53 mutant cells is associated with brain
tumour progression. Nature 355: 846-847.
Sievers E.L. and Loken M.R. (1995) Detection ofminimal residual disease in acute
myelogenous leukemia. Jounral ofPediatric Hematology / Oncology 17:123-133.
Simpson S.J., Vachula M., Kennedy M.J., Kaizer H., Coon J.S., Ghalie R., Williams
S. and Van Epps D. (1995) Detection of tumor cells in the bone marrow, peripheral
blood, and apheresis products ofbreast cancer patients using flow cytometry.
Experimental Hematology 23: 1062-1068.
221
Slingerland J., Minden M.D. and Benchimol S. (1991) Mutation of the p53 gene in
human acute myelogenous leukemia. Blood 77: 1500-1507.
Sommer S.S., Cunningham J., McGovern R.M., Saitoh S., Schroeder J.J., Wold L.E.
and Kovach J.S. (1992a) Pattern of p53 gene mutations in breast cancers ofwomen of
the Midwestern United States. Journal of the National Institute ofCancer 84: 246-
252.
Sommer S.S., Groszbach A.R. and Bottema D.K. (1992b) PCR amplification of
specific alleles (PASA) is a general method for rapidly detecting known single-base
changes. BioTechniques 12: 82-87.
Soto D. and Sukumar S. (1992) improved detection ofmutation in the p53 gene in
human tumors as single-stranded conformation polymorphs and double-stranded
heteroduplex DNA. PCR Methods and Applications 2: 96-98.
Soussi T., Caron de Fromentel C. and May P. (1990) Structural aspects of the p53
protein in relation to gene evolution Oncogene 5: 945-952.
Soussi T. (1995) The p53 tumour suppressor gene: from molecular biology to clinical
investigation. In Molecular Genetics ofCancer, ed. Cowell J.K. pp. 135-178.
Steward C.G., Goulden N.J., Katz F., Baines D., Martin P.G., Langlands K., Potter
M.N., Chessells J.M. and Oakhill A. (1994) A polymerase chain reaction study of the
stability of Ig heavy-chain and T-cell receptor a gene rearrangements between
presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood
83: 1355-1362.
Stork P., Loda M., Bosari S., Wiley B., Poppenhusen K. and Wolfe H. (1991)
Detection ofK-ras mutations in pancreatic and hepatic neoplasms by non-isotopic
mismatched polymerase chain reaction. Oncogene 6: 857-862.
Strachan T. and Read A.P. (1996) Human Molecular Genetics. Bios Scientific
Publishers.
Sugimoto K., Hirano N., Toyoshima H., Chiba S., Mano H., Takaku F., Yazaki Y.
and Hirai H. (1993) Mutations of the p53 gene in myelodysplastic syndrome (MDS)
and MDS-derived leukemia. Blood 81: 3022-3026.
Takeda S., Ichii S. and Nakamura Y. (1993) Detection ofK-ras mutations in sputum
by mutant allele-specific amplification (MASA). Human Mutation 2: 112-117.
Tannock I.F., Boyd N.F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C.,
Perrault D. and Sutherland H. (1988) A randomised trial of two dose levels of
cyclophosphamide, methotrexate, and fluoracil chemotherapy for patients with
metastatic breast cancer. Journal of Clinical Oncology 6: 1377-1387.
222
Terstappen L.W.M.M., Safford M., Konemann S., Loken M.R., Zurlutter K.,
Buchner T., Hiddemann W. and Wormann B. (1991) Flow cytometric characterisation
of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia
6: 70-80.
Theocharous P., Lowdell M.W., Jones A.L. and Prentice H.G. (1997)
Immunocytochemical detection ofbreast cancer cells: a comprison of three
attachment factors. Journal ofHematotherapy 6: 21-29.
Theophilus B.D.M., Latham T., Grabowski G.A. and Smith F.I. (1989) Comparison
ofRNase A, a chemical cleavage and GC-clamped denaturing gradient gel
electrophoresis for the detection ofmutations in exon 9 of the human acid P-
glucosidase gene. Nucleic Acids Research 17: 7707-7722.
Thorlacius S., Thorgilsson B., Bjornsson J., Tryggvadottir L., Borresen A-L.,
Ogmundsdottir H.M. and Eyfjord J.E. (1995) TP53 mutations and abnormal p53
protein staining in breast carcinomas related to prognosis. European Journal of
Cancer 31A: 1856-1861.
Tincello D.G. (1995) Investigation of androgen receptor gene DNA sequence in
patients with complete or partial androgen insensitivity syndrome or unexplained
infertility. M.D. Thesis, University ofEdinburgh.
Traystman M.D., Cochran G.T., Hake S.J., Kuszynski C.A., Mann S.L., Murphy B.J.,
Pirruccello S.J., Zuvanich E. and Sharp J.G. (1997) Comparison ofmolecular
cytokeratin 19 reverse transcriptase polymerase chain reaction (CK19 RT-PCR) and
immunocytochemical detection ofmicrometastatic breast cancer cells in
hematopoietic harvests. Journal ofHematotherapy 6: 551-561.
Trecca D., Longo L., Biondi A., Cro L., Calori R., Grignani F., Maiolo A.T., Pelicci
P.G. and Neri A. (1994) Analysis of p53 mutations in acute myeloid leukemia.
American Journal ofHematology 46: 304-309.
Uckun F.M., Kersey J.H., Haake R., WeisdorfD., Nesbit M.E. and Ramsay N.K.C.
(1993) Pretransplantation burden of leukemic progenitor cells as a predictor of relapse
after bone marrow transplantatin for acute lymphoblastic leukemia. New England
Journal ofMedicine 329: 1296-1301.
van der Akker E., Braun J.E.F., Pals G., Lafleru M.V.M. and Retel J. (1992) Single
base mutations can be unequivocally and rapidly detected by analysis ofDNA
heteroduplexes, obtained with deletion-mutant instead ofwild-type DNA. Nucleic
Acids Research 20: 6745-6746.
Vogelstein B. and Kinzler K.W. (1992) p53 function and dysfunction. Cell 70: 523-
526.
223
Vredenburgh J.J., Silva O., Tyer C., DeSombre K., Abou-Ghalia A., Cook M.,
Layfield L., Peters W.P. and Bat Jr. R.C. (1996) A comparison of
immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell
sorting for the detection ofmicrometastatic breast cancer in the bone marrow. Journal
ofHematotherapy 5: 57-62.
Vredenburgh J.J., Silva 0., Broadwater G., Berry D., DeSombre K., Tyer C., Petros
W.P., Peters W.P. and Bast Jr. R.C. (1997) The significance of tumor contamination
in the bone marrow from high-risk primary breast cancer patients treated with high-
dose chemotherapy and hematopoietic support. Biology ofBlood and Marrow
Transplantation 3: 91-97.
Wada H., Asada M., Nakazawa S., Iton H., Kobayashi Y., Inoue T., Fukumuro K.,
Chan L.C., Sugita K., Hanada R., Akuta N., Kobayashi N. and Mizutani S. (1994)
Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8:
53-59.
Wada M., Bartram C.R., Nakamura H., Hachiya M., Chen D-L., Borenstein J., Miller
C.W., Ludwig L., Hansen-Hagge T.E., Ludwig W-D., Reiter A., Mizoguchi H. and
Koeffler P. (1993) Analysis of p53 mutations in a large series of lymphoid
hematologic malignancies of childhood. Blood 82: 3163-3169.
Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I.,
Morel P. and Fenaux P. (1994) p53 mutations are associated with resistance to
chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157.
Wenham P.R., Newton C.R. and Price W.H. (1991a) Analysis ofApolipoprotein E
Genotypes by the amplification refractory mutation system. Clinical Chemistry 37:
241-244.
Wenham P.R., Newton C.R., Houlston R.S. and Price W.H. (1991b) Rapid diagnosis
of familial defective apolipoprotein B-100 by amplification refractory mutation
system. Clinical Chemistry 37: 1983-1987.
White M.B., Carvalho M., Derse D., O'Brien S.J. and Dean M. (1992) Detecting
single base substitutions as heteroduplex polymorphisms. Genomics 12: 301-306.
Wood W.C., Budman D.R., Korzun A.H., Cooper M.R., Younger J., Hart R.D.,
Moore A., Ellerton J.A., Norton L., Ferree C.R., Ballow A.C., Frei E. Ill and
Henderson I.C. (1994) Dose and dose intensity of adjuvant chemotherapy for stage II,
node-positive breast carcinoma. New England Journal ofMedicine 330: 1253-1259.
Wu D.Y., Ugozzoli L., Pal B.K. and Wallace B. (1989) Allele-specific enzymatic
amplification of P-globin genomic DNA for diagnosis of sickle cell anemia.
Proceedings of the National Academy of Sciences U.S.A. 86: 2757-2760.
224
Zhu Y-M., McQuaker I.G. and Russell N.H. (1996) Relapse of adult acute leukaemia
is frequently associated with the presence of p53 mutations which are only detectable
in a minor subclone at presentation. British Journal ofHaematology 93 (Suppl.l): 54.
Ziegler R.G., Hoover R.N., Pike M.C., Hildesheim A., Nomura M.Y., West D.W.,
Wu-Williams A.H., Kolonel L.N., Horn-Ross PL., Rosenthal J.F. and Hyer M.B."
(1993) Migration patterns and breast cancer risk in Asian-American women. Journal
of the National Cancer Institute 85: 1819-1827.
Zittoun R.A., Mandelli F., Willemze R., de Witte T., Labar B., Resegotti L., Leoni F.,
Damasio E., Visani G., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B.,
Leoni P., Peetermans M.E., Dardenne M., Vegna M.L., Petti M.C., Solbu G. and
Suciu S. (1995) Autologous or allogeneic bone marrow transplantation compared




Published Works and Presentations
Dang R.K.B., Anthony R.S., Craig J.I.O. and Parker A.C. (1998)
A novel 8-bp insertion in codon 281 of p53 in a patient with acute lymphoblastic
leukaemia and 2 separate leukaemic clones.
HumanMutation (in press and on website).
Dang R.K.B., Craig J.I.O., Hendry L., Horton Y., Anthony R.S. and Parker A.C. (1997)
Mutations of the p53 tumour suppressor gene in acute leukaemias studied with PCR-
DGGE.
British Journal ofHaematology 97 (Suppl 1):54.
Dang R.K.B., Anthony R.S., Craig J.I.O., Parker A.C. and Leonard R.C.F. (1998)
Potential use of p53 point mutations as markers for minimal residual disease (MRD)
detection in the breast cancer model.
British Journal ofHaematology 101 (Suppl 1): 92.
Dang R.K.B., Anthony R.S., Massie C.E., Craig J.I.O., Leonard R.C.F. and Parker A.C.
(1998)
Optimisation of p53 allele-specific primers - potential application in minimal residual
disease (MRD) detection.
BoneMarrow Transplantation 21 (Suppl 1): S182.
Dang R.K.B., Anthony R.S., Leonard R.C.F. and Parker A.C. (1998)
The use of p53 gene mutations as markers ofminimal residual disease (MRD) detection in
breast cancer and leukaemias.
Presented at the Scottish Society for Experimental Medicine meeting, 13th November
1998.
226
